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Synopsis 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide. In COPD, an imbalance is believed to exist between the activities of 
neutrophil serine proteinases (NSPs) such as neutrophil elastase (NE) and proteinase 3 
(PR3), and their endogenous inhibitors such as alpha-1-antitrypsin (A1AT). Hence, a 
deficiency of A1AT predisposes to the development of COPD. 
 
Following their release from neutrophils, NSPs may bind to local inhibitors depending on 
their concentrations and affinities, to substrate such as lung elastin or to the neutrophil cell 
membrane where they remain active. This work has demonstrated that; NSPs bound to the 
proteinase “inhibitor” alpha-2-macroglobulin (A2M) remain active, and A2M:NE 
complexes are able to degrade elastin in vitro; NE bound to elastin is poorly inhibited by 
A1AT; and PR3 binding to the neutrophil cell membrane is greater when the local 
concentration of A1AT is reduced. 
 
The role of PR3 has not previously been studied in detail. However, PR3 activity was 
found to be present in sputum from clinically stable subjects with COPD or A1AT 
deficiency and was greater than NE activity. Hence, PR3 is likely to be important in the 
pathogenesis of COPD and could potentially be a target for therapeutic inhibitors. 
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1 Introduction 
1.1 Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide [1] and is estimated to kill around 25,000 people per year in England 
and Wales [2]. In the UK, it is estimated that 3 million people have COPD; approximately 
900,000 cases have been diagnosed and a further 2 million people remain undiagnosed [3]. 
COPD is a major cause of hospital admissions and is estimated to be responsible for over 
one million hospital bed days per year [4]. For these reasons, further research into the 
pathophysiology and treatment of this condition is vital. 
 
COPD is characterised by airflow obstruction that is not fully reversible following 
administration of short acting bronchodilators, and pulmonary inflammation in response to 
inhaled substances. The airflow obstruction is usually progressive over time. Airflow 
obstruction is diagnosed by performing spirometry and is defined by the ratio of the forced 
expiratory volume in one second (FEV1) to the forced vital capacity (FVC) being less than 
0.7 [5], although depending on the subject’s age and gender this may result in a slight 
over- or under-diagnosis of the condition, and some studies use alternative spirometric 
criteria (lower limit of normal) [6]. Severity is classified according to the post-
bronchodilator FEV1 compared to that predicted by the subject’s age, sex and height 
(FEV1 % predicted). The grades of severity of airflow obstruction are summarised in 
Table 1.1.  
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Table 1.1-Severity of airflow obstruction according to the National Institute for 
Clinical Excellence (NICE) 2010 clinical guidelines 
Post-bronchodilator FEV1 (% predicted) Severity of airflow obstruction 
≥80% Mild 
50-79% Moderate 
30-49% Severe 
<30% Very Severe 
 
Although the main risk factor for the development of COPD is cigarette smoking [7], only 
around 20% of smokers develop clinically significant disease [8] indicating that other 
environmental and genetic risk factors are important in the aetiology. However, a 
deficiency of alpha-1-antitrypsin (A1AT) is the only widely accepted genetic 
predisposition to this disease. 
 
1.1.1 Clinical features 
COPD usually presents in middle age in subjects who are current or ex-smokers. 
Symptoms include exertional breathlessness, chronic cough, sputum production and 
wheeze. In addition, exacerbations occur which are associated with a rapid and sustained 
worsening of symptoms beyond normal day-to-day variability. Exacerbations can be 
infective (bacterial or viral) or non-infective (e.g. related to air pollution) in aetiology [9]. 
 
Significant heterogeneity exists within COPD and several pulmonary phenotypes have 
been recognised including; chronic bronchitis, emphysema, small airways disease and 
 3 
 
bronchiectasis. These conditions can co-exist to varying degrees in affected individuals 
[10], with some showing a predominance of a particular phenotype. These pulmonary 
phenotypes are discussed in further detail below, and the pathophysiology is discussed 
further in sections 1.1.3 and 1.1.4, where the importance of the neutrophil and neutrophil-
derived serine proteinases is considered. 
 
Most subjects with COPD exhibit fixed airflow obstruction as measured by spirometry, 
although some may have an element of bronchodilator reversibility. Pulmonary function 
testing may also reveal an increase in lung volumes and gas trapping as measured by total 
lung capacity (TLC) and residual volume (RV). Small airways abnormalities may be 
identified by measurement of the forced mid expiratory flow (FEF25-75%). Emphysema is 
associated with the destruction of lung parenchyma and is associated with a reduction in 
gas transfer corrected for lung volumes (KCO). 
 
In addition to pulmonary inflammation, COPD is associated with systemic inflammation 
[11]. It has been recognised that systemic features and other diseases are more common in 
COPD [12], including skeletal muscle dysfunction [13], cardiovascular disease [14], 
osteoporosis [15] and diabetes [16]. However, whether this represents independent 
physiological processes, common generalised processes or “overspill” inflammation [17] 
from one organ to another remains uncertain. 
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1.1.1.1 Chronic bronchitis 
Chronic bronchitis is defined clinically as a cough productive of sputum for most days 
over at least a three month period in two consecutive years [18]. Subjects with the chronic 
bronchitis phenotype show a higher airway inflammatory burden compared to subjects 
who do not spontaneously expectorate sputum, which is not related to smoking status [19]. 
Chronic bronchitis is associated with several clinical consequences, including an 
accelerated decline in FEV1 [20], a predisposition to lower respiratory tract infections and 
greater exacerbation frequency [21], and increased mortality [22]. Chronic bronchitis is 
generally believed to be due to chronic mucus hypersecretion by goblet cells, which leads 
to worsening airflow obstruction by luminal obstruction of small airways, epithelial 
remodelling, and alteration of airway surface tension predisposing to collapse [23]. 
 
1.1.1.2 Emphysema 
Emphysema is defined histologically as the destruction of alveolar walls and enlargement 
of airspaces distal to the terminal bronchioles [24]. More recently, emphysema has been 
diagnosed by computed tomography (CT) scanning [25]. Emphysema may be further sub-
classified into centrilobular, panacinar and paraseptal emphysema, which may show 
different distributions throughout the lung [26]. For example, emphysema associated with 
cigarette smoking is typically centrilobular and predominantly affects the upper zones, 
whereas emphysema associated with A1AT deficiency (A1ATD) is typically panacinar in 
appearance and predominantly affects the lower zones [27]. These CT scan appearances 
are shown in Figure 1.1. Progressive destruction of lung parenchyma may lead to the 
formation of bullae, which are thin-walled air-filled spaces which do not take part in gas 
exchange. 
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1.1.1.3 Small airways disease 
Small airways disease has been recognised as an important pathological finding associated 
with COPD [28]. The small airways are defined as non-cartilaginous airways with an 
internal diameter of 2mm or less [29]. In COPD, increased thickness of the small airway 
walls leads to luminal narrowing, which may be further occluded by mucus. These changes 
lead to increased peripheral airway resistance, air trapping and breathlessness on exertion. 
At present, the measurement of small airway function remains clinically difficult, and the 
delivery of inhaled drugs to the small airways requires further optimisation. A detailed 
review of the pathophysiology of the small airways in COPD can be found elsewhere [30]. 
 
1.1.1.4 Bronchiectasis 
Bronchiectasis is usually diagnosed by high resolution CT (HRCT) scanning and clinical 
history. The condition is characterised by irreversible airway dilatation with chronic 
bronchial infection/inflammation [31]. Clinical features include a chronic productive 
cough, frequent exacerbations, fatigue and basal crepitations on respiratory examination. 
HRCT findings include bronchial dilatation and a lack of bronchial tapering [32]. 
Bronchiectasis may be sub-classified into cylindrical, varicose and cystic bronchiectasis 
according to CT scan appearance, and examples of such HRCT findings are shown in 
Figure 1.2. 
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Figure 1.1-CT scan appearances of centrilobular and panacinar emphysema 
 
Figure 1.1: HRCT scans showing centrilobular emphysema in A with patchy low 
density areas (arrowed) and panacinar emphysema in B with a more diffuse pattern. 
Panacinar emphysema predominantly affects the lower zones and is associated with 
A1ATD. Images reproduced from [33]. 
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Figure 1.2- CT scan appearances of bronchiectasis 
 
 
 
Figure 1.2: HRCT scans showing cylindrical bronchiectasis in A (with the classic 
signet ring sign arrowed), varicose bronchiectasis in B and cystic bronchiectasis in C. 
Images reproduced from [34]. 
A 
B 
C 
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1.1.2 Treatment options 
Cigarette smoking is an important risk factor for COPD, and smoking cessation is one 
accepted intervention which reduces disease progression [35], as well as long term oxygen 
therapy (LTOT) in hypoxic patients which reduces mortality [36]. Inhaled therapies target 
airflow obstruction and inflammation, and include short or long-acting bronchodilators and 
corticosteroids. Non-pharmacological therapies such as pulmonary rehabilitation are also 
used [37]. Exacerbations are managed by using oral corticosteroids and/or antibiotic 
therapy. Pneumococcal and annual influenza vaccines also provide some benefit to 
patients with COPD [3]. 
 
At present, the pharmacological therapies available for COPD do not convincingly alter 
disease progression or mortality, and therefore there is an urgent need for novel therapies. 
Increasing our understanding of the complex pathophysiology of COPD will aid the 
development of specific therapies in the future. Some of the newer anti-inflammatory 
therapies for COPD in development are described elsewhere [38, 39]. 
 
1.1.3 The role of the neutrophil in COPD 
Overall there is a strong body of evidence that the neutrophil and neutrophil-derived 
proteinases play a central role in the pathophysiology of COPD. Patients with COPD have 
increased numbers of neutrophils in sputum and bronchoalveolar lavage (BAL) fluid 
compared with asymptomatic smokers [40, 41]. Studies of neutrophilic factors in the 
airway at baseline have been shown to predict the subsequent progression of disease [42] 
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and rapid progression in COPD is associated with greater neutrophilic inflammation in the 
airways [43]. Furthermore, exacerbations of COPD are also associated with an increased 
neutrophilic inflammation [44] which could explain the greater progression of disease in 
individuals with frequent exacerbations [45]. Finally, both neutrophil numbers and the 
concentration of NE complex with A1AT are reduced following smoking cessation [46], 
consistent with the beneficial effects of this intervention. 
 
In patients with COPD there is also evidence of altered circulating neutrophil function. For 
example; increased spontaneous adherence to endothelium under flow conditions [47], 
enhanced chemotaxis, increased spontaneous extracellular proteolysis [48], and greater 
production of reactive oxygen species [12]. More recent studies have confirmed that 
neutrophils show an aberrant chemotactic response at all degrees of severity of COPD 
which is not related to treatment or smoking habit, suggesting it is an inherent abnormality 
[49]. 
 
1.1.4 The role of serine proteinases in COPD 
The serine proteinases are a diverse group of enzymes which possess a reactive serine 
residue within the active site. The family includes digestive enzymes such as trypsin and 
chymotrypsin, enzymes that participate in blood coagulation such as thrombin, and other 
bacterial enzymes [50]. The neutrophil serine proteinases (NSPs) are serine proteinases of 
the chymotrypsin family that are released from the azurophilic granules of activated 
neutrophils during inflammation. This family includes neutrophil elastase (NE), proteinase 
3 (PR3) and cathepsin G (CG). The basic structure of chymotrypsin-like serine proteinases 
is shown in Figure 1.3. Their activities depend on a catalytic triad consisting of aspartate, 
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histidine and serine residues which are separated in their primary sequence but brought 
together at the enzyme’s active site in their tertiary structures [51]. Substitution of amino 
acids at the active site gives individual proteinases their substrate specificities. The 
interactions between proteinases and their substrates were described by Schechter and 
Berger [52]; the S subsites of the enzyme accommodate P residues of the substrate 
upstream of the cleavage site, whilst Sˊ subsites accommodate Pˊ residues downstream of 
the cleavage site [51], as shown in Figure 1.4. 
 
Figure 1.3-Structure of chymotrypsin-like serine proteinases 
 
Figure 1.3: The serine proteinases are composed of two β-barrel domains (each 
consisting of six antiparallel β sheets) and a C-terminal α-helix. The catalytic triad of 
aspartate, histidine and serine is located within the substrate binding cleft. The 
structure of bovine chymotrypsin is shown as an example. 
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Figure 1.4- Interactions between proteinases and their substrates 
 
Figure 1.4: Nomenclature described by Schechter and Berger for interactions 
between enzymes and their substrates. The scissile bond of the substrate is subject to 
enzymatic cleavage. The S subsites of the enzyme accommodate P residues of the 
substrate towards the N-terminal and Sˊ subsites accommodate Pˊ residues towards 
the C-terminal of the substrate. 
 
The NSPs have both intracellular and extracellular functions. They play an important role 
in the destruction of intracellular pathogens by digesting phagocytosed bacteria within 
phagolysosomes [53]. Enzymatically active NSPs are found on the cell membrane of 
activated neutrophils [54] which may facilitate penetration through tissue barriers and 
enable local degradation of extracellular matrix proteins without significant injury to 
surrounding tissues. Neutrophil activation and degranulation results in the extracellular 
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release of NSPs, which are involved in bacterial killing [55, 56] and local tissue damage 
during inflammation. Extracellular NSPs are important regulators of innate immunity, 
infection and inflammation [57, 58]. For example; they have bactericidal properties [56, 
59, 60] which may be independent of their proteinase activities, and they can control cell 
signalling via the processing of chemokines, modulating cytokines and activating cell 
surface receptors [51]. Extracellular killing of pathogens by neutrophils can also occur 
following the formation of neutrophil extracellular traps (NETs) [61]. NETs are formed 
following neutrophil activation and consist of a DNA backbone with embedded 
antimicrobial peptides and enzymes [62]. NETs are believed to be produced by dying 
neutrophils in a process distinct from apoptosis [63], referred to as NETosis [64]. NSPs 
associated with NETs have extracellular roles in bacterial killing and degradation of 
virulence factors [65], and are more resistant to inhibition by proteinase inhibitors 
compared to free NSPs [66]. 
 
However, excessive proteinase activity is associated with damage to lung elastin and other 
critical components of the extracellular matrix in the lung parenchyma. This 
proteinase/anti-proteinase imbalance has dominated research in COPD as a result of 
observations from the 1960s [67, 68]. This hypothesis states that an imbalance exists, 
either from increased proteinase activity or a deficiency in their inhibitors (the anti-
proteinases) resulting in excessive tissue destruction. To date, NSPs have been the best 
proven mediators replicating the pathological features of COPD and, in particular, 
emphysema. 
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The NSPs are both directly and indirectly implicated in the pathophysiology of lung tissue 
destruction (as observed in emphysema) due to their ability to degrade many components 
of the extracellular matrix including; elastin, type IV collagen, fibronectin and laminin 
[69-71], and to stimulate the release of pro-inflammatory cytokines [57, 72]. NE and PR3 
have been shown directly to cause pathological changes consistent with emphysema in 
animal models [73, 74], and NSPs can produce other features of COPD including mucous 
gland hyperplasia, mucus hypersecretion and impaired mucociliary function (as observed 
in the chronic bronchitis phenotype) [75-77]. These observations are consistent with the 
susceptibility of individuals with a deficiency of the main plasma serine proteinase 
inhibitor (A1AT) to develop early onset severe emphysema [67].  Together these findings 
have provided the crucial support to the proteinase/anti-proteinase hypothesis. 
 
Characteristics of the individual NSPs and their roles in the pathophysiology of lung 
disease are discussed in further detail below. 
 
1.1.4.1 Neutrophil elastase 
NE is a 29.5KDa glycoprotein which is coded for by the ELA2 (or more recently named 
ELANE) gene and is predominantly localised to neutrophil azurophilic granules, although 
it is also found in a subset of monocytes [78]. Its substrate specificity is determined not 
only by the P1 amino acid but also by its interactions with S and Sˊ subsites due to its 
extended substrate binding site [79]. NE shows a preference for small hydrophobic 
residues such as  Ala, Val, Ser or Cys as the P1 amino acid [51]. The hydrophobic 
properties of the S2 subsite explain why proline is preferred at the P2 position, whilst 
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substrates with charged residues at P2 are less well cleaved. Additionally, Ala residues are 
preferentially accommodated at P3 and P4, rather than positively charged residues [51]. 
 
Animal and in vitro studies have shown that exogenous NE causes mucous gland 
hyperplasia [80] and mucus secretion [81], which are features of human chronic bronchitis. 
NE deficient mice exposed to cigarette smoke are 60% protected from airspace 
enlargement and show impaired recruitment of neutrophils and monocytes into the lung 
compared to smoke-exposed wild type control mice [82]. Wright et al [83] showed that a 
synthetic NE inhibitor could reduce cigarette smoke-induced emphysema in guinea pigs. 
The specific NE inhibitor sivelestat (ONO-5046) has been shown to reduce endotoxin-
induced lung injury in guinea pigs [84] and suppress bleomycin-induced pulmonary 
fibrosis by blocking neutrophil chemotaxis and by inhibiting NE-induced lung cell 
apoptosis [85]. These studies suggest that sivelestat treatment reduces inflammation, and 
may act through NF-kB inhibition [86]. An oral reversible inhibitor of NE, AZD9668, has 
been shown in animal models to reduce human NE-induced lung injury, and prevent 
airspace enlargement and small airway wall remodelling in guinea pigs exposed to tobacco 
smoke [87]. The oral NE inhibitor ONO-6818 has also been shown to inhibit the 
development of emphysematous changes in rats, including lung hyperinflation, reduction 
of elastic recoil, and airspace enlargement [88]. 
 
In human studies, sputum positive for NE from subjects with bronchiectasis has been 
shown to reduce ciliary beat frequency of epithelial cells [89]. There is a direct relationship 
between the severity of emphysema in human tissue and the amount of NE in the 
interstitium [90], and subjects with high levels of A1AT:NE complex in BAL fluid have a 
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significantly accelerated decline in lung function as measured by FEV1, suggesting that 
NE in the lung is related to progression in COPD [91, 92]. Furthermore, a fibrinogen 
cleavage product detectable in plasma which is a marker of pre-inhibition NE activity 
showed a positive correlation with A1AT:NE complexes and a negative correlation with 
FEV1 % predicted [93]. 
 
In human clinical studies, the NE inhibitor sivelestat reduces lung injury associated with 
systemic inflammatory response syndrome (SIRS) [94] and can reduce serum cytokine 
levels [95] in patients with acute respiratory distress syndrome (ARDS) although it is not 
associated with a reduction in mortality of these patients in a meta-analysis [96]. Studies of 
NE inhibitors in COPD patients have shown that midesteine (MR889), a reversible NE 
inhibitor, has low toxicity when given over a 4 week period in a randomised placebo 
controlled study [97]. However, the development of ONO-6818 was discontinued when 
data from a phase IIa study in COPD patients revealed abnormalities in liver function 
related to the treatment [98]. More recently, Kuna et al [99] demonstrated in a 12 week 
randomised placebo controlled phase IIb trial of 615 COPD patients that the reversible NE 
inhibitor AZD9668 was well tolerated. However, in this short-term study, there was no 
improvement in lung function, respiratory signs and symptoms or quality of life scores 
when added to budesonide/formoterol maintenance therapy in COPD patients. 
 
Despite the above evidence many uncertainties remain; the association of NE with human 
emphysema has been inconsistent, and limited short-term studies of selective NE inhibitors 
have not been fully effective in controlling neutrophil-mediated damage in the airways, 
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suggesting that other proteinases implicated in experimental models of emphysema [100] 
may play a role. 
 
1.1.4.2 Proteinase 3 
PR3 is a multifunctional serine proteinase mainly located in the azurophilic granules and 
on the cell surface of neutrophils [101]. PR3 can also be found in specific granules and 
secretory vesicles in contrast to NE [102]. It is a 29KDa glycoprotein alternatively named 
myeloblastin, AGP7 and p29b [60, 103]. The PR3 gene (PRTN3) is found in the same 
region of chromosome 19p13.3 as NE [104] and its structure is similar to that of NE with 
57% sequence homology [105]. PR3 has an extended substrate binding site that influences 
substrate specificity. The S2, S1ˊ, S2ˊ, and S3ˊ subsites predominantly determine the 
substrate specificity of PR3, and explain its difference from NE [106]. PR3 shows a 
preference for small hydrophobic residues such as Cys, Ala, Val and norVal as the P1 
amino acid [51]. The main structural differences between NE and PR3 are described in 
detail elsewhere [107].  
 
PR3 is the most abundant serine proteinase in the neutrophil with each cell being estimated 
to store 3, 1.1, and 0.85 pg of PR3, NE, and CG, respectively [108]. Another study 
reported that neutrophils release more PR3 than NE during phagocytosis [109]. Its 
biological roles are diverse and include its ability to cleave the human cathelicidin hCAP-
18 to generate the antibacterial peptide LL-37 [110], and a pro-inflammatory role for PR3 
has been suggested by its ability to activate TNFα, IL-8, IL-1β, IL-18 and IL-32 [58, 111-
113]. Kuckleburg et al [114] reported that PR3 may also play a role in neutrophil 
transmigration via its cell membrane interaction with the NB1 receptor, as the interaction 
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between endothelial cell PECAM-1 and neutrophil NB1 plays an important role in 
neutrophil transmigration. The authors found that neutrophils expressing NB1 and PR3 on 
their surface were selectively recruited, and that the efficiency of transmigration positively 
correlated with PR3 activity. In addition, PR3 is the main antigenic target of antineutrophil 
cytoplasmic antibodies (ANCAs) in Wegener’s granulomatosis (WG), a systemic disease 
associated with small vessel vasculitis and necrotising granulomatosis of the respiratory 
tract [115]. ANCAs can bind to PR3 expressed on neutrophil cell membranes and amplify 
cell activation [116]. 
 
The role of PR3 in respiratory diseases has been less well studied. In animal and in vitro 
studies, PR3 can degrade extracellular matrix proteins such as elastin and fibronectin, 
resulting in tissue injury (as observed in human emphysema) [117] and can induce mucus 
secretion (as observed in human chronic bronchitis) [75]. Intra-tracheal administration of 
PR3 to hamsters leads to the development of bullous emphysema [74]. Knockout mice for 
both PR3 and NE demonstrate less neutrophilic inflammation compared to wild-type mice 
and mice deficient in NE alone [118]. In this study, the defects in mice lacking both PR3 
and NE were directly linked to the accumulation of the anti-inflammatory protein, 
progranulin. The authors concluded that PR3 and NE may enhance neutrophil activation 
by degrading oxidative burst-suppressing progranulin. However, species differences in 
physico-chemical properties, substrate specificities and enzyme kinetics towards synthetic 
peptide substrates have been shown [119] and therefore results from animal models should 
be interpreted with caution when considering human disease. In vivo studies have indicated 
that apoptosis of lung endothelial cells can lead to emphysematous changes [120] and PR3 
has been shown to be pro-apoptotic [121, 122]. The pro-apoptotic mechanism of PR3 is 
likely to be due to cleavage of NF-κB and the cell cycle inhibitor p21 [58]. 
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Studies in human disease have been few, which may reflect the paucity of specific reagents 
to quantify PR3 and its activity. However, Witko-Sarsat et al [75] found that PR3 
concentration exceeded NE concentration in sputum from patients with cystic fibrosis (CF) 
and showed a negative correlation with FEV1 % predicted. 
 
The anti-proteinase screen for PR3 in the lungs is less efficient than that for NE since PR3 
is not inhibited by secretory leukoproteinase inhibitor (SLPI) [109], and the remaining 
airway inhibitors A1AT and elafin bind to NE more readily than to PR3 [123]. This 
together with the greater concentration of PR3 suggests it may play a more significant role 
in neutrophil mediated lung damage. To date, there have been no studies of specific PR3 
inhibitors in animal or human models of respiratory disease. Table 1.2 summarises the 
biological functions of PR3 and its potential roles in the pathophysiology of COPD. 
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Table 1.2- Functions of PR3 and its potential roles in the pathophysiology of COPD 
Function of PR3 References 
Degradation of components of the extracellular matrix [117] 
Activation of chemokines/cytokines [58, 111-113] 
Mucus secretion from airway submucosal gland serous cells [75] 
Endothelial cell apoptosis [121, 122, 124] 
Bactericidal properties [125] 
Platelet activation [126] 
Inactivation of proteinase inhibitors [127] 
Neutrophil transendothelial migration [114] 
Target of autoantibodies in Wegener’s granulomatosis [128] 
 
1.1.4.3 Cathepsin G 
CG is a 28.5KDa glycoprotein which is coded for by the CTSG gene on chromosome 
14q11.2 [129] and is predominantly located in neutrophil azurophilic granules. The role of 
CG in lung diseases may also be clinically relevant and distinct from other NSPs. In 
animal and in vitro studies, CG does not produce emphysema-like lesions but has been 
shown to induce mucous gland hyperplasia [73] and mucus secretion [81]. Further 
evidence for the role of CG in the pathogenesis of suppurative lung diseases has been 
shown in animal models of endobronchial inflammation where ability to clear 
Pseudomonas aeruginosa is inhibited [130], and a dual inhibitor of CG and chymase has 
been shown to reduce airway inflammation [131]. To date, the role of CG in COPD has 
not been studied in human subjects, so the relevance and mechanisms involved remain 
largely unknown. 
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1.1.5 Inhibitors of serine proteinases 
Endogenous inhibitors of serine proteinases include the serpins, chelonianin inhibitors and 
alpha-2-macroglobulin (A2M), and are discussed in further detail below. 
 
1.1.5.1 The serpins 
The serine proteinase inhibitors (serpins) are a diverse family of proteins found in several 
species. The family includes A1AT, α1-antichymotrypsin, monocyte/neutrophil elastase 
inhibitor (MNEI or serpin B1), antithrombin, C1 inhibitor and plasminogen activator 
inhibitor-1 [132]. These proteins are key regulators of inflammation, coagulation and the 
complement and fibrinolytic pathways. They account for around 2% of total protein in 
human plasma, the most common being A1AT [51]. The serpins share a similar conserved 
tertiary structure and the superfamily is classified into sixteen clades, with human serpins 
belonging to the first nine clades (A to I) [132]. The structure of serpins consists of three 
β-sheets (A-C) and eight or nine α-helices (hA-hI) with an exposed mobile reactive centre 
loop (RCL) between β-sheets A and C, as shown in Figure 1.5. The RCL typically contains 
20 residues that act as a pseudo-substrate for the target proteinase [133]. The enzyme and 
serpin initially form a Michaelis complex [134] followed by cleavage of the RCL between 
P1 and P1ˊ. This allows insertion of the cleaved RCL into the β-sheet A of the serpin and 
movement of the enzyme from the upper to the lower pole of the serpin with distortion of 
the active site of the enzyme [133, 135]. This suicide substrate inhibition mechanism 
renders both molecules inactive. The serpin-proteinase complex is then rapidly cleared 
from the circulation [136]. 
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Figure 1.5- Serpin structure 
 
Figure 1.5: The structure of A1AT. The α-helices are shown in grey and labelled hA 
to hI. The three β-sheets are shown; the A sheet in red, the B sheet in green and the C 
sheet in yellow. The RCL is between β-sheets A and C. The position of P1 is shown. 
Reproduced from [132]. 
 
  
 
 
 22 
 
Dysfunction of serpins leads to diseases such as emphysema, thrombosis, angioedema, 
cancer and dementia [137]. The so-called “serpinopathies” result from point mutations 
within members of the serpin family and are characterised by the formation of polymers 
that are retained in the cell of synthesis [138, 139]. Pathological consequences result from 
a “toxic gain of function” from the accumulated polymers and a loss of function from the 
deficiency of the inhibitor. This is exemplified by A1ATD which is described in further 
detail below. 
 
Alpha-1-antitrypsin 
A1AT is a 52 kDa circulating glycoprotein mostly secreted by hepatocytes [140] and, to a 
much lesser extent, by lung epithelial cells [141] and phagocytes [142]. It enters the lungs 
primarily by passive diffusion from plasma. A1AT is coded for by the protease inhibitor 
(Pi) locus on chromosome 14 at q32.1. [143]. A1AT is able to inhibit the NSPs NE, PR3 
and CG as well as other serine proteinases including thrombin, trypsin and chymotrypsin 
[144]. Circulating levels of A1AT are in the range 20-53µM/L in healthy (PiMM) 
individuals [145] and can increase during the acute phases of infection and inflammation 
[146]. The RCL of A1AT is cleaved at the Met358-Ser359 bond by target NSPs [135]. NE 
is irreversibly inhibited with 1:1 stoichiometry, whereas with PR3 and CG the 
inhibitor/enzyme stoichiometry is slightly greater than 1 due to partial proteolytic 
inactivation of some A1AT during the interaction (the “substrate pathway”) [129]. The 
normal M variant of A1AT is a less competent inhibitor of PR3 and CG compared to NE 
with the second order association rate constants (Kass) being ten-fold and one hundred-
fold lower for PR3 and CG respectively [117, 147]. The activity of A1AT can be 
modulated by genetic and environmental factors, for example, lung A1AT is potentially 
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susceptible to local oxidation of methionine residues in its RCL (P1 Met358 and P8 
Met351) by cigarette smoke and myeloperoxidase released from activated neutrophils 
[148]. Oxidised A1AT has a greatly reduced inhibitory capacity, with its Kass for NE 
being reduced by a factor of more than 2000 [147]. 
 
A1ATD was first described in 1963 [67] and is inherited as an autosomal co-dominant 
disorder. Over 100 naturally occurring genetic variants of A1AT have been described. 
Each variant is named according to its speed of migration in an isoelectric pH gradient. 
The slower migrating variants are named with letters towards the end of the alphabet, for 
example, M (medium), S (slow) and Z (very slow). The normal variant is M (of which 
there are at least four subtypes) which is associated with normal levels of A1AT. The most 
common allele associated with marked deficiency of A1AT is the Z variant which results 
from a single amino acid substitution where glutamate at residue 342 is replaced by lysine 
[149, 150]. The Z variant results in a marked reduction in secretion, releasing 
approximately 20% of that produced by the M variant, and accumulation of the protein in 
the rough endoplasmic reticulum of hepatocytes [151, 152] forming periodic acid Schiff 
(PAS) positive hepatic inclusions. This accumulation can lead to liver disease including 
hepatitis, cirrhosis and hepatocellular carcinoma [153]. The resulting deficiency in 
circulating A1AT means that the lungs are not adequately protected from NSP activity 
leading to an increased risk of developing emphysema. Previous studies of the Kass of 
A1AT have shown that Z variant A1AT is a less competent inhibitor of NE than normal M 
A1AT [154]. Thus, individuals with the PiZZ genotype not only have lower concentrations 
of A1AT, but it is also less functional as an inhibitor of NE [155]. A review of genotype 
frequencies has suggested that the homozygous PiZZ genotype occurs in approximately 1 
in 3500 individuals in the UK, with the heterozygous PiMZ genotype occurring in 
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approximately 1 in 25 individuals [156]. Population and in vitro studies [157] suggest a 
minimum serum A1AT threshold of 11µM is critical, and below this level A1AT is 
decreasingly able to protect the lungs, leading to an increasing risk of developing 
emphysema. This concept of a protective threshold emerged following the observation that 
a subset of individuals with the PiSZ phenotype (with serum A1AT levels below 11µM) 
were at increased risk of emphysema, whereas those with concentrations exceeding this 
threshold (including PiMZ heterozygotes) were not deemed at increased risk [158, 159]. 
 
Other A1AT variants described in this thesis include the S, F and I variants. The S variant 
results from a single amino acid substitution where glutamate at residue 264 is replaced by 
valine [160, 161] and is associated with a serum protein level of approximately 60% of 
that produced by the M allele due to reduced secretion from hepatocytes [162]. The F 
variant has an allelic frequency of approximately 0.002 in the Caucasian population and 
was first identified in 1965 [163, 164]. The F variant results from a single amino acid 
substitution where arginine at residue 223 is replaced by cysteine. Serum levels of A1AT 
in individuals carrying the F allele are usually normal, although there have been reports of 
an increased risk of emphysema in PiFZ heterozygotes [165]. To date, no PiFF 
homozygotes have been reported in the literature, although there is one case report of an 
individual with COPD and the PiFnull phenotype [166]. The observation of emphysema in 
PiFZ individuals raises the question about the function of F variant A1AT. The I variant 
results from a single base substitution where arginine at position 39 is replaced by cysteine 
[167]. The PiIZ phenotype was first reported in 1987 and has also been associated with 
both respiratory disease [168] and liver cirrhosis [169] perhaps because that is where it is 
most assessed. Nevertheless, these observations suggest that the I variant of A1AT may 
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also be less functional than the normal M variant. Several null allelic variants have also 
been described which result in an absence of A1AT and are reviewed elsewhere [170]. 
 
The Z variant of A1AT (and to a lesser extent the S and I variants [169]) has an increased 
tendency to fold aberrantly and form polymers in the liver. However, the formation of 
polymers is not only restricted to the liver, and polymers have been found in the 
circulation [171] and in BAL fluid [172]. Furthermore, Z type A1AT purified from plasma 
can form polymers under physiological conditions [173]. Polymeric A1AT does not 
function as an enzyme inhibitor, thereby further reducing the anti-proteinase protection in 
PiZZ homozygotes beyond that expected by the depleted A1AT levels. Co-inheritance of 
an S or I allele with a Z allele can lead to interaction between the A1AT variants and the 
formation of heteropolymers within hepatocytes [169]. The Z mutation of A1AT is at 
residue P17 at the head of strand 5 of the A sheet and the base of the mobile RCL [151]. 
This substitution of glutamate by lysine leads to a conformational change in the protein 
and formation of an unstable intermediate characterised by partial insertion of the RCL and 
opening of β-sheet A [174]. The A sheet is then more able to accept the RCL of a second 
A1AT molecule to form a dimer, which can extend to form a polymer, as shown in Figure 
1.6. Alternative mechanisms of polymerisation have been described, including C sheet 
linkages, although the A sheet linkage is thought to be most likely in vivo [173]. Formation 
of polymers is accelerated by exposure of Z A1AT to cigarette smoke and its resultant 
oxidation [175]. Polymers of A1AT in the lung have chemotactic properties in vivo and act 
as pro-inflammatory stimuli leading to neutrophil recruitment [176]. These findings are 
consistent with the processes resulting in the early onset and progression of emphysema in 
PiZZ homozygotes, particularly those who smoke. 
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Figure 1.6- Polymerisation of A1AT 
 
Figure 1.6: Mutations such as the Z mutation (arrowed) or mutations within the 
shutter domain (blue circle) such as Mmalton or Siiyama lead to a conformational 
change in the monomer (M) and opening of β-sheet A (green) to form an unstable 
intermediate (M*). The A sheet can accept the RCL (red) of a second A1AT molecule 
to form a dimer (D) and can extend to form a polymer (P). Alternatively, the open A 
sheet can accept its own RCL resulting in latent A1AT (L). Image reproduced from 
[151]. 
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Inhibitors of polymerisation could potentially play a therapeutic role in A1ATD and other 
serpinopathies. Small molecule peptides that can inhibit polymerisation of Z A1AT have 
been studied in vitro [152, 177]. However, further in vivo studies are now warranted to 
determine any therapeutic benefit for subjects with PiZZ A1ATD related diseases. 
 
Other serpins 
Other serpins relevant to NSPs include MNEI and α1-antichymotrypsin. MNEI is found in 
the cytoplasm of neutrophils and monocytes [178], and is able to irreversibly inhibit all 3 
NSPs by forming a 1:1 complex [179]. It is a 42KDa intracellular serpin which has two 
functional sites in the RCL (Phe343-Cys344 and Cys344-Met345) [129]. α1-
antichymotrypsin (also known as SERPINA3) is a 68KDa glycoprotein produced in the 
liver and secreted into the circulation. Its reactive site is at the Leu358-Ser359 bond and it 
inhibits CG but not PR3 or NE [129]. 
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1.1.5.2 Chelonianin inhibitors 
The chelonianin inhibitors are a family of canonical inhibitors which bind to their target 
enzymes through an exposed convex binding loop with a conformation which is 
complementary to the active site of the enzyme [180]. Endogenous chelonianin inhibitors 
that are important in controlling the activities of NSPs include SLPI, and elafin and its 
precursor trappin-2. 
 
Secretory leukoproteinase inhibitor 
SLPI is an 11.7KDa protein produced locally in the lungs by epithelial cells, alveolar type 
2 cells, Clara cells and by phagocytes [181, 182]. It is a reversible inhibitor of NE and CG 
but does not inhibit PR3 [109]. Bacterial proteinases, human cysteine proteinases and PR3 
can inactivate SLPI [127, 183, 184] hence potentiating the activities of other NSPs 
normally inhibited by SLPI. Unlike A1AT, SLPI can inhibit NE bound to elastin [185]. 
 
Elafin 
Elafin is a 6KDa inhibitor produced locally in the lungs by alveolar type 2 cells and Clara 
cells [182]. Elafin and its precursor trappin-2 can reversibly inhibit NE and PR3 but not 
CG [186]. It can also inhibit NE and PR3 expressed on the cell surface of activated 
neutrophils [187]. In addition to its role as a proteinase inhibitor, elafin has anti-microbial 
activity against both gram positive and gram negative respiratory pathogens [188]. Elafin 
can be cleaved by NE, and although cleaved fragments of the inhibitor can still inhibit NE 
activity, its anti-microbial role is diminished [189]. 
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1.1.5.3 Alpha-2-macroglobulin 
A2M is a 725 kDa glycoprotein produced by the liver and composed of four identical 
subunits of approximately 185 kDa [190]. All four classes of proteinases (serine, aspartic 
acid, cysteine and matrix metalloproteinases) can be irreversibly trapped by A2M. The 
normal blood levels of A2M are around 2mg/ml [191]. The ultrastructure of A2M shows 
the molecule to be a twin trap capable of binding 2 NE molecules when the concentration 
of NE is high [192]. A2M predominantly enters the lungs by diffusion, although some 
local production may occur [193]. Diffusion from the blood may be restricted by the large 
molecular size of A2M, but increases in the presence of inflammation [194]. 
 
A2M has a 25 amino acid stretch known as the “bait region” which can be cleaved by 
different proteinases [195]. Cleavage of the bait region results in a conformational change 
of the A2M molecule which mediates “trapping” of the proteinase and physical exclusion 
of large substrates from the active site of the enzyme. Therefore “inhibition” of proteinases 
by A2M does not block the active site and the proteinase retains activity towards small 
substrates [196]. This is in contrast to other mechanisms of proteinase-inhibitor complex 
formation, which involves irreversible active site inhibition [197]. Cleavage of the bait 
region also results in exposure of new sites that are recognised by receptors on several cell 
types [198, 199]. Therefore, A2M may function predominantly to remove proteinases from 
the circulatory system by steric shielding and rapid clearance [200], rather than inhibiting 
their activity. Complexes of NE with A2M can retain their activity even in the presence of 
other inhibitors such as A1AT [201]. 
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1.1.6 The role of other proteinases in COPD 
The proteinase/anti-proteinase hypothesis has predominantly highlighted the importance of 
NSPs in the pathogenesis of COPD due to direct experimental and clinical observations. 
There are, however, other enzyme systems that have been explored as potential 
mechanisms in COPD and particularly emphysema. These include the matrix 
metalloproteinases (MMPs) and the cysteine proteinases. Proteinases implicated in the 
pathophysiology of COPD are summarised in Table 1.3. In addition, complex interactions 
exist between NSPs, MMPs, cysteine proteinases and proteinase inhibitors. These 
interactions are summarised in Figure 1.7. 
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Table 1.3- Proteinases implicated in the pathogenesis of COPD 
 
Proteinase Class Source Inhibitors References 
NE Serine proteinase PMN 
Pro-inflammatory 
monocytes 
A1AT 
A2M 
SLPI 
Elafin 
[80-82, 90-92, 
202] 
PR3 Serine proteinase PMN A1AT 
A2M 
Elafin 
[74, 75, 117] 
CG Serine proteinase PMN A1AT 
A2M 
SLPI 
Alpha-1 antichymotrypsin 
[73, 81] 
MMP-1 Matrix 
metalloproteinase 
Macrophages 
Fibroblasts 
Epithelial cells 
Endothelial cells 
TIMP 1-4 
A2M 
[203, 204] 
MMP-2 Matrix 
metalloproteinase 
PMN 
Macrophages 
Fibroblasts 
Epithelial cells 
Endothelial cells 
TIMP 1-4 
A2M 
[205] 
MMP-8 Matrix 
metalloproteinase 
PMN 
Fibroblasts 
Endothelial cells 
TIMP 1-4 
A2M 
[206, 207] 
MMP-9 Matrix 
metalloproteinase 
PMN 
Macrophages 
Eosinophils 
Fibroblasts 
Epithelial cells 
Endothelial cells 
TIMP 1-4 
A2M 
[205, 207-209] 
MMP-12 Matrix 
metalloproteinase 
Macrophages TIMP 1-4 
A2M 
[208, 210, 211] 
Cathepsin B Cysteine 
proteinase 
Macrophages 
Epithelial cells 
Endothelial cells 
Cystatins A, C, S 
A2M 
Kininogens 
[212, 213] 
Cathepsin L Cysteine 
proteinase 
Macrophages 
Endothelial cells 
Fibroblasts 
Cystatins A, C, S 
A2M 
Kininogens 
[214] 
Cathepsin S Cysteine 
proteinase 
Macrophages 
Endothelial cells 
Cystatins A, C, S 
A2M 
Kininogens 
[215] 
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Figure 1.7- Interactions between different classes of proteinases and their biological 
inhibitors 
 
Figure 1.7: The complex interactions between proteinases (shown in bold) and their 
inhibitors (shown in italics). The serine proteinases NE and PR3, MMPs and 
cathepsin B are capable of producing tissue damage leading to emphysema. MMPs 
indirectly enhance the activity of serine proteinases by inactivating A1AT [216, 217].  
In a complex relationship, NE further activates MMPs [218] and inactivates their 
inhibitors, the TIMPs [219]. The cysteine proteinases, including cathepsin B, have 
been shown to inactivate SLPI [184], and cathepsins B and L can inactivate A1AT 
[220, 221]. NE can activate cathepsin B [222] and inactivate its inhibitor, cystatin C 
[223]. This inflammatory cascade facilitates the activity of proteinases in the presence 
of neutrophilic inflammation.  
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1.2 Alpha-1-antitrypsin deficiency 
1.2.1 Clinical features 
A1ATD is associated with panacinar emphysema which is usually of an earlier onset than 
in patients with usual COPD and shows a lower zone predominance. Disease severity is 
often out of proportion to the smoking history [27]. Other respiratory features include 
chronic bronchitis and bronchiectasis [224], although not all subjects develop respiratory 
disease suggesting that environmental and other genetic factors may play a role.  
 
In addition to respiratory disease, A1ATD has been associated with liver disease in some 
subjects due to the accumulation of aggregated protein [153], including neonatal 
cholestasis, cirrhosis and hepatocellular carcinoma. Evidence to support the “toxic gain of 
function” from the polymers accumulated in the hepatocytes is provided by the recognition 
that null alleles, which do not produce A1AT, are not associated with cirrhosis [225]. 
Polymerisation of A1AT is accelerated with increasing temperature [139] and it has been 
hypothesized that febrile illness in infancy is a predisposing factor for infantile hepatitis 
[226]. A1ATD has also been associated with panniculitis [227] and Wegener’s 
granulomatosis [228]. 
 
1.2.2 Treatment options 
Treatment for A1ATD depends on the individual presentation. For most subjects this will 
involve standard treatments for COPD such as inhaled bronchodilators and corticosteroids. 
Bacterial exacerbations should be identified and especially treated promptly, since they are 
associated with a greater proteinase/anti-proteinase imbalance [229] and hence more tissue 
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damage than in usual COPD. Indications for LTOT and pulmonary rehabilitation are the 
same as those in usual COPD. There is also even more emphasis on avoidance of cigarette 
smoking, maintenance of nutrition, and preventative vaccination against influenza and 
pneumococcus. Lung transplantation may be considered in subjects with very severe 
respiratory disease [230]. 
 
Newer approaches targeting the molecular basis of the disease are the subject of current 
research. These include A1AT augmentation therapy (discussed in Chapter 7), inhibitors of 
polymerisation within hepatocytes and gene therapy. A1AT augmentation therapy does not 
affect polymerisation of Z A1AT in the liver and is therefore not effective for liver disease 
associated with A1ATD. Similarly, it does not prevent the local production of Z A1AT 
polymers in the lungs which act as neutrophil chemoattractants [231]. Small molecule 
peptides that can inhibit polymerisation of Z A1AT have been studied in vitro [177]. 
However, in vivo studies are still awaited to determine their efficacy. 
 
Numerous strategies for gene therapy have been employed including recombinant adeno-
associated viral vectors, non-viral vectors and induced pluripotent stem cells (iPSCs). A 
phase 2 clinical study of a recombinant adeno-associated viral vector expressing A1AT 
[232] administered intramuscularly to 9 A1ATD subjects showed that vector-derived 
expression of normal M A1AT was dose-dependent and persisted for at least 90 days. 
Vector administration was well tolerated in these subjects with no serious adverse events. 
All subjects developed antibodies to adeno-associated virus (which may influence long 
term efficacy of this approach) but not to A1AT. Further research will be required into the 
design or delivery of viral vectors in order to achieve therapeutic efficacy in A1ATD. 
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Human iPSCs have been used to correct the point mutation in Z A1AT in both in vitro and 
animal studies [233]. However, stem cells accumulate mutations within their genome 
which can occur at random, and therefore there are concerns about the long-term risks of 
malignancy with stem cell therapy, as previously highlighted in a patient who received 
stem cell therapy for ataxia telangiectasia [234]. These safety concerns will need to be 
addressed before stem cell therapy can be considered in clinical practice.  
 
Liver transplantation from a PiMM individual can return A1AT levels to normal and is 
associated with favourable outcomes [235], but is only available to subjects with end stage 
liver disease at present due to a shortage of donor organs. 
 
Newer anti-inflammatory treatments for usual COPD may also be of particular benefit to 
subjects with lung disease associated with A1ATD. These include antioxidants, inhibitors 
of p38 mitogen-activated protein kinase (MAPK) and antagonists of the interleukin (IL)-8 
receptor CXCR2 and are reviewed elsewhere [39]. In particular, inhibitors of NSPs could 
be beneficial due to the greater proteinase/anti-proteinase imbalance in subjects with 
A1ATD. However, the roles of individual NSPs need to be established to determine their 
relative importance to the overall proteolytic burden. 
 
1.2.3 Alpha 1 antitrypsin deficiency as a model for usual COPD 
A1ATD is associated with all the clinical features of usual COPD including symptoms, 
recurrent exacerbations and development of emphysema. Neutrophilic inflammation is 
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increased in these individuals and reflects an exaggerated form of that seen in usual COPD 
[229]. The condition is easily monitored, and due to its more rapid progression, allows the 
validation of neutrophilic biomarkers over a shorter period of time. Studies in A1ATD 
have pioneered the use of CT scanning as a tool to assess degree and progression of 
emphysema. CT scan appearance has been shown to be the best predictor of mortality in 
A1ATD [236], and this has subsequently been confirmed in usual COPD [237], providing 
further support for A1ATD as a predictive model for usual COPD. 
 
1.3 Aims and structure of this thesis 
The predominant aims of this thesis are twofold; firstly to study the interactions of the 
NSPs NE and PR3 with their biological inhibitors of varying efficacies and substrates of 
different molecular sizes, and secondly to explore the potential role of PR3 in COPD, both 
with and without A1ATD. 
 
In Chapter 3, the potential for serum samples from both healthy controls and subjects with 
A1ATD to inhibit NE or PR3 activities has been examined. Serum contains the proteinase 
inhibitors A1AT and A2M. The partitioning of NSPs between these inhibitors is of interest 
because NE bound to A2M can retain its proteolytic activity towards low molecular weight 
peptide substrates [196], whereas NE bound to A1AT is inactivated. The proteolytic 
potential of PR3 complexes with A2M has not previously been explored. In this section, 
serum samples of different A1AT genotypes (e.g. PiMM, PiSZ, PiFZ, PiZZ) have been 
used to assess how NSPs partition between the two serum inhibitors in the presence of 
different A1AT variants, and any resultant effects on their activities. These results have 
been explored further in Chapter 4 where the activities of NE and PR3 bound to A2M have 
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been studied, and the partitioning of NSPs has been studied by using purified inhibitors 
(A2M and A1AT) in the equivalent concentrations found in the serum samples. 
 
In Chapter 5, elastin degradation by NE and PR3 has been studied. Elastin is a large 
molecular weight natural substrate of both NE and PR3 and its destruction in vivo leads to 
the development of emphysema. Elastin degradation has been examined both in the 
presence of serum from subjects with different A1AT genotypes, and with pure A1AT and 
A2M. Any biological relevance of complexes between A2M and NE or PR3 has been 
studied by determining their ability to degrade elastin in vitro. In addition, the inhibitory 
ability of A1AT towards NE and PR3 in the presence of elastin has been considered. 
 
The focus of Chapter 6 is on the association rate constants between NE or PR3 and 
different variants of A1AT. Previous work has suggested that Z variant A1AT is a less 
competent inhibitor of NE than M variant A1AT [154], and M variant A1AT is a less 
competent inhibitor of PR3 than NE [117]. Therefore, in the presence of neutrophilic 
inflammation in usual COPD, A1AT will preferentially inhibit NE. This together with the 
greater amount of neutrophil PR3 may potentially increase the damaging potential of this 
enzyme. The association rate constants of PR3 and A1AT variants (other than M A1AT) 
have not been studied previously. The clinical consequences of co-inheriting a 
“dysfunctional” AlAT variant with the Z variant are also considered by studying the 
clinical phenotypes of PiFZ heterozygotes. 
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At present, the only specific therapy available for A1ATD is A1AT augmentation therapy 
but randomised controlled studies to date have not convincingly demonstrated its efficacy 
in clinical practice [238]. In Chapter 7, the in vitro effects of augmenting A1ATD serum 
with normal M A1AT and the altered distribution of NSPs between the serum inhibitors 
have been assessed. In addition, elastin degradation by augmented and non-augmented 
serum samples has been measured. 
 
Activated neutrophils express NSPs on their cell surfaces that remain enzymatically active 
[54, 108], and therefore may play a role in the tissue damage associated with COPD. In 
Chapter 8, the neutrophil cell surface expression of NE and PR3 has been measured in 
subjects with A1ATD or usual COPD, and healthy controls. In addition, the influence of 
local proteinase inhibitor concentrations on the cell membrane expression of NE and PR3 
has been evaluated by incubating and stimulating neutrophils in either normal or A1ATD 
plasma and determining the effect of local A1AT concentration on NSP expression. 
 
Finally, the role of NE in lung diseases has previously been studied in detail [239]. 
However, PR3 has not been well studied. The amino acid sequence and crystal structure of 
PR3 is similar to that of NE [105], and until recently no substrates or inhibitors were 
available that could discriminate between the two proteinases [240]. In Chapter 9, recently 
developed specific NE and PR3 substrates have been used to measure the activities of 
these NSPs in sputum samples from subjects with A1ATD or usual COPD. This has 
allowed comparisons to be made of the activities of individual proteinases. Results have 
been related to other inflammatory markers, bacterial colonisation and clinical status. 
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Overall, the data presented here provides new information on the contribution of PR3 to 
the proteinase/anti-proteinase imbalance found in A1ATD and COPD. Such knowledge 
may provide novel insights into therapeutic targets for these important medical conditions. 
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2 General methods 
This section provides a general overview of methods used for subject selection, sample 
collection, diagnostic tests, buffers used for experiments, active site titration of enzymes 
and statistical analyses. Specific methods are described in the relevant chapters. 
 
2.1 Subject selection 
Subjects with A1ATD were identified from the UK national registry. The Antitrypsin 
Deficiency Assessment and Programme for Treatment (ADAPT) reviews subjects with 
A1ATD on an annual basis, and is located in Birmingham, UK. It is funded by a non-
commercial grant from Grifols Therapeutics. All subjects registered with ADAPT have 
their diagnosis confirmed by phenotyping and genotyping (Heredilab, Salt Lake City, 
USA). Presently, the UK database contains over 1,000 patients who have been assessed 
annually for up to 16 years. These well characterised patients have full demographic data 
recorded including; medical history, clinical examination, quality of life measures, full 
lung physiology, biochemical and haematological parameters, radiology, and stored 
plasma, serum and sol-phase sputum. All patients provided written informed consent and 
ethical approval was obtained for all aspects of this project (South Birmingham Research 
Ethics Committee LREC3359). 
 
Subjects with usual COPD (normal PiMM A1AT phenotype) were recruited from primary 
care at the start of an acute exacerbation (infective or non-infective). These subjects had a 
clinical diagnosis of COPD based on a history of chronic bronchitis and exertional 
breathlessness, with or without supportive spirometry at presentation. Exacerbations were 
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defined by increased breathlessness, cough and sputum production. Subjects were assessed 
at the start of an acute exacerbation (day 1) and provided blood samples and a spontaneous 
sample of sputum. The sputum samples were analysed using a standardised colour chart 
(Bronkotest, Heredilab, USA) and subjects with mucopurulent or purulent sputum were 
treated with antibiotics, whilst those with mucoid sputum were not. Subjects were 
followed up after resolution of the episode during convalescence (day 56). At this visit, 
blood and spontaneously produced sputum samples were collected and full pulmonary 
function tests (PFTs) and HRCT scans were performed. Additional subjects with usual 
COPD were recruited from hospital outpatient clinics when clinically stable. These 
subjects had their diagnosis confirmed by spirometry and provided blood samples for 
research during their visit. All subjects provided written informed consent to participate in 
this study. 
 
Healthy controls who were partners of patients with A1ATD (and therefore age-matched) 
were also recruited. The healthy controls had a normal PiMM A1AT phenotype, no 
significant medical history and normal spirometry, were on no regular medication and 
were non- or ex-smokers. The healthy controls provided blood samples for research 
purposes and had plasma and serum stored. All subjects gave written informed consent to 
participate. 
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2.2 Sample collection, processing and storage 
2.2.1 Plasma and serum samples 
Venous blood was collected from all subjects and processed within 30 minutes of 
collection. Plasma was obtained using ethylenediaminetetraacetic acid (EDTA)-containing 
Vacuette
®
 tubes (Greiner bio-one, UK) and serum was obtained using Vacuette
®
 serum 
tubes, allowing clot formation. The tubes were centrifuged at 1800 x g for ten minutes at 
room temperature. Plasma and serum were harvested and stored at -70 ºC until analysis. 
 
2.2.2 Neutrophil extraction 
Neutrophils were isolated in a biological safety class 2 cabinet to ensure a sterile 
environment. Venous blood was collected into heparinised Vacuette® tubes and placed in 
a 50ml Falcon tube (Becton Dickinson, UK).  A 2% dextran solution was prepared by 
adding 2g of dextran 500 (Sigma, UK) to 0.9% saline and the solution was filter sterilised. 
For every 6ml of blood collected, 1ml of the 2% dextran solution was added and the 
contents were mixed. The blood was then left for 30-40 minutes to allow sedimentation of 
the red cells. The top layer was the “buffy layer” which contained the leukocytes. 
 
A Percoll® gradient was prepared in a 15ml Falcon tube (Becton Dickinson, UK) as 
shown in Figure 2.1. The “100%” Percoll® was made by adding 45ml of pure Percoll® 
(Sigma, UK) to 5ml of 9% saline. The 9% saline was prepared by dissolving 9g of NaCl in 
100ml of deionised water and then sterilised by autoclaving. Subsequently, 80% Percoll® 
solution was made by adding 40ml of “100%” Percoll® to 10ml of 0.9% saline, and 56% 
Percoll® solution was made by adding 28ml of “100%” Percoll® to 22ml of 0.9% saline. 
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A gradient was formed by adding 5ml of 56% Percoll® to a 15ml Falcon tube. Slowly, 
2.5ml of 80% Percoll® was added beneath the 56% Percoll® solution. The buffy layer 
from the blood was then added slowly onto the surface of the 56% Percoll® solution. 
Caution was taken to avoid air bubbles, which can lead to neutrophil activation. The tube 
was centrifuged at 220 x g for 20 minutes at room temperature with minimal acceleration 
and no brake. Following separation of the cells in the Percoll® gradient, the top plasma 
layer was removed and discarded. Next, the peripheral blood mononuclear cell (PBMC) 
layer was removed with a small pipette and discarded. The neutrophil layer was then 
removed from the interface between the 80% and 56% Percoll® and added to sterile 
phosphate buffered saline (PBS) in a 50ml Falcon tube. The tube was topped up to 30ml 
with PBS and the cells washed by centrifuging the tube at 460 x g for 10 minutes at room 
temperature. The excess PBS was poured out of the tube to leave a pellet of neutrophils. 
The neutrophil pellet was then re-suspended in RPMI 1640 medium (Sigma, UK). 
 
In order to count the number of cells present, 10µL of the solution was extracted and 
examined on a haemocytometer. The dilution of the neutrophils was varied to achieve a 
final neutrophil concentration of 2 million cells per ml. To confirm purity of the neutrophil 
preparation, a cytospin was prepared with 100µL of the cell solution and spun at 500 RPM 
for 3 minutes. Using a Reastain® quick-diff kit (Reagena Ltd, UK) the cells were 
examined for purity. All neutrophil preparations used were >95% pure, the remaining cells 
being predominantly eosinophils. 
 
Methods for isolating neutrophils from blood are associated with a risk of activation and 
modification of the cell surface properties. The use of dextran increases cell attachment 
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and reduces subsequent cell movement, whereas greater cell motility has been observed 
when the cells are separated in the presence of Percoll® [241]. Another study comparing 
the anticoagulant used during blood collection showed that heparin and citrate increased 
phorbol myristate acetate (PMA)-induced activation compared to EDTA [242]. The 
methods used throughout this thesis for neutrophil isolation were standardised and 
designed to minimise cell activation whilst preserving yield and purity. Therefore any 
differences in cell surface expression observed between subject groups are likely to reflect 
basic rather than activated differences. 
 
  
 45 
 
Figure 2.1- Neutrophil isolation using a Percoll® gradient 
 
Figure 2.1: A Percoll® gradient was prepared as shown on the left side of the Figure 
and the buffy layer from the blood was added onto the surface of the 56% Percoll® 
solution. Following centrifugation, cell separation occurred as shown on the right 
hand side of the diagram. A full description is given in the text. 
 
2.2.3 Processing sputum samples and quantitative sputum culture 
Spontaneously produced sputum samples were collected into a sterile container from 
waking over a four hour period. A mouthwash was used prior to obtaining the sample to 
minimise contamination by saliva. Each sputum sample was analysed by its macroscopic 
Neutrophil layer 
Red Blood Cells 
PBMC layer 
Plasma 
56% Percoll 
80% Percoll 
“Buffy layer” from blood 
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appearance using a standardised colour chart (Bronkotest, Heredilab, USA) and allocated a 
number. Values of 1-2 (colourless-white) were classed as mucoid whilst values of 3-5 
(yellow-green) were classed as mucopurulent or purulent. Sputum samples were analysed 
within two hours of arrival and were divided into three aliquots. One aliquot (with a 
minimum weight of 1g) was used to obtain quantitative microbiological culture as 
described previously [243], and results were expressed as colony forming units per 
millilitre of sputum (cfu/ml). The second aliquot (minimum 1g) was ultracentrifuged 
(50,000 x g for 90 minutes at 4°C) to obtain the sol-phase which was stored at -70°C until 
analysis. The third aliquot was used for cytospin preparation to obtain cell counts and 
viability as described previously [244]. 
 
2.3 Pulmonary function tests 
PFTs were performed in the stable clinical state following the administration of 
bronchodilators by trained Respiratory Physiologists at the Lung Function Department, 
Queen Elizabeth Hospital, Birmingham, UK. Post-bronchodilator (salbutamol 400 mcg 
and ipratropium 60 mcg via a spacer) spirometry was performed using a wedge bellows 
spirometer (Vitalograph, Buckinghamshire, UK), static lung volume measurements 
including TLC and RV were assessed using helium dilution [245] and gas transfer by the 
single breath carbon monoxide method. The European Community for Steel and Coal 
reference equations [246] were used to derive predicted values for spirometry and static 
lung volumes, and Cotes reference equation [247] was used for KCO. 
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2.4 High resolution CT scanning 
HRCT scans of the thorax were performed using Prospeed and Lightspeed scanners 
(General Electrical Systems, Milwaukee, USA) to determine the presence or absence of 
emphysema (Figure 1.1) or bronchiectasis (Figure 1.2), and were reported by a single 
radiologist. 
 
2.5 Buffers used for experiments 
The buffers used commonly in subsequent experiments are listed in Table 2.1. Further 
buffers used in specific chapters are described in the relevant sections. 
 
Table 2.1- Buffers used for experiments 
Name of buffer Description 
Porcine pancreatic elastase (PPE) buffer 0.2M Tris-HCl, pH 8.6, 0.1% v/v Triton X100 
PPE substrate buffer 0.1M Hepes, pH 7.5, 9.5% DMSO 
NE assay buffer 0.01M Tris-HCl, 0.5M NaCl, 0.1% Triton 
X100, pH 8.6 
NSP assay buffer 50mM Hepes, pH 7.4, 150mM NaCl, 0.05% 
Igepal CA-630 (v/v) 
Elastin buffer 0.2M Tris base, pH 8.8 
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2.6 Active site titration of enzymes 
The experiments described in this thesis depend on using pure enzymes of known specific 
activity. NE and porcine pancreatic elastase (PPE) obey the Michaelis-Menten model of 
enzyme kinetics [248] in that the rate of catalysis (V) is a function of the concentration of 
substrate [S]. At a fixed concentration of enzyme, the rate of substrate catalysis (V) is 
related to [S] in a linear fashion provided that V is significantly below its maximal value 
(Vmax). The Michaelis constant (Km) is the concentration of substrate at which the 
reaction rate is at half of its maximal value (Vmax/2) and is an inverse measure of the 
substrate’s affinity for the enzyme. The Km value is independent of the enzyme and 
substrate concentrations. The Michaelis-Menten model is given by the following formula 
(equations taken from [248]); 
      
  
→     
 
The enzyme E combines with substrate S to form as ES complex with a rate of K1. The ES 
complex may then dissociate to E and S with a rate of K-1 or form the product with a rate 
of K2. The initial rate of catalysis (V) is equal to the product of the concentration of the ES 
complex and K2;  
    [  ] 
 
The quantity of ES is given by its rates of formation and breakdown;  
                       [ ][ ] 
                             [  ] 
K1 
K-1 
(1) 
(2) 
(3) 
 
 (2) (4) 
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In the steady state, the concentration of ES stays constant and the rate of formation equals 
the rate of breakdown. Therefore;  
  [ ][ ]          [  ] 
 
Rearranging equation 5 gives;  
[ ][ ]
[  ]
 
        
  
 
 
This equation can be simplified by defining the Michaelis constant Km; 
   
      
  
 
 
Combining equations 6 and 7 and solving for ES gives;  
[  ]  
[ ][ ]
  
 
 
In equation 8, [S] is very nearly equal to the total substrate concentration provided that the 
concentration of the enzyme is much lower than that of the substrate, and the concentration 
of the enzyme [E] is equal to the total enzyme concentration [E]T minus the concentration 
of the ES complex. This gives the equation; 
(5) 
(6) 
(7) 
(8) 
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[ ]  [ ]  [  ] 
 
Substituting [E] from equation 9 into equation 8 gives; 
[  ]  
 [ ]  [  ] [ ]
  
 
 
Rearranging equation 10 gives; 
[  ]  [ ] 
[ ]
[ ]    
 
 
Substituting this expression for ES into equation 2 gives; 
    [ ] 
[ ]
[ ]    
 
 
When Vmax is achieved, the active sites of the enzyme are saturated with substrate and 
therefore [ES]=[E]T. Putting this information into equation 2 gives;  
       [ ]  
 
The Michaelis-Menten equation is obtained by substituting equation 13 into equation 12 
where V0 is the initial reaction velocity; 
       
[ ]
[ ]    
 
(9) 
(10) 
(11) 
(12) 
(13) 
(14) 
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The definition of Km can be derived from equation 14; when [S]=Km, then V0=Vmax/2. 
The Km value for an enzyme depends on the substrate used as well as conditions such as 
pH and temperature. The Vmax gives the turnover number of an enzyme which is the 
number of molecules of substrate converted to product in unit time when the enzyme is 
fully saturated with substrate. This is equal to K2 and is also known as Kcat. When the 
substrate concentration is much less than Km, V depends on the values of Kcat/Km, [S] 
and [E]T. In these circumstances, Kcat/Km is the rate constant for the interaction of the 
enzyme and the substrate and may be used as a measure of catalytic efficiency. Therefore 
it is possible to compare an enzyme’s preference for different substrates [248]. 
 
It is possible to derive the specific enzyme activity from values of Vmax which can in turn 
be derived from measurements of the dependence of V on [S]. These data can be analysed 
by construction of a Lineweaver-Burk double reciprocal plot (Figure 2.2). 
 
The activity assays described in this Chapter were repeated at regular time intervals to 
ensure consistency. 
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Figure 2.2- Lineweaver-Burk double reciprocal plot 
 
 
Figure 2.2: Example of a Lineweaver-Burk double reciprocal plot- a graphical 
method for analysis of the Michaelis-Menten equation. 1/V is plotted on the y-axis 
against 1/[S] on the x-axis. The y intercept is equivalent to the inverse of Vmax and 
the x intercept represents -1/Km. The slope represents Km/Vmax. 
 
2.6.1 Methods for active site titration experiments 
2.6.1.1 Active site titration of PPE by Lineweaver-Burk double reciprocal plot 
analysis 
PPE (Sigma, UK) was prepared at a stock concentration of 1mg/ml in PPE buffer (the 
molecular weight of PPE is 25.9KDa). All buffers used for PPE activity experiments were 
free of sodium chloride (NaCl) as it has previously been suggested that this can affect the 
specific activity of PPE, although this is not the case for human NE [79, 249]. Stock PPE 
was aliquoted, rapidly frozen with liquid nitrogen and stored at -70 ºC until required. Fresh 
aliquots were used for all assays and freeze/thaw cycles were avoided. The elastase 
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substrate N-succinyl-ala-ala-ala-p-nitroanilide (SlaaapN, Sigma, UK) was used for PPE 
activity assays in PPE substrate buffer at the following concentrations; 7.5mM, 5mM, 
2.5mM, 1mM and 0.5mM.  One ml of each concentration of substrate was added to a 
polystyrene cuvette with a 1cm pathlength. The spectrophotometer (Jasco V550) was 
blanked against the assay buffer, and the absorbance of the substrate solution was 
measured at 410nm. PPE was diluted to 10µg/ml, and 10µL was added to the substrate. 
The change in optical density (absorbance) was measured over a 10 minute period. Each 
experiment was performed in triplicate and average results taken. 
 
The reaction velocity (V) was calculated by substituting the absorbance (410nm) values 
into the Beer-Lambert equation; 
      
Where; 
A= Absorbance (410nm) 
e= Extinction coefficient [8,800 M
-1
 cm
-1
 for SlaaapN [250]] 
c= Concentration of product (M) 
l= cell pathlength (cm) 
 
The reaction velocity (V) was determined in terms of moles of product produced per unit 
time, and was used to construct a Lineweaver Burk plot of 1/V against 1/[S]. The y 
intercept gives 1/Vmax.  
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The molar concentration of active enzyme is equal to Vmax/Kcat (by rearranging equation 
13). The kinetic constants under these conditions have previously been published [251]. 
 
2.6.1.2 Activity assessment of PPE with PiMM plasma 
Once the activity of PPE was determined it was then titrated against healthy (PiMM) 
plasma of known A1AT concentration (where the A1AT is assumed to be predominantly 
functional) to provide further support to the results obtained by Lineweaver-Burk double 
reciprocal plot analysis. The A1AT concentration was measured using a modified version 
of an in-house enzyme linked immunosorbent assay (ELISA), as described below.  
 
A1AT ELISA 
This was performed by adding 200µL of 2µL/ml goat anti-human A1AT antibody 
(Binding site, Birmingham UK) in coating buffer (0.05M Na2CO3, 0.05M NaHCO3, pH 
9.6) to a Maxisorp microtitre plate (Nunc, Glasgow UK) using only the inner wells. The 
plate was incubated over night at 4ºC, and then washed 3 times with 300µL wash buffer 
[phosphate buffered saline (PBS), albumin 0.1% (w/v), Tween 0.05% (v/v)]. Next, 200µL 
of blocking solution [50mM Tris base, 0.14M NaCl, 1% bovine serum albumin (BSA), pH 
8] was added to each well and incubated for 1 hour at room temperature, followed by 
washing as before. A human serum protein calibrator (Dako, UK) containing 1.24g/L 
A1AT was used as a standard. This was serially diluted in wash buffer to generate 
standards ranging from 62ng/ml to 1.94ng/ml. The plasma or serum samples were diluted 
in wash buffer in the range of 1 in 20,000 to 1 in 60,000. Then 200µL of standard or 
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sample was added to the plate, left to incubate for 2 hours at room temperature, and then 
the plate was washed as previously. Next, 200µL of 2.6µL/ml goat anti-human A1AT 
peroxidase conjugate (Binding site, Birmingham UK) in wash buffer was added to the 
plate and allowed to incubate for two hours at room temperature. Following a washing 
step, 200µL of tetramethylbenzidine (TMB) solution (Sigma, UK) was added to the plate 
and incubated in the dark until a colour change occurred. The reaction was stopped with 
50µL per well of 0.1M H2SO4. The absorbance was then read at 450nm with a 570nm 
wavelength correction using a Biotek Synergy HT plate reader. The concentration of 
A1AT in the samples was determined by interpolation from the linear portion of the 
standard curve using Microsoft Excel 2007. Samples with values falling outside of the 
standard curve were repeated at a more appropriate dilution. The intra- and inter- assay 
coefficients of variation (CVs) were 4.66% and 4.35% respectively. 
 
Titration of PPE with PiMM plasma 
The major elastase inhibitors in plasma include A1AT and A2M. Elastase that is bound to 
A2M can retain its proteolytic activity towards low molecular weight nitroanilide 
substrates [252], and therefore inhibition of PPE by plasma largely reflects the inhibitory 
capacity due to A1AT. 
 
PPE was diluted to 10µg/ml and fresh PiMM plasma was diluted 1 in 200 in PPE buffer.  
PPE (10µL) was added to a 96 well plate (Costar, USA) in triplicate sets. Control wells did 
not contain any PPE, but contained all other components. Reducing volumes of diluted 
plasma (18-0µL) were added to the wells, to give reducing concentrations of inhibitor 
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(A1AT present in plasma irreversibly inhibits PPE) until the final wells contained no 
plasma. PPE buffer was then added to each set of wells to make up to a final volume of 
110µL. The plate was covered and incubated with gentle shaking at 37ºC for 20 minutes to 
allow the enzyme to form a complex with the inhibitor. Residual activity was measured by 
adding 100µL SlaaapN at a concentration of 1mg/ml in PPE substrate buffer. The 
absorbance at 410nm was then read at 5 minute intervals up to 60 minutes using a Biotek 
Synergy HT plate reader at 37ºC. Mean results were taken of all triplicates and control 
values were subtracted.  
 
An inhibition curve was constructed by plotting the percentage of remaining enzyme 
activity against the molar ratio of A1AT:PPE. The linear portion of the curve was 
extrapolated to the x-axis, and the number of moles of A1AT required to inhibit each mole 
of PPE was determined. 
 
This method was optimised by including control wells for every volume of plasma. This 
was important since the inherent colour of diluted plasma could interfere with the optical 
density (OD) measured. Also, the substrate solution was added to all of the wells 
(including the control wells) since the substrate solution had a different OD to the buffer. 
For these reasons, the control wells contained all of the components of the other wells 
apart from the enzyme. Extra buffer (10µL) was added to control wells to ensure that the 
total volumes of the wells were the same. 
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The specific activity of PPE was therefore calculated using Lineweaver-Burk double 
reciprocal plot analysis and confirmed by titration with PiMM plasma. This specific 
activity value was then used in all subsequent calculations. Lineweaver-Burk double 
reciprocal plot analysis can be prone to errors since the y-axis uses the inverse of V which 
may increase any small errors in measurement. To reduce potential errors, experiments 
were performed in triplicate and mean results taken, and more points were plotted for 
larger values of [S] and hence smaller values for 1/[S] to increase the accuracy of 
extrapolation to the y-axis. Similar data may also be obtained by computational data fitting 
using non-linear regression. 
 
2.6.1.3 Activity of pure A1AT by titration with PPE 
Pure A1AT (Athens Research and Technology, USA) was titrated with PPE of known 
specific activity. A1AT is an irreversible inhibitor of PPE and forms a complex with 1:1 
stoichiometry. PPE was diluted to 10µg/ml in PPE buffer and A1AT was diluted to 
20µg/ml in the same buffer. The inhibition assay was performed as described in section 
2.6.1.2. 
 
2.6.1.4 Activities of pure NE and PR3 
Pure NE (Athens Research and Technology, USA) and pure PR3 (Merck, UK) were 
titrated with the pure A1AT, which had been titrated with PPE of known activity (as 
above). Both NE and PR3 were taken as forming complexes with A1AT with 1:1 
stoichiometry, and their specific activities were determined by performing enzyme 
inhibition assays as described below.  
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All enzyme and inhibitor concentrations quoted in subsequent experiments refer to active 
concentrations. 
 
NE inhibition assay with pure A1AT 
Pure NE was diluted in NE assay buffer to 10µg/ml. Pure A1AT of known activity was 
diluted so that the concentration of active inhibitor was equal to the concentration of NE. 
NE (10µL) was added to a 96 well plate (Costar, USA) in triplicate sets. Increasing 
volumes of pure A1AT (0-18µL) were added to the wells. Each triplicate had an 
appropriate control containing no enzyme. All wells were made up to 110µL with NE 
assay buffer. The plate was then covered and incubated with gentle shaking at 37ºC for 20 
minutes. Residual activity was measured by adding 100µL SlaaapN at a concentration of 
1mg/ml in NE assay buffer. The absorbance at 410nm was read at 5 minute intervals up to 
60 minutes using a Biotek Synergy HT plate reader at 37ºC. Mean results were taken of all 
triplicates and control values were subtracted. The activity of NE was determined by 
constructing an inhibition curve and determining the intercept with the known amount of 
active A1AT. 
 
PR3 inhibition assay with pure A1AT 
Pure PR3 was diluted in NSP assay buffer. The detergent was added to the buffer to 
minimise adherence of free proteinases to plastic and glass surfaces when in dilute solution 
[240]. The PR3 was diluted to a concentration of 1.5µM and pure A1AT of known activity 
was diluted so that the concentration of active inhibitor was equal to the concentration of 
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PR3. The method was carried out as described for NE, except a different buffer (above) 
and substrate were used. The elastase substrate SlaaapN is not a suitable substrate for PR3 
experiments as it shows no significant hydrolysis. However, an alternative elastase 
substrate, N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (MSaapvN) (Sigma, UK) 
which is not specific for NE, can also be used for pure PR3 experiments. The catalytic 
efficiencies are different for the two enzymes and are shown in Table 2.2. For these 
experiments, 150µL of MSaapvN was used per well at a concentration of 0.2mg/ml in NSP 
assay buffer. The activity of PR3 was determined by constructing an inhibition curve and 
determining the intercept with the known amount of active A1AT. 
 
Table 2.2- Kinetic parameters for NE and PR3 enzyme activities 
 (adapted from reference [119]) 
 
 
2.6.2 Results of active site titration experiments 
2.6.2.1 Active site titration of PPE by Lineweaver-Burk double reciprocal plot 
analysis 
The mean results of three experiments are summarised in Table 2.3 and Figure 2.3. 
Substrate Parameter NE PR3 
SlaaapN Kcat/Km (M
-1
s
-1
) 465 Very low activity 
MSaapvN Kcat/Km (M
-1
s
-1
) 33915 499 
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Table 2.3- Reaction velocities for PPE at different substrate concentrations (SlaaapN) 
[S] (mM/L) 1/[S] (mM/L
-1
) V (mM/L/s) 1/V (mM/L/s
-1
) 
7.5 0.133 0.0001 10000 
5 0.2 0.0000933 10741 
2.5 0.4 0.0000833 12037 
1 1 0.00004 26111 
0.5 2 0.0000267 38889 
 
Figure 2.3- Lineweaver-Burk double reciprocal plot for PPE 
 
Figure 2.3: Lineweaver-Burk double reciprocal plot for PPE. The points show the 
mean results of three experiments ± standard error of the mean (SEM). 
 
From these results, Vmax was calculated as 0.133µM/L/s. Using the equation of active 
enzyme=Vmax/Kcat (where the Kcat for PPE with this substrate is 37s
-1 
[251]) the 
y = 16121x + 7518.5 
R² = 0.9833 
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concentration of active enzyme was found to be 0.36µM/L. The total concentration of 
enzyme was 0.39µM/L and therefore the PPE was 92% active as determined by this 
method. 
 
2.6.2.2 Active site titration of PPE with PiMM plasma 
The concentration of A1AT in the PiMM plasma sample was found to be 30.3µM by 
ELISA. The intra-assay and inter- assay CVs for the A1AT ELISA were 4.66% and 4.35% 
respectively. The inhibition slope of PPE by PiMM plasma is shown in Figure 2.4. 
 
Figure 2.4- Inhibition of PPE by PiMM plasma (SlaaapN) 
 
Figure 2.4: Inhibition slope of PPE with PiMM plasma. Each point shows the mean 
result from 3 experiments. The SEM was small and fell within the points plotted. 
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Extrapolation of the slope shows that the A1AT in PiMM plasma inhibits PPE at a molar 
ratio of 1.07:1. Therefore the results confirm the PPE to be almost fully active. Since this 
result is in keeping with the result obtained by Lineweaver-Burk double reciprocal plot 
analysis, 92% activity for PPE has been used throughout the following experiments. 
 
2.6.2.3 Activity of pure A1AT by titration with PPE 
The inhibition slope of PPE by pure A1AT is shown in Figure 2.5. Extrapolation of the 
slope shows that the pure A1AT inhibited PPE at a molar ratio of 1.1:1. Therefore the pure 
A1AT was 84% active. This value was used for subsequent experiments. 
 
Figure 2.5- Inhibition of PPE by pure A1AT (SlaaapN) 
 
Figure 2.5: Inhibition slope of PPE activity with pure A1AT with SlaaapN used as the 
substrate. The points show the mean results ± SEM. 
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2.6.2.4 Activities of pure NE and PR3 
The inhibition slopes of NE and PR3 activities by pure A1AT are shown in Figures 2.6 
and 2.7. Extrapolation of the slopes demonstrates that the pure A1AT inhibited NE at a 
molar ratio of 0.87:1 and PR3 at a molar ratio of 0.85:1. Therefore, the NE and PR3 were 
87% and 85% active respectively. These results were used for all subsequent experiments. 
 
Figure 2.6- Inhibition of NE by pure A1AT (SlaaapN) 
 
Figure 2.6: Inhibition of NE activity with pure A1AT with SlaaapN used as the 
substrate. Each point shows the mean result from three experiments. The SEM was 
small and fell within the points plotted. 
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Figure 2.7- Inhibition of PR3 by pure A1AT (MSaapvN) 
 
Figure 2.7: Inhibition of PR3 activity with pure A1AT with MSaapvN used as the 
substrate. Each point shows the mean result from three experiments. The SEM was 
small and fell within the points plotted. 
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The experiments described in this thesis depend on using proteins of known activity, rather 
than known concentration. Lineweaver-Burk double reciprocal plot analysis was used as 
the standard for determining PPE activity and these results were confirmed by using A1AT 
in PiMM plasma where most of the A1AT is functional. The methods for determining the 
activities of pure A1AT, NE and PR3 are summarised in Figure 2.8. 
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Enzyme activity can be influenced by many factors including salt concentration, 
temperature, pH and freeze/thaw cycles. For these reasons, experimental conditions were 
kept consistent throughout and fresh aliquots of enzyme were used for all experiments. 
 
The baseline experiments described here were repeated at regular time intervals to ensure 
consistency of results. All concentrations referred to in subsequent chapters represent the 
active protein concentration unless otherwise stated. 
 
Figure 2.8- Summary of active site titration experiments 
 
Figure 2.8: Series of experiments performed in order to determine the activities of 
enzymes and inhibitors used throughout this thesis. 
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2.7 Statistical analysis 
Statistical analyses were performed using PASW statistics 18 for Windows. Normality was 
tested using the Kolmogorov-Smirnov test. Parametric data are presented as mean 
±standard error of mean (SEM) and independent or paired T-tests were used for 
comparisons of data for independent or related measures respectively. Non-parametric data 
are presented as medians and inter-quartile ranges (IQR). Mann-Whitney U tests or 
Wilcoxon signed rank tests were used for comparisons of independent or related data 
respectively. Correlations were assessed using Spearman’s rank correlation coefficient. 
Results were deemed statistically significant if p≤0.05. 
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3 The ability of serum samples to inhibit proteinase 
activity  
3.1 Introduction 
Excessive proteolytic activity of NSPs is associated with tissue damage in COPD [100]. 
The major serum inhibitors of NE and PR3 are A1AT and A2M which differ in their 
mechanism of inhibition. Complex formation between A1AT and NSPs results in the 
enzyme being inactivated. However, the inhibitory mechanism of A2M is predominantly 
by steric hindrance and NE that is bound to A2M retains its proteolytic activity towards 
low molecular weight nitroanilide substrates [252]. The proteolytic potential of PR3 
complexes with A2M has not been previously studied. In this Chapter, serum samples 
from subjects with different A1AT genotypes have been used to assess how NE and PR3 
partition between these two serum inhibitors in the presence of different A1AT variants, 
and any resultant effects on their activities. 
 
3.2 Methods 
3.2.1 SlaaapN assays 
3.2.1.1 Inhibition of NE with serum from various A1AT genotypes 
Pure NE of pre-determined activity was diluted in NE assay buffer to 1.5µM active 
enzyme. Serum samples from subjects with various A1AT genotypes (PiMM, PiSZ, PiFZ 
and PiZZ) were taken and the A1AT concentration was measured by ELISA as described 
in section 2.6.1.2. Each serum sample was then diluted in NE assay buffer so that the 
concentration of A1AT was 1.5µM. Ten µL of NE was added to a 96-well plate (Costar, 
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USA) in triplicate sets and increasing volumes of serum were then added to each set of 
wells. Each experimental set had an appropriate control containing no NE, but containing 
all other components including diluted serum. This was important because the inherent 
colour of diluted serum affects the OD. All wells were made up to 110µL with NE assay 
buffer, and the plate was covered and incubated with gentle shaking at 37ºC for 20 minutes 
to allow the NE to form complexes with the serum inhibitors. Residual activity was 
measured by adding 100µL of the NE specific substrate SlaaapN at a concentration of 
1mg/ml in NE assay buffer. The absorbance at 410nm was read at 5 minute intervals up to 
60 minutes using a Biotek Synergy HT plate reader at 37ºC. Average results were taken 
for all triplicates and control values were subtracted. Inhibition slopes were constructed by 
plotting the percentage of remaining enzyme activity against the molar ratio of A1AT:NE. 
Each experiment was performed in triplicate to ensure consistency. 
 
These experiments were also performed once in the presence of EDTA (Sigma, UK) at a 
final concentration of 5mM (an inhibitor of MMPs) and E-64 (Sigma, UK) at a final 
concentration of 10µM (an inhibitor of cysteine proteinases) to ensure that measured 
enzyme activity could not be attributable to other classes of proteinase. The experiments 
were also repeated once in NSP assay buffer (at a physiological pH of 7.4) rather than NE 
assay buffer (pH 8.6) to determine whether this change in pH would influence the pattern 
of results. 
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3.2.2 MSaapvN assays 
3.2.2.1 Inhibition of NE with serum from various A1AT genotypes 
These experiments were performed using NSP assay buffer to facilitate comparison of 
results between NE and PR3 assays. MSaapvN was made at a concentration of 0.2mg/ml 
in this buffer. Initially, it was necessary to determine the optimal concentration of NE for 
these experiments due to different kinetic parameters between SlaaapN and MSaapvN 
(Table 2.2). A range of NE concentrations were made (0.03-1.5µM) and 10µL of NE was 
added to each well of a 96 well plate. MSaapvN (150µL) was added to each well and the 
absorbance at 410nm was read at 5 minute intervals up to 60 minutes using a Biotek 
Synergy HT plate reader at 37ºC. The OD was plotted against time, and the optimal 
concentration of NE was selected where the graph remained linear, indicating that the 
reaction was not limited by [S]. Subsequent experiments were performed using this 
concentration of NE with this substrate. 
 
It was also necessary to establish whether any other proteinases in the serum samples 
could affect the results, since MSaapvN is not specific for NE. To do this, 20µL of each 
diluted serum sample was added to a 96 well plate and 150µL of MSaapvN was added. 
The OD was measured as described above and plotted against time. 
 
The NE inhibition assays were performed in a similar manner to the SlaaapN assays with 
the following exceptions; NE was diluted to 0.1µM, serum samples were diluted so that 
the concentration of A1AT was 0.1µM, NSP assay buffer was used, and 150µL of 
MSaapvN was used at a concentration of 0.2mg/ml. 
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3.2.2.2  Inhibition of PR3 with serum from various A1AT genotypes 
These experiments were carried out as described in section 2.6.1.4 for pure A1AT, except 
diluted serum samples were used with an A1AT concentration of 1.5µM. Briefly, 10µL of 
1.5µM active PR3 was added to a 96-well plate in triplicate sets. Increasing volumes (0-
16µL) of diluted serum (A1AT concentration 1.5µM) were added to each triplicate set and 
the total volume of each well was made up to 110µL with NSP assay buffer. Control wells 
for each triplicate set contained all components except for the PR3. An extra 10µL of 
buffer was added to control wells to ensure that the volumes were equal. The plate was 
covered and incubated with gentle shaking at 37ºC for 20 minutes to allow the PR3 to 
form complexes with the serum inhibitors. Residual PR3 activity was measured by adding 
150µL of MSaapvN at a concentration of 0.2mg/ml in NSP assay buffer. The absorbance 
at 410nm was read at 5 minute intervals up to 60 minutes using a Biotek Synergy HT plate 
reader at 37ºC. Mean results were taken of all triplicates and control values were 
subtracted. Inhibition slopes were constructed by plotting the percentage of remaining 
enzyme activity against the molar ratio of A1AT:PR3. 
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3.3 Results 
3.3.1 A1AT ELISA 
The A1AT concentrations (measured by ELISA) of the serum samples used throughout 
this thesis are shown in Table 3.1. Values are consistent with published ranges [145]. 
 
Table 3.1- A1AT concentrations in serum of different A1AT genotypes 
A1AT genotype Serum A1AT concentration (µM) 
PiMM 30.3 
PiMZ 19.8 
PiSZ 16.2 
PiSS 14.4 
PiFZ 21.6 
PiFM 35.2 
PiIZ 16.6 
PiZZ 4.3 
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3.3.2 SlaaapN assays 
3.3.2.1 Inhibition of NE with PiMM serum 
The inhibition slope of NE with PiMM serum is shown in Figure 3.1. For comparison, the 
inhibition slope of NE with pure A1AT is also shown. The results show that pure A1AT 
fully inactivated NE when the molar ratio of A1AT:NE exceeded 1:1, as would be 
expected. PiMM serum also inhibited NE activity in a linear fashion until the molar ratio 
of A1AT:NE reached 1:1. However, when the A1AT in PiMM serum was in a molar 
excess of NE, 17.1 ± 0.1% (mean ± SEM) residual NE activity was still observed, 
suggesting that PiMM serum did not completely inactivate NE even when the main 
inhibitor A1AT was in a molar excess. Possible reasons for this finding are discussed in 
section 3.4 (Discussion). 
 
  
 73 
 
Figure 3.1- Inhibition assays of NE with PiMM serum and pure A1AT (SlaaapN) 
 
 
Figure 3.1: Inhibition assays of NE activity with PiMM serum and pure A1AT. Points 
show the mean values and the SEM falls within the symbol for most of these data 
points. 
 
0
20
40
60
80
100
120
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
%
 A
ct
iv
it
y 
N
E 
Molar ratio A1AT:NE 
NE inhibition with PiMM serum 
0
20
40
60
80
100
120
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
%
 A
ct
iv
it
y 
N
E 
Molar ratio A1AT:NE 
NE inhibition with pure A1AT 
 74 
 
3.3.2.2 Inhibition of NE with PiSZ serum 
The inhibition slope of NE with PiSZ serum is shown in Figure 3.2. Initially, NE activity 
was increasingly inhibited by PiSZ serum as the molar ratio of A1AT:NE approached 1:1. 
However, even when the A1AT in the serum was in a molar excess of the NE, residual NE 
activity remained at 60.6 ± 1.0% which was greater than the residual NE activity observed 
with PiMM serum. 
 
Figure 3.2-Inhibition of NE with PiSZ serum (SlaaapN) 
 
Figure 3.2: Inhibition of NE activity with PiSZ serum using SlaaapN as the substrate. 
Points show the mean values and the SEM falls within the points plotted. 
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3.3.2.3 Inhibition of NE with PiFZ serum 
The inhibition slope of NE with PiFZ serum is shown in Figure 3.3. As observed with 
PiSZ serum (Figure 3.2), PiFZ serum also did not fully inactivate NE when the serum 
A1AT was in a molar excess, and 56.0 ± 0.5% residual NE activity was observed. 
 
Figure 3.3-Inhibition of NE with PiFZ serum (SlaaapN) 
 
Figure 3.3: Inhibition of NE activity with PiFZ serum using SlaaapN as the substrate. 
Points show the mean values and the SEM falls within the points plotted. 
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3.3.2.4 Inhibition of NE with PiZZ serum 
The inhibition slope of NE with PiZZ serum is shown in Figure 3.4. These results were 
different to those observed with PiMM, PiSZ and PiFZ sera. Initially, inhibition of NE 
activity was observed, but as the molar ratio of A1AT:NE increased, enhanced NE activity 
was seen above that measured with NE alone. This experiment was therefore repeated in 
the presence of inhibitors of MMPs and cysteine proteinases (Figure 3.6) to establish 
whether this effect could be attributable to other classes of proteinases, and the experiment 
was also performed at a different pH to determine whether pH changes could influence the 
results (Figure 3.7). 
 
Figure 3.4-Inhibition of NE with PiZZ serum (SlaaapN) 
 
Figure 3.4: Inhibition of NE activity with PiZZ serum using SlaaapN as the substrate. 
Points show the mean values and the SEM falls mostly within the points plotted. 
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3.3.2.5 Summary of SlaaapN assays 
Figure 3.5 shows a summary of the NE inhibition slopes described above. These results 
have used pure A1AT or serum samples from different A1AT genotypes as the inhibitors, 
and SlaaapN as the substrate. Table 3.2 summarises the amount of residual NE activity 
observed when the different serum samples were used and the A1AT was in a molar 
excess. The molar ratio of serum A2M to NE is also shown for the different serum 
samples. Lower serum concentrations of A1AT were associated with a greater molar ratio 
of A2M:NE and also greater residual NE activity when A1AT was in a molar excess. 
 
Figure 3.5- Comparison of NE inhibition slopes with pure A1AT and serum samples from 
different A1AT genotypes (SlaaapN) 
 
Figure 3.5: A comparison of inhibition slopes of NE activity with pure A1AT and 
PiMM, PiSZ, PiFZ and PiZZ sera. SlaaapN was used as the substrate for these 
experiments. 
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Table 3.2- Residual NE activity observed when serum samples from different A1AT 
genotypes were used and the A1AT was in a molar excess (SlaaapN) 
A1AT 
genotype 
Residual NE activity observed 
when A1AT was in a molar excess 
Molar ratio of A2M:NE when 
the ratio of A1AT:NE was 1:1 
PiMM 17.1 ± 0.1% 0.09:1 
PiFZ 56.0 ± 0.5% 0.12:1 
PiSZ 60.6 ± 1.0% 0.16:1 
PiZZ 111.2 ± 0.7% 0.60:1 
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3.3.2.6 Inhibition of NE with PiMM or PiZZ serum in the presence of EDTA & E-64 
The inhibition slopes of NE with PiMM or PiZZ serum in the presence of the MMP and 
cysteine proteinase inhibitors are shown in Figure 3.6. The enhanced activity of NE with 
increasing volumes of PiZZ serum was still observed. 
 
Figure 3.6- Inhibition of NE with PiMM or PiZZ serum in the presence of EDTA & E-64 
(SlaaapN) 
 
Figure 3.6: Inhibition of NE activity with PiMM or PiZZ serum in the presence of 
inhibitors of MMPs and cysteine proteinases. SlaaapN was used as the substrate. The 
results of single experiments for each serum sample are shown. 
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3.3.2.7 Inhibition of NE with PiMM or PiZZ serum in NSP assay buffer (pH 7.4) 
The inhibition slopes of NE with PiMM or PiZZ serum in NSP assay buffer are shown in 
Figure 3.7. The pattern of results was not significantly different to those obtained using NE 
assay buffer and the enhanced activity of NE with increasing volumes of PiZZ serum was 
still observed. 
 
Figure 3.7- Inhibition of NE with PiMM or PiZZ serum in NSP assay buffer (SlaaapN) 
 
Figure 3.7: Inhibition of NE activity by PiMM or PiZZ serum in a buffer with a 
physiological pH of 7.4. SlaaapN was used as the substrate. The results of single 
experiments for each serum sample are shown. 
 
3.3.3 MSaapvN assays 
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since MSaapvN is not a specific substrate and is hydrolysed by more than one proteinase. 
Data was then collected following these optimisation experiments. 
 
3.3.3.1 Determining the optimal concentration of NE for MSaapvN assays 
The optimal concentration of NE which produced a reasonable change in OD at 60 
minutes was found to be 0.1µM. At this concentration, the graph remained linear 
throughout the time course used, indicating that the reaction was not limited by [S]. These 
results are shown in Figure 3.8. 
 
Figure 3.8- Determination of the optimal concentration of NE for MSaapvN experiments 
 
Figure 3.8: The optimal concentration of NE for MSaapvN assays was 0.1µM. At this 
concentration, the slope remained linear throughout the time course used indicating 
that the reaction was not limited by [S], and an acceptable change in absorbance was 
observed over this time course. The results from a single experiment are shown. 
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3.3.3.2 Determining the suitability of MSaapvN for use with serum samples 
When MSaapvN was added to the diluted serum samples to be used in subsequent 
experiments, there was no change in OD over the time course of the experiments. These 
results showed that there was no detectable free proteinase activity in the serum samples 
that could affect the results of the NE and PR3 inhibition assays. The results from a single 
experiment using PiMM serum are shown in Figure 3.9. The results were similar for other 
A1AT genotype serum samples (data not shown). 
 
Figure 3.9-Determining the change in OD over time using PiMM serum and MSaapvN 
 
Figure 3.9: When MSaapvN was added to diluted PiMM serum there was no change 
in absorbance noted over the time course of the experiment, indicating that no other 
proteinases in the serum could interfere with the serine proteinase assays. The results 
from a single experiment are shown. 
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3.3.3.3 Inhibition of NE and PR3 with PiMM serum 
The inhibition slopes of NE and PR3 with PiMM serum are shown in Figure 3.10. For 
comparison, the inhibition slope of PR3 with pure A1AT is also shown. The results show 
that pure A1AT fully inactivated PR3 when the molar ratio of A1AT:PR3 exceeded 1:1, as 
would be expected. PiMM serum was initially able to inhibit NE or PR3 activity in a linear 
pattern as the molar ratio of A1AT to the enzyme increased. Experiments were performed 
separately for each proteinase but the results are presented together for comparison. When 
the A1AT in PiMM serum was in a molar excess, 5.4 ± 1.1% residual NE activity 
remained and 7.7 ± 0.8% residual PR3 activity remained, suggesting that PiMM serum 
was not able to fully inactivate either NE or PR3 even when the predominant inhibitor 
A1AT was in a molar excess of the enzyme. The inhibition assays using PiMM serum and 
NE or PR3 were similar to each other. The residual NE activity observed was less when 
MSaapvN was used as the substrate than when SlaaapN was used (Figure 3.1). 
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Figure 3.10-Inhibition assays of NE and PR3 with PiMM serum and PR3 with pure A1AT 
(MSaapvN) 
 
 
Figure 3.10: Inhibition of NE and PR3 activities by PiMM serum with MSaapvN as 
the substrate. Individual experiments were performed using a single proteinase and 
the data for NE and PR3 are presented together for comparison. The points show the 
mean ± SEM. The inhibition slope of PR3 with pure A1AT is also shown for 
comparison. 
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3.3.3.4 Inhibition of NE and PR3 with PiSZ serum 
The inhibition slopes of NE and PR3 with PiSZ serum are shown in Figure 3.11. The 
results show that NE or PR3 were both initially inhibited by PiSZ serum as the molar ratio 
of A1AT to the enzyme increased but neither enzyme was fully inactivated by PiSZ serum 
even when A1AT was in a molar excess. Separate experiments were performed for each 
proteinase but the results are presented together for comparison. The residual activities for 
NE and PR3 were 13.6 ± 1.2% and 18.2 ± 0.7% respectively. 
 
Figure 3.11- Inhibition of NE and PR3 with PiSZ serum (MSaapvN) 
 
Figure 3.11: Inhibition of NE and PR3 activities by PiSZ serum with MSaapvN as the 
substrate. Single experiments were performed for each proteinase and the data for 
NE and PR3 are presented together for comparison. 
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3.3.3.5 Inhibition of NE and PR3 with PiFZ serum 
The inhibition slopes of NE and PR3 with PiFZ serum are shown in Figure 3.12. The 
initial linear portion of the slope shows that PiFZ serum was able to inhibit NE and PR3 as 
the molar ratio of serum A1AT to the enzyme increased. However, residual NE activity at 
56.4 ± 0.5% was observed which was greater than the 36.8 ± 0.3% residual PR3 activity. 
 
Figure 3.12- Inhibition of NE and PR3 with PiFZ serum (MSaapvN) 
 
Figure 3.12: Inhibition of NE and PR3 activities by PiFZ serum with MSaapvN as the 
substrate. Individual experiments were performed for each proteinase and the data 
for NE and PR3 are presented together for comparison. 
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3.3.3.6 Inhibition of NE and PR3 with PiFM serum 
The inhibition slopes of NE and PR3 with PiFM serum are shown in Figure 3.13. Again, 
the initial linear portion of the slope shows that PiFM serum was able to inhibit NE and 
PR3 as the molar ratio of serum A1AT to the enzyme increased. However, residual NE 
activity at 41.9 ± 1.6% was observed which was greater than the 9.6 ± 0.6% residual PR3 
activity. Experiments with each proteinase were performed separately but the data are 
presented together for comparison. 
 
Figure 3.13- Inhibition of NE and PR3 with PiFM serum (MSaapvN) 
 
Figure 3.13: Inhibition of NE and PR3 activities by PiFM serum with MSaapvN as 
the substrate. Individual experiments were performed for each proteinase and the 
data for NE and PR3 are presented together for comparison. 
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3.3.3.7 Inhibition of NE and PR3 with PiIZ serum 
The inhibition slopes of NE and PR3 with PiIZ serum are shown in Figure 3.14. The 
residual activity of NE (when the serum A1AT was in a molar excess of the enzyme) was 
greater than the residual activity observed with PR3 (47.8 ± 1.4% vs 19.5 ± 1.0%). 
 
Figure 3.14- Inhibition of NE and PR3 with PiIZ serum (MSaapvN) 
 
Figure 3.14: Inhibition of NE and PR3 activities by PiIZ serum with MSaapvN as the 
substrate. Individual experiments were performed for each proteinase and the data 
for NE and PR3 are presented together for comparison. 
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3.3.3.8 Inhibition of NE and PR3 with PiZZ serum 
The inhibition slopes of NE and PR3 with PiZZ serum are shown in Figure 3.15. The 
initial linear portion of the slopes shows that PiZZ serum increasingly inhibited NE and 
PR3 activities as the molar ratio of serum A1AT to enzyme increased. However, PiZZ 
serum did not fully inactivate NE or PR3 even when the serum A1AT was in a molar 
excess and the residual activities were 35.7 ± 0.5% for NE and 44.2 ± 0.8% for PR3. 
Unlike the PiZZ serum experiments using SlaaapN as the substrate (Figure 3.4), no 
enhancement of enzyme activity (above that measured with free enzyme) was observed 
with this substrate. 
 
Figure 3.15- Inhibition of NE and PR3 with PiZZ serum (MSaapvN) 
 
Figure 3.15: Inhibition of NE and PR3 activities by PiZZ serum with MSaapvN as the 
substrate. Individual experiments were performed using a single proteinase and the 
data for NE and PR3 are presented together for comparison. The points show the 
mean of 3 experiments ± SEM. 
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3.3.3.9 Summary of MSaapvN assays 
Table 3.3 summarises the residual NE and PR3 activities observed when the different 
serum samples were used and the A1AT was in a molar excess. 
 
Table 3.3- Residual NE and PR3 activities observed when serum samples from 
different A1AT genotypes were used and the A1AT was in a molar excess (MSaapvN) 
A1AT 
genotype 
Residual NE activity observed 
when A1AT was in a molar excess. 
Residual PR3 activity observed 
when A1AT was in a molar excess. 
PiMM 5.4 ± 1.1% 7.7 ± 0.8% 
PiSZ 13.6 ± 1.2% 18.2 ± 0.7% 
PiFZ 56.4 ± 0.5% 36.8 ± 0.3% 
PiFM 41.9 ± 1.6% 9.6 ± 0.6% 
PiIZ 47.8 ± 1.4% 19.5 ± 1.0% 
PiZZ 35.7 ± 0.5% 44.2 ± 0.8% 
 
3.4 Discussion 
The NE inhibition assays using SlaaapN as the substrate presented in this Chapter have 
given differing results. As shown in Figure 3.1, pure A1AT completely inactivated NE 
when the molar ratio of A1AT:NE exceeded 1:1, as expected. However, this was not the 
case with PiMM serum which increasingly inhibited NE activity as the molar ratio of 
A1AT:NE approached 1:1, but when A1AT was in a molar excess of NE, 17.1 ± 0.1% 
residual NE activity was still observed. This suggests that PiMM serum could not 
 91 
 
completely inactivate NE even when the main inhibitor A1AT was in a molar excess. 
When partially A1AT deficient (PiSZ) serum was used to inhibit NE, the activity of NE 
decreased initially as the molar ratio of A1AT:NE increased (Figure 3.2). However, NE 
activity was inhibited less effectively than with PiMM serum, and when A1AT was in a 
molar excess, 60.6 ± 1.0% NE activity remained. Figure 3.3 shows that the results were 
similar when PiFZ serum was used, with 56.0 ± 0.5% of the NE activity remaining. These 
results indicate a failure of serum to completely inactivate NE and most likely reflect 
ongoing activity of NE bound to A2M. Binding of NE to A2M does not involve direct 
interaction with the enzyme’s active site, and animal studies have shown that A2M:NE 
complexes retain proteolytic potential whereas A1AT:NE complexes do not [201]. The 
results obtained could have clinical significance. Indeed, active A2M:NE complexes have 
been implicated in the pathogenesis of emphysema in animal models [201]. Other studies 
have shown that A2M:NE complexes may also play a role in the adult respiratory distress 
syndrome in humans [253], and the degradation of cartilage matrix in rheumatoid arthritis 
[254]. These concepts are explored further in Chapters 4 and 5. 
 
The NE inhibition assays using SlaaapN as the substrate and PiZZ serum as the inhibitor 
gave different results to those described above. Figure 3.4 shows that PiZZ serum initially 
inhibited NE activity, but as the ratio of A1AT:NE increased and greater volumes of serum 
were added, enhanced activity of NE was detected (>100% of that seen with free NE). 
This result was consistently obtained and was believed to be correct for several reasons. 
Firstly, the result could not be due to an artefact relating to the inherent colour of the 
serum interfering with the OD measurements because the control wells contained the same 
volume of diluted serum. Secondly, for the same reasons, the results could not be due to 
free NE activity in the serum samples. Thirdly, Figure 3.6 shows that the effect was not 
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due to the activity of another class of proteinase, since the same effect was seen in the 
presence of inhibitors of MMPs and cysteine proteinases. In addition, Figure 3.7 shows 
that the effect was not due to experimental changes in pH, since the same effect was seen 
when the experiment was performed at a physiological pH of 7.4. Overall, the enhanced 
activity is likely to result from NE bound to A2M. Previous authors have reported 
enhanced activity of NE bound to A2M compared to free NE when using small peptide 
substrates such as SlaaapN [255]. These interactions between NE and A2M are discussed 
further in Chapter 4. 
 
PR3 activity was also not completely inhibited by PiMM serum (Figure 3.10) even when 
A1AT was in a molar excess (7.7 ± 0.8% of PR3 activity remained), whereas pure A1AT 
completely inactivated PR3 as expected. When PiSZ serum was used as an inhibitor of 
PR3, Figure 3.11 shows that initially its activity decreased as the molar ratio of A1AT:PR3 
increased, but total inhibition of PR3 activity was less efficient than with PiMM serum, 
and 18.2 ± 0.7% residual PR3 activity was observed when the A1AT was in a molar 
excess. When PiZZ serum was used, the residual activity of PR3 was 44.2 ± 0.8% (Figure 
3.15). This pattern of results was similar to that of NE, and again most likely reflects 
ongoing activity of PR3 bound to A2M in the serum samples. The proteolytic activity of 
PR3 complexes with A2M has not been explored previously, but may have clinical 
significance particularly since PR3 has a lower Kass for M type A1AT compared to NE 
[117]. Therefore in situations where the concentration of A1AT is inadequate to inhibit 
both proteinases, NE would be preferentially inhibited by A1AT, and PR3 may be more 
likely to form a complex with A2M. This scenario could be even more relevant in 
situations where A1AT is deficient or dysfunctional. 
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When PiFZ, PiFM or PiIZ sera (Figures 3.12, 3.13 and 3.14 respectively) were used to 
inhibit NSP activities, the baseline activities of NE (when the A1AT was in a molar 
excess) were greater than that of PR3. The partitioning of proteinases between their 
inhibitors is influenced by the differences in their rates of association and their 
concentrations. The association rate constants of A1AT variants and NSPs are discussed 
further in Chapter 6. However, these factors are unlikely to fully explain the differences 
observed because the residual NE activities when PiFZ, PiFM or PiIZ sera were used were 
greater than that observed with PiZZ serum, in addition to being greater than PR3 
activities. The exact reasons for these findings remain uncertain, but several hypotheses 
will be discussed. Firstly, it is possible that the A1AT:NE complexes formed by F or I 
variant A1AT can dissociate in the presence of A2M resulting in the transfer of the 
enzyme from A1AT to A2M. This phenomenon has previously been described by Ohlsson 
[256] using trypsin in dog serum, and Meyer et al [257] using PPE in the presence of the 
two inhibitors. Secondly, it could be hypothesized that F or I variant A1AT may be 
proteolytically inactivated to some degree by NE during the interaction (the “substrate 
pathway”), resulting in inactivated A1AT and free NE (which could then bind to A2M). 
Further studies into the function of F and I variants of A1AT and the stability of their 
complexes with NE are therefore necessary. 
 
The inhibition assays of NE with PiZZ serum (Figures 3.4 and 3.15) demonstrated 
differing interactions between enzymes and their substrates. When SlaaapN was used as 
the substrate, an enhancement of NE activity was observed in the presence of higher 
volumes of serum, consistent with enhanced activity of NE bound to A2M compared to 
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activity of free NE. However, this enhancement of NE activity was not seen when 
MSaapvN was used as the substrate. Twumasi et al [255] previously demonstrated that the 
degree of activation of NE bound to A2M varied depending on the synthetic peptide 
substrate used, and varied from little or no activation to 15-fold activation. Interestingly, 
they also showed that the activity of PPE towards SlaaapN was inhibited by human A2M, 
thus highlighting species differences in enzyme inhibition and kinetics towards synthetic 
peptide substrates, and reinforcing the observation that results from animal studies should 
be interpreted with caution when considering human disease. 
 
The partitioning of NSPs between their serum inhibitors is dependent on several factors 
including local concentrations of inhibitors and their functional activities. Mutant variants 
of A1AT have different rates of association with NSPs (as discussed further in Chapter 6) 
which affect their anti-proteinase capabilities. In addition, mutant variants of A1AT are 
susceptible to conformational transitions which may further reduce the levels of functional 
proteinase inhibitor in vivo. For example, the formation of loop sheet polymers reduces the 
anti-proteinase capabilities of mutant variants of A1AT beyond that expected for the 
reduced concentration and Kass. Other conformational transitions of mutant variants of 
A1AT which may affect their anti-proteinase function include the formation of unstable 
intermediates and latent A1AT (as shown in Figure 1.6), or cleaved A1AT following its 
interaction with NSPs. To gain further insight into the relative importance of these factors 
affecting the anti-proteinase capacity of A1AT, PiMZ serum could be studied in future 
experiments. In PiMZ heterozygotes, the serum A1AT concentration is within the same 
range as that for PiFZ and PiIZ heterozygotes, but the M variant is less susceptible to 
conformational transitions. Therefore, studying the partitioning of NSPs in PiMZ serum 
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would assist in determining the relative importance of A1AT concentration against other 
factors (described above) that influence its anti-proteinase capability. 
 
This Chapter has studied how NE and PR3 partition between their two serum inhibitors in 
the presence of different A1AT variants, and has suggested that proteinases bound to A2M 
are not inactivated and retain their proteolytic potential. Further studies to consolidate 
these findings are discussed in Chapter 4 when pure A1AT and A2M are used in 
equivalent concentrations to those found in serum samples with different A1AT genotypes. 
The physiological relevance of active proteinases bound to A2M is then explored in 
Chapter 5 when elastin is used as a biologically relevant substrate. 
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4 Interactions of serine proteinases with A2M 
4.1 Introduction 
Results from Chapter 3 have suggested that both NE and PR3 retain their proteolytic 
activities towards synthetic peptide substrates when bound to A2M. When NE or PR3 are 
added to serum, they partition between the two serum inhibitors A1AT and A2M 
depending on the local concentrations of inhibitors and their association rate constants as 
shown in Figure 4.1. In addition, the susceptibility of mutant variants of A1AT to form 
polymers or other conformations may further influence partitioning. 
 
The aim of this Chapter is to establish whether the residual activities of NE or PR3 
observed in Chapter 3 are due to binding to A2M, and not due to other features of the 
serum. This will be determined by using mixtures of pure A1AT and A2M in the 
concentrations found in serum samples, and comparing the results with those obtained in 
Chapter 3. 
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Figure 4.1- Partitioning of NSPs between their serum inhibitors 
 
Figure 4.1: When NE is released in the presence of serum, it will partition between 
the serum inhibitors A1AT and A2M. The amounts of NE:A1AT or NE:A2M 
complexes formed will be dependent on the concentrations of these inhibitors and 
their association rate constants (Kass). The same applies to PR3. 
 
4.2 Methods 
4.2.1 Inhibition of pure proteinases with pure A2M 
Pure A2M (Sigma, UK) was diluted in NE assay buffer at a concentration of 1mg/ml or 
1.38µM. This stock A2M was then aliquoted, rapidly frozen with liquid nitrogen and 
stored at -70ºC until required. Pure NE or PR3 were diluted to an active concentration of 
1.38µM, and 10µL of proteinase was added per well to a 96 well plate in triplicate sets 
with appropriate controls. Increasing volumes of A2M were added to each triplicate set, 
and all wells were made up to a total volume of 110µL with buffer. For NE experiments, 
NE assay buffer was used. For PR3 experiments, NSP assay buffer was used. The plate 
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was covered and incubated with gentle shaking at 37ºC for 20 minutes to allow the 
proteinases to form complexes with the A2M. The NE experiments were performed with 
both SlaaapN (100µL of 1mg/ml) and MSaapvN (150µL of 0.2mg/ml) as substrates. The 
PR3 experiments were performed with MSaapvN only. The absorbance at 410nm was read 
at 5 minute intervals up to 60 minutes using a Biotek Synergy HT plate reader at 37ºC. 
Mean results were taken of all triplicate sets and control values were subtracted. Inhibition 
slopes were constructed by plotting the percentage of remaining enzyme activity against 
the molar ratio of A2M:proteinase. 
 
4.2.2 A2M ELISA 
The A2M concentrations of serum samples were determined using a commercially 
available A2M ELISA kit (Universal Biologicals Cambridge, UK). Serum samples with 
the following A1AT genotypes were used; PiMM, PiMZ, PiFZ, PiFM and PiZZ. The 
ELISA used a quantitative competitive sandwich enzyme immunoassay technique to 
measure A2M and was performed at room temperature. A polyclonal antibody specific for 
human A2M was pre-coated onto a 96 well microplate. Serum samples were diluted 1 in 
400 in the diluent provided. Standards of pure human A2M were prepared by performing 
serial dilutions of the top standard (40µg/ml). Standards and samples (25µL) were added 
to the 96-well plate in triplicate, with the diluent being used as a blank for the assay. 
Immediately following this step, 25µL of biotinylated A2M was added to each well and 
mixed gently with the standard or sample. The plate was then covered and incubated for 
two hours. After incubation, the plate was washed six times with 300µL per well of the 
wash buffer provided using a labtech LT-3500 microplate washer. Next, 50µL of 
streptavidin-peroxidase conjugate was added to each well followed by a 30 minute 
incubation. The plate was washed as described above, and then 50µL of TMB substrate 
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was added to each well. The plate was incubated in the dark until a colour change occurred 
(approximately 10 minutes) and then 50µL of the stop solution (0.5N hydrochloric acid) 
was added to each well. The colour then changed from blue to yellow. The absorbance was 
read using a Biotek Synergy HT plate reader at 450nm with 570nm wavelength correction. 
The mean of the triplicate sets was calculated and a standard curve generated. The sample 
concentrations were determined from the standard curve and multiplied by the dilution 
factor. The minimum detectable level of A2M was 1µg/ml and the intra- and inter- assay 
CVs were 5% and 7.2% respectively. 
 
4.2.3 Inhibition of proteinases with mixtures of pure A2M and pure A1AT 
Using the values obtained from the A2M and A1AT ELISAs (section 2.6.1.2) for serum 
samples, mixtures of pure A2M and pure M variant A1AT were created in the same 
concentrations as would be found in some of the serum samples from Chapter 3 (PiMM, 
PiFZ and PiZZ). NE or PR3 were diluted to an active concentration of 1.5µM. The 
mixtures of pure inhibitors were diluted so that they contained 1.5µM of active A1AT. NE 
or PR3 (10µL) was added to a 96-well plate, and increasing volumes of the mixtures were 
added to the proteinases with appropriate controls. The total well volume was then made 
up to 110µL with buffer. For the NE experiments, NE assay buffer was used and for the 
PR3 experiments, NSP assay buffer was used. The proteinase and inhibitors mixtures were 
then incubated for 30 minutes with gentle shaking at 37ºC, followed by the addition of the 
substrate. The NE experiments were performed using either SlaaapN (100µL of 1mg/ml) 
or MSaapvN (150µL of 0.2mg/ml) as the substrate, and the PR3 experiments were 
performed using MSaapvN. The NE experiments using MSaapvN as the substrate were 
performed using NE and A1AT at active concentrations of 0.1µM. The absorbance at 
410nm was read at 5 minute intervals up to 60 minutes using a Biotek Synergy HT plate 
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reader at 37ºC. Control values were subtracted and inhibition slopes were constructed by 
plotting the percentage of remaining enzyme activity against the molar ratio of 
A1AT:proteinase. 
 
In addition, the above experiments were repeated using Z variant A1AT purified from 
human plasma instead of pure M A1AT. The pure Z A1AT was a kind gift from the 
research group of Professor Lomas at the University of Cambridge, UK, and was purified 
as described previously [258]. The Z A1AT was active site titrated against NE as described 
in section 2.6 and was found to be 54% active. Active concentrations of Z A1AT were 
used in these experiments. 
 
Purified variants of A1AT other than M and Z (for example, S or F variants) were not 
available for these experiments due to both time constraints and lack of availability of 
sufficient volumes of plasma for the purification process. Therefore, the experiments 
described in this Chapter were predominantly performed to assess the effects of altering 
the relative concentrations of A1AT and A2M on the partitioning of NSPs. The limitations 
of this approach are discussed further in section 4.4 (Discussion). 
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4.3 Results 
4.3.1 Inhibition of pure proteinases with pure A2M 
The relationship between NE activity and increasing volumes of pure A2M using SlaaapN 
as the substrate is shown in Figure 4.2. These results demonstrate that NE showed 
enhanced activity (compared to free NE) as the concentration of A2M increased. When 
MSaapvN was used as the substrate, A2M did not inhibit NE or PR3 activities up to a 
molar ratio of 1.4:1, but no enhancement of proteinase activity was observed. These results 
are shown in Figure 4.3. 
 
Figure 4.2-“Inhibition” of NE with pure A2M (SlaaapN) 
 
Figure 4.2: The relationship between NE activity and increasing amounts of A2M 
using SlaaapN as the substrate. The points show the mean values of 3 experiments 
and the SEM falls within the points plotted. 
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Figure 4.3- “Inhibition” of NE and PR3 with pure A2M (MSaapvN) 
 
Figure 4.3: NE and PR3 activities in the presence of increasing amounts of A2M 
using MSaapvN as the substrate. The results from individual experiments for each 
proteinase are shown, but data for NE and PR3 are shown together for comparison. 
 
4.3.2 A2M ELISA 
The serum A2M concentrations as measured by ELISA are shown in Table 4.1. The A1AT 
concentrations of these serum samples are also shown. A1AT was measured by ELISA as 
described in section 2.6.1.2. 
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Table 4.1- A2M concentrations in serum samples of different A1AT genotypes 
A1AT genotype Serum A1AT concentration (µM) Serum A2M concentration (g/L) 
PiMM 30.3 2.198 (3.0µM) 
PiMZ 19.8 1.827 (2.5µM) 
PiFZ 21.6 1.927 (2.7µM) 
PiFM 35.2 1.042 (1.4µM) 
PiZZ (1) 4.3 1.260 (1.7µM) 
PiZZ (2) 4.9 2.089 (2.9µM) 
 
4.3.3 Inhibition of proteinases with mixtures of pure A2M and pure A1AT 
4.3.3.1 Inhibition of NE with mixtures of pure A2M and pure M A1AT 
The inhibition slopes of NE activity using mixtures of pure A2M and pure M variant 
A1AT equivalent to the concentrations found in PiMM, PiFZ and PiZZ sera are shown in 
Figure 4.4, using SlaaapN as the substrate. The results show that NE was increasingly 
inhibited as the molar ratio of A1AT:NE increased up to a ratio of 1:1. However, NE 
activity was not completely inhibited in the presence of A2M, and the residual NE activity 
was greater with increasing proportional concentrations of A2M. Therefore, the residual 
NE activity was greatest when using the mixture of proteins equivalent to the relative 
proportions found in PiZZ serum (15.6% residual activity, Graph C), and least when using 
the mixture of proteins in the proportions found in PiMM serum (3.5% residual activity, 
Graph A). The residual NE activity observed when the A1AT was in a molar excess was 
intermediate when using the mixture of proteins equivalent to the proportions found in 
PiFZ serum (8.9% residual activity, Graph B). 
 
 104 
 
The results of similar experiments using MSaapvN as the substrate are shown in Figure 4.5 
and for comparison the inhibition slope of NE activity with pure M A1AT alone is also 
shown. These results show that NE activity was fully inhibited by pure M A1AT alone 
(Graph D), as expected. However, NE activity was not fully inhibited when A2M was 
present. The residual NE activity observed when A1AT was in a molar excess was greatest 
when using the mixture of proteins in the proportions found in PiZZ serum (4.5% residual 
activity, Graph C), and least when using the mixture of proteins in the proportions found in 
PiMM serum (0.9% residual activity, Graph A). The residual NE activity was intermediate 
when using the mixture of proteins equivalent to the proportions found in PiFZ serum 
(1.7% residual activity, Graph B). 
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Figure 4.4 (A-C)- Inhibition of NE activity with mixtures of A2M and M A1AT in 
proportions equivalent to PiMM, PiFZ and PiZZ sera (SlaaapN) 
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Figure 4.4 (A-C): Inhibition of NE activity using mixtures of M variant A1AT and 
A2M equivalent to proportions found in PiMM, PiFZ and PiZZ sera. SlaaapN was 
used as the substrate for these experiments. The results from single experiments are 
shown. 
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Figure 4.5 (A-D)- Inhibition of NE activity with mixtures of A2M and M A1AT in 
proportions equivalent to PiMM, PiFZ and PiZZ sera, and with pure M A1AT (MSaapvN) 
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Figure 4.5 (A-D): Inhibition of NE activity using mixtures of M variant A1AT and 
A2M equivalent to proportions found in PiMM, PiFZ and PiZZ sera. Graph D shows 
inhibition of NE activity with pure M A1AT. MSaapvN was used as the substrate for 
these experiments. The results from single experiments are shown. The residual 
activities of NE when A1AT was in a molar excess were as follows; Graph A 0.9%, 
Graph B 1.7%, Graph C 4.5% and Graph D 0%. 
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4.3.3.2 Inhibition of PR3 with mixtures of pure A2M and pure M A1AT 
The inhibition slopes of PR3 activity using mixtures of pure A2M and pure M variant 
A1AT equivalent to proportions found in PiMM, PiFZ and PiZZ sera are shown in Figure 
4.6, and MSaapvN was used as the substrate for these experiments. The results show that 
PR3 activity was increasingly inhibited as the molar ratio of A1AT:PR3 increased up to 
1:1, but when A1AT was in a molar excess, PR3 activity was not fully inhibited in the 
presence of A2M. The residual PR3 activity observed when the A1AT was in a molar 
excess was similar for the mixtures of proteins equivalent to the proportions found in 
PiMM (Graph A), PiFZ (Graph B) and PiZZ (Graph C) sera at around 5%. 
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Figure 4.6 (A-C)- Inhibition of PR3 activity with mixtures of A2M and M A1AT in 
proportions equivalent to PiMM, PiFZ and PiZZ sera (MSaapvN) 
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Figure 4.6 (A-C): Inhibition of PR3 activity using mixtures of M variant A1AT and 
A2M equivalent to proportions found in PiMM, PiFZ and PiZZ sera. MSaapvN was 
used as the substrate for these experiments. The results from single experiments are 
shown. The residual activities of PR3 when A1AT was in molar excess were similar in 
Graphs A, B and C at around 5%. 
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4.3.3.3 Inhibition of NE with mixtures of pure A2M and pure Z A1AT 
The inhibition slopes of NE activity with mixtures of pure A2M and pure Z variant A1AT 
equivalent to the proportions of inhibitors found in PiMM, PiFZ and PiZZ sera are shown 
in Figure 4.7 and SlaaapN was used as the substrate for these experiments. The results 
show that NE activity was increasingly inhibited as the molar ratio of Z A1AT:NE 
increased up to 1:1, but again, NE was not fully inhibited in the presence of A2M. The 
residual NE activity when the Z A1AT was in a molar excess was greater as the 
concentration of A2M increased. Therefore, the mixture of inhibitors equivalent to the 
proportions found in PiZZ serum had the greatest residual NE activity (18.3%, Graph C) 
and the mixture of inhibitors equivalent to the proportions found in PiMM serum had the 
least (4.9%, Graph A), with the mixture of inhibitors equivalent to proportions found in 
PiFZ serum being intermediate (9.0%, Graph B). The experiment using pure Z A1AT and 
pure A2M in the proportions equivalent to PiZZ serum did not replicate the earlier results 
using serum (Figure 3.4) and no enhancement of NE activity (above that of free NE) was 
observed, as had been observed with PiZZ serum. 
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Figure 4.7 (A-C)- Inhibition of NE activity with mixtures of A2M and Z A1AT in 
proportions equivalent to PiMM, PiFZ and PiZZ sera (SlaaapN) 
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Figure 4.7 (A-C): Inhibition of NE activity using mixtures of Z variant A1AT and 
A2M in proportions equivalent to those found in PiMM, PiFZ and PiZZ sera. 
SlaaapN was used as the substrate and results from single experiments are shown. 
The baseline activities of NE when Z A1AT was in a molar excess were as follows; 
Graph A 4.9%, Graph B 9.0% and Graph C 18.3%. 
 
4.3.3.4 Inhibition of PR3 with mixtures of pure A2M and pure Z A1AT 
The inhibition slopes of PR3 activity using mixtures of pure A2M and pure Z variant 
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Figure 4.8 (A-C)- Inhibition of PR3 activity with mixtures of A2M and Z A1AT in 
proportions equivalent to PiMM, PiFZ and PiZZ sera (MSaapvN) 
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Figure 4.8 (A-C): Inhibition of PR3 activity using mixtures of Z variant A1AT and 
A2M in proportions equivalent to those found in PiMM, PiFZ and PiZZ sera. 
MSaapvN was used as the substrate and results from single experiments are shown. 
The residual activities of PR3 when Z A1AT was in molar excess were similar in 
Graphs A, B and C at around 5%. 
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affinity of the enzyme for the substrate, was not affected by A2M despite the marked 
enhancement in the catalytic efficiency of the enzyme as measured by Kcat. They 
hypothesized that the conformational change in A2M during entrapment of the enzyme 
uncovers a hydrophobic cavity which, in conjunction with a positively charged group, 
orientates the substrate into a position which is more favourable for the enzyme. Figure 4.3 
demonstrates that when MSaapvN was used as the substrate, A2M did not reduce the 
activities of NE or PR3 up to a molar ratio of 1.4:1. However, no enhancement of 
proteinase activity was seen when this substrate was used, at least within the 
concentrations of A2M studied here, highlighting that differences exist in how enzymes 
interact with different substrates. Potentially, A2M may function predominantly to remove 
proteinases from the circulatory system [200], rather than inhibiting their activity. 
 
The NE inhibition slopes with mixtures of pure M A1AT and A2M (using SlaaapN as the 
substrate) shown in Figure 4.4 demonstrate that residual NE activity was seen even when 
A1AT was in a molar excess, similar (although not equivalent) to results seen with serum. 
Extrapolation of the initial part of the slope to the x-axis shows that NE was inhibited in a 
1:1 molar ratio of A1AT:NE suggesting that A1AT was the predominant inhibitor of NE in 
these mixtures. The results also confirm that the residual NE activity observed with the 
serum samples (Chapter 3) was the result of NE bound to A2M since the baseline NE 
activity was absent when using A1AT alone. The effect was greatest when A1AT and 
A2M were studied in concentrations equivalent to those found in PiZZ serum compared to 
concentrations found in PiFZ serum, which in turn was greater than that with 
concentrations found in PiMM serum. Figure 4.5 shows the same pattern of results when 
MSaapvN was used as the substrate, but with no enhancement of NE activity with this 
substrate as described previously. A similar phenomenon has been described elsewhere 
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using PPE [259] where the residual activity of PPE increased as the ratio of A2M to A1AT 
increased. Ohlsson et al [260] reported that in normal human serum (PiMM), 92% of 
added NE binds to A1AT and 8% binds to A2M in vitro. Deficiency or dysfunction of 
A1AT (as occurs with mutant variants) would therefore alter these proportions leading to 
greater amounts of proteinases forming complexes with A2M where they remain active. 
 
The PR3 inhibition slopes with mixtures of pure M A1AT and A2M (Figure 4.6) show that 
residual PR3 activity was still present when A1AT was in a molar excess. Again, these 
findings were similar (but not equivalent) to those obtained with serum (Chapter 3) and 
suggest that the residual PR3 activity observed with the serum samples was the result of 
PR3 bound to A2M. However, when inhibiting PR3 activity with mixtures of pure A1AT 
and A2M, the residual activity was not altered by increasing the ratio of A2M to A1AT, 
unlike the results obtained with serum samples. The exact reason for this discrepancy is 
unclear, and no previous work has studied the partitioning of PR3 between its two serum 
inhibitors. However, the observed differences may be due to a degree of inactivation or 
altered Kass of A1AT in PiFZ and PiZZ sera (see below) and hence greater partitioning of 
PR3 to A2M in these serum samples where the mutant variants of A1AT are present. 
 
The experiments using pure Z A1AT and pure A2M in proportions found in PiZZ serum 
(Figures 4.7 and 4.8) did not replicate the earlier results using serum (Chapter 3). One 
explanation for this discrepancy could be that the pure Z A1AT used in this Chapter was 
active-site titrated against NE of known activity, and active concentrations were used in 
these experiments. However, in the serum experiments, active-site titration of Z A1AT was 
not performed due to the presence of A2M and the impurity of serum, and therefore the 
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concentration of A1AT was taken as the value measured by ELISA. The Z A1AT in the 
serum however is unlikely to be 100% active due to some potential complexes with NSPs, 
and its tendency to form inactive polymers [173] and possible other intermediate 
conformations, which will influence the partitioning of NSPs more towards binding to 
A2M. 
 
Brissenden and Cox [261] measured serum A2M concentrations in 178 subjects with 
emphysema (59 with PiZZ genotype, 5 with A1AT null genotype and 7 with rarer A1ATD 
genotypes) and 115 healthy controls with a similar age and sex distribution. They found 
that subjects with A1ATD (regardless of genotype) had significantly greater serum A2M 
concentrations compared to controls, which was not related to the presence of emphysema. 
This observation may suggest an even greater shift in the partitioning of NSPs towards 
binding to A2M in subjects with A1ATD. However, Gaillard et al [262] showed that the 
elastase binding activity of A2M (using PPE) was reduced in subjects with A1ATD 
compared to subjects with the normal PiMM phenotype, which may further influence the 
partitioning of NSPs between their serum inhibitors if the same were true for human 
enzymes. 
 
Although A2M is not a major proteinase inhibitor in the airways (at least in the absence of 
inflammation), the results described in this Chapter may have clinical significance in 
circumstances where A1AT is deficient or shows reduced anti-proteinase activity (such as 
in PiZZ subjects), and proteinases are more likely to be bound to A2M. Although NE 
bound to A2M can still be inhibited by SLPI in the upper airways [263], SLPI may play a 
less important role in the anti-proteinase protection of the alveoli. The partitioning of PR3 
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towards A2M could potentially be of greater significance since free PR3 is inhibited less 
avidly by A1AT compared to NE [123], and PR3 is not inhibited by SLPI. The studies 
presented in this Chapter show that PR3 bound to A2M can retain its proteolyic activity 
(similar to NE) even in the presence of an excess of A1AT. To date, no studies have 
determined the ability of elafin to inhibit the activity of PR3 bound to A2M. 
 
In future experiments, it would be ideal to use purified A1AT variants (including pure S 
and F variants not studied here) to replicate the serum experiments described in Chapter 3 
more closely. The use of mutant variants of A1AT could potentially allow factors other 
than concentration to be considered when studying the partitioning of NSPs between their 
inhibitors. For example, mutant A1AT variants differ from M A1AT in their association 
rate constants (See Chapter 6) and their susceptibility to form polymers or other 
conformations which may lead to their inactivation in vivo. However, the use of purified 
active-site titrated Z A1AT in this Chapter did not replicate the results observed using 
PiZZ serum, as discussed earlier. The data did show a slight increase in partitioning to 
A2M even when pure Z A1AT was used in comparable active concentrations to those used 
with M A1AT (see Figures 4.4 and 4.7), indicating that the association rate constant also 
had an effect on partitioning. The data however did not take into account any polymers or 
other conformations (intermediate, latent or cleaved forms) of A1AT present in the serum. 
The reduced partitioning to A2M observed with the pure active Z A1AT protein compared 
to that observed with PiZZ serum suggests that inactive forms are likely to be present in 
the serum. The Z A1AT purified from plasma and used in these experiments was found to 
be approximately 50% inactive following active-site titration. Whether this was the result 
of the purification process alone or was a reflection of serum activity remains unknown at 
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present, but highlights a potential difficulty of performing in vitro experiments to 
determine in vivo effects. 
 
Overall, the data in this Chapter has confirmed that complexes of NE or PR3 with A2M 
retain their proteolytic activities (and may show enhanced activities compared to free 
enzyme), at least towards low molecular weight peptide substrates. In addition, the results 
have demonstrated that greater concentrations of A2M relative to A1AT are associated 
with a greater residual enzyme activity, which supports the data presented in Chapter 3. To 
determine the relevance of these studies to the pathogenesis of emphysema, it is important 
to study inhibition in the presence of a physiological substrate, and therefore experiments 
using elastin as a substrate were undertaken and described in Chapter 5.  
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5 Elastin degradation by serine proteinases  
5.1 Introduction 
Although the NSPs exhibit a wide range of physiological functions, their excessive 
activities can result in tissue damage and can potentiate the inflammatory response. In 
emphysema, the imbalance between the activities of NSPs and their inhibitors leads to the 
functional loss of elastin and damage to the alveolar structures [76]. Elastin consists of 
molecules of its soluble precursor tropoelastin [264] that are cross-linked at lysine 
residues. As a result of its extensive cross-linking and its hydrophobicity, elastin is 
insoluble and does not undergo significant turnover in healthy tissue [265]. NE can bind to 
and degrade lung elastin in human emphysema [90], and PR3 can degrade elastin in vitro 
and cause emphysema when administered into the trachea of hamsters [74]. Airway 
inhibitors such as A1AT and SLPI are less effective against elastin-bound NE compared to 
free NE [266]. An in vitro study [123] has suggested that elastin bound PR3 can be 
inhibited by A1AT but these findings have yet to be explored in vivo or in situations where 
the A1AT concentration is low or the protein is dysfunctional. 
 
In this Chapter, the inhibition of NE and PR3 activities by serum samples or pure 
inhibitors has been assessed using labelled elastin as the substrate (elastin-fluorescein). 
The main aims are to determine the inhibitory capacities of A1AT and A2M in the 
presence of elastin, and to establish whether complexes of NE or PR3 with A2M are able 
to degrade elastin. 
  
 123 
 
5.2 Methods 
5.2.1 Preparation of elastin-fluorescein 
Elastin-fluorescein (Elastin products, USA, purified from bovine neck ligament and 
labelled with fluorescein-isothiocyanate) was prepared by adding 20mg/ml of elastin-
fluorescein (particle size pass 400 mesh, smaller than 37 microns,) to 0.2M Tris base, pH 
8.8, 0.01% Triton X-100. The solution was stirred until all particles were wetted. The 
substrate was then washed on Whatman 41 filter paper (Fisher Scientific, UK) with elastin 
buffer until the filtrate was colourless. The elastin was then re-suspended in elastin buffer. 
 
5.2.2 Inhibition of NE or PR3 with serum of different A1AT genotypes 
Pure NE or PR3 was diluted in elastin buffer to an active concentration of 1.5µM and 
20µL was added to an eppendorf 1.5ml tube (Eppendorf, UK). Serum was diluted in 
elastin buffer so that the concentration of A1AT was 1.5µM and increasing volumes of 
serum were added to each eppendorf tube. The total volume in each tube was made up to 
300µL with elastin buffer and the tubes were incubated for 20 minutes at 37ºC to allow the 
NE or PR3 to form complexes with inhibitors. The control tube contained buffer alone. 
After incubation, 200µL of elastin-fluorescein was added and the tubes were incubated on 
a blood tube rotator at 37ºC for 20 hours. The tubes were then spun in a MSE micro 
centaur centrifuge at 13,000 RPM for 10 minutes. Next, 100µL of supernatant was taken 
and added to a 96-well plate and the absorbance was read at 495nm in a Biotek Synergy 
HT plate reader. Control values were subtracted and inhibition slopes were constructed by 
plotting the percentage of remaining enzyme activity against the molar ratio of A1AT to 
NE or PR3. 
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This method was optimised by introducing the blood tube rotator to ensure adequate 
mixing of elastin particles in the solution. Also, the incubation time was determined 
following time course experiments in order to obtain a suitable inhibition slope. 
 
The experiments were also performed with NE or PR3 being added last (after the addition 
of serum, buffer and elastin) for comparison. This experimental procedure was designed to 
be more representative of events taking place in vivo, where NSPs are released in the 
presence of local inhibitors and lung elastin. 
 
5.2.3 Inhibition of NE or PR3 with pure A2M or pure A1AT 
These experiments were carried out as described for serum samples, except that pure 
A1AT or A2M was used instead of serum. For the A2M experiments, concentrations of 
pure A2M and active NE or PR3 were 1.38µM. 
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5.3 Results 
5.3.1 Inhibition of NE or PR3 with PiMM serum 
The inhibition slopes of NE (Graph A) and PR3 (Graph B) by PiMM serum using elastin-
fluorescein as the substrate are shown in Figure 5.1. In these experiments, elastin was 
added as the final step following pre-incubation of NE or PR3 with PiMM serum. The 
results show that PiMM serum increasingly inhibited NE activity as the molar ratio of 
serum A1AT to NE increased. However, even when the serum A1AT was in a molar 
excess, 10% residual NE activity towards elastin-fluorescein was observed. In contrast, 
PR3 activity towards elastin was fully inhibited by PiMM serum when the molar ratio of 
serum A1AT to PR3 was 1:1.  
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Figure 5.1-Inhibition of NE or PR3 with PiMM serum (elastin-fluorescein) 
 
 
Figure 5.1: Inhibition of NE (A) or PR3 (B) with PiMM serum using elastin-
fluorescein as the substrate. Graph A shows the mean results of 3 experiments and 
error bars show the SEM. Graph B shows the results from a single experiment. The 
baseline activities when A1AT was in a molar excess were 10% (Graph A) and 0% 
(Graph B). 
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The inhibition assays when NE or PR3 were added as the final step to a mixture of PiMM 
serum, elastin and buffer are shown in Figure 5.2. Individual experiments were performed 
for each proteinase but the results are presented together for comparison. This 
experimental procedure is more representative of events taking place in vivo when the 
NSPs are released in the presence of local inhibitors and lung elastin. The results show that 
both proteinases (but particularly NE) were inhibited less effectively in the presence of 
elastin. 
 
Figure 5.2-Inhibition of NE or PR3 added to a mixture of PiMM serum, elastin-fluorescein 
and buffer 
 
Figure 5.2: Inhibition of NE or PR3 added to a mixture of PiMM serum, elastin-
fluorescein and buffer. The results from single experiments are shown. 
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5.3.2 Inhibition of NE or PR3 with PiZZ serum 
The inhibition slopes of NE (Graph A) and PR3 (Graph B) by PiZZ serum using elastin-
fluorescein as the substrate are shown in Figure 5.3. In these experiments, elastin was 
added as the final step following pre-incubation of NE or PR3 with PiZZ serum. The 
results show that PiZZ serum increasingly inhibited NE activity as the molar ratio of serum 
A1AT to NE increased. However, even when the serum A1AT was in a molar excess, 12% 
residual NE activity towards elastin-fluorescein was observed. In contrast, PR3 activity 
towards elastin was fully inhibited by PiZZ serum when the molar ratio of serum A1AT to 
PR3 was approximately 1:1. 
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Figure 5.3- Inhibition of NE or PR3 with PiZZ serum (elastin-fluorescein) 
 
 
Figure 5.3: Inhibition of NE (A) or PR3 (B) with PiZZ serum using elastin-fluorescein 
as the substrate. Graph A shows the mean results of 3 experiments and error bars 
show the SEM. Graph B shows the results from a single experiment. The baseline 
activities when A1AT was in a molar excess were 12% (Graph A) and 0% (Graph B). 
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The inhibition assays when NE or PR3 were added as the final step to a mixture of PiZZ 
serum, elastin and buffer are shown in Figure 5.4. Individual experiments were performed 
for each proteinase but the results are presented together for comparison. The results show 
that both proteinases (but particularly NE) were inhibited less effectively in the presence of 
elastin. 
 
Figure 5.4-Inhibition of NE or PR3 added to a mixture of PiZZ serum, elastin-fluorescein 
and buffer 
 
Figure 5.4: Inhibition of NE or PR3 added to a mixture of PiZZ serum, elastin-
fluorescein and buffer. The results from single experiments are shown. 
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The activity of PR3 could be completely inhibited by both PiMM and PiZZ sera with 
approximately 1:1 stoichiometry when elastin-fluorescein was introduced following pre-
incubation of the serum with PR3.  
 
Due to restrictions on time and resources, the experiments with PiFZ and PiSZ sera 
described below were performed with NE only. 
 
5.3.3 Inhibition of NE with PiFZ serum 
The inhibition slope of NE by PiFZ serum using elastin-fluorescein as the substrate is 
shown in Figure 5.5. In this experiment, elastin was added as the final step following pre-
incubation of NE with PiFZ serum. When the serum A1AT was in a molar excess, 12.7% 
residual NE activity towards elastin-fluorescein was still observed. 
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Figure 5.5- Inhibition of NE with PiFZ serum (elastin-fluorescein) 
 
Figure 5.5: Inhibition of NE with PiFZ serum using elastin-fluorescein as the 
substrate. Points show the mean of three experiments ±SEM. The baseline activity 
when A1AT was in a molar excess was 12.7%. 
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5.3.4 Inhibition of NE with PiSZ serum 
The inhibition slope of NE by PiSZ serum using elastin-fluorescein as the substrate is 
shown in Figure 5.6. In this experiment, elastin was added as the final step following pre-
incubation of NE with PiSZ serum. When the serum A1AT was in a molar excess, 10.7% 
residual NE activity towards elastin-fluorescein was still observed. 
 
Figure 5.6- Inhibition of NE with PiSZ serum (elastin-fluorescein) 
 
Figure 5.6: Inhibition of NE with PiSZ serum using elastin-fluorescein as the 
substrate. The results from a single experiment are shown. The baseline activity when 
A1AT was in a molar excess was 10.7%. 
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5.3.5 Inhibition of NE by pure A1AT 
The inhibition slope of NE by pure A1AT using elastin-fluorescein as the substrate is 
shown in Figure 5.7. Pure A1AT was able to fully inhibit NE at a molar ratio of 1.2:1. In 
this experiment, elastin was added as the final step following pre-incubation of NE with 
pure A1AT. 
 
Figure 5.7- Inhibition of NE by pure A1AT (elastin-fluorescein) 
 
Figure 5.7: Inhibition of NE with pure A1AT using elastin-fluorescein as the 
substrate. The results from a single experiment are shown. NE activity was 
completely inhibited by pure A1AT. 
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5.3.6 Inhibition of NE or PR3 with pure A2M 
The inhibition slopes of NE and PR3 by pure A2M using elastin-fluorescein as the 
substrate are shown in Figure 5.8. In these experiments, A2M was pre-incubated with each 
proteinase prior to addition of elastin-fluorescein, up to a molar ratio of 3:1. The results 
show that the activities of both proteinases (but particularly NE) towards elastin were not 
fully inhibited by A2M. 
 
Figure 5.8-Inhibition of NE or PR3 with pure A2M (elastin-fluorescein) 
 
Figure 5.8: Inhibition of NE or PR3 with A2M using elastin-fluorescein as the 
substrate. Separate experiments were performed for each proteinase and the results 
from single experiments are shown on the same graph for comparison. 
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5.4 Discussion 
The results presented in this Chapter have shown that NE activity towards elastin-
fluorescein was not completely inhibited following pre-incubation with PiMM (Figure 
5.1A), PiZZ (Figure 5.3A), PiFZ (Figure 5.5) or PiSZ (Figure 5.6) sera when the A1AT 
was in a molar excess of the enzyme. The residual NE activity was around 10-15% and 
could be explained either by elastolytic activity of NE complexes with A2M, or by 
dissociation of A1AT:NE complexes over the 20 hour incubation period. The hypothesis 
that NE complexes with A2M are able to degrade elastin is supported by the results in 
Figure 5.8, which shows that pre-incubation of NE with A2M for 20 minutes up to a molar 
excess of A2M of 3:1 does not fully inhibit NE activity towards elastin-fluorescein, and a 
three-fold molar excess of A2M should have theoretically been sufficient to bind all of the 
free NE (Moore et al [254] found that a 1.5 molar excess of A2M was sufficient to bind all 
free NE under similar experimental conditions). In contrast, pure A1AT could fully 
inactivate NE when the enzyme and inhibitor were pre-incubated prior to the addition of 
elastin-fluorescein (Figure 5.7) indicating that significant dissociation of active NE from 
A1AT did not occur. 
 
It may be expected that when elastin is used as the substrate, NE activity would be 
completely inhibited by serum samples since elastin has a high molecular mass and should 
be less accessible to elastolysis by NE bound to A2M. Previous studies [257] however 
have shown that PPE is capable of digesting chemically solubilised elastin even when 
complexed with A2M. Furthermore, I have demonstrated that following incubation with a 
two-fold molar excess of A2M, PPE retains 100% of its activity towards elastin-
fluorescein (data not shown). Nevertheless, other studies have shown that NE complexes 
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with A2M are unable to degrade mature elastin [253, 267]. Some of these discrepancies 
may relate to experimental conditions, since the elastin used for the experiments described 
in this Chapter had a particle size of less than 37 microns (pass 400 mesh), and some 
previously published studies used a particle size of 37-75 microns (200-400 mesh) [268]. 
Stone et al [201] reported that complexes of PPE with A2M retained their elastolytic 
potential and promoted lung injury in animal studies. Furthermore, NE bound to A2M may 
be able to degrade the elastin precursor tropoelastin [269], which is secreted into the 
extracellular space prior to formation of the cross linkages found in elastin [270] and hence 
could affect the repair process. Therefore NE complexes with A2M could potentially play 
a role in the development of emphysema, particularly in subjects with A1ATD when NE is 
more likely to partition to A2M, and further work is therefore required to explore the 
implications of this possibility. 
 
The NE inhibition assays presented in this Chapter suggest that A1AT is less functional as 
an inhibitor when elastin-fluorescein is used as the substrate and added following pre-
incubation of NE with serum or pure A1AT. Extrapolation of the slopes in Figures 5.1A, 
5.3A, 5.5, 5.6 and 5.7 to zero activity shows that NE is inhibited when the molar ratio of 
A1AT:NE is 1.2-1.4:1. Previous work by Kramps et al [271] has also reported that A1AT 
has a specific inhibitory activity of 40-85% of that observed with synthetic nitroanilide 
substrates when elastin-fluorescein is used. The authors hypothesized that the lower 
inhibitory capacity of A1AT when using elastin-fluorescein could potentially be due to 
dissociation of the enzyme-inhibitor complex during the 20 hour incubation period, 
resulting in free enzyme which could then bind to elastin. NE bound to elastin is then 
poorly inhibited by A1AT compared to free NE [266]. However, the results presented here 
do not support this hypothesis because pure A1AT was able to fully inactivate NE (Figure 
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5.7) under similar experimental conditions suggesting that significant dissociation did not 
occur. 
 
The results presented in this Chapter show that PR3 activity towards elastin was 
completely inhibited by PiMM (Figure 5.1B) and PiZZ (Figure 5.3B) sera. In addition, 
PR3 activity towards elastin was inhibited more effectively than NE by pure A2M (Figure 
5.8). Overall, these results suggest that PR3 complexes with A2M are less likely to play an 
important role in elastin degradation. Despite these findings, PR3 may still be responsible, 
at least in part, for the tissue damage associated with emphysema because it is more 
abundant than NE and has fewer airway inhibitors. These concepts are explored further in 
Chapter 9. 
 
This Chapter has also highlighted differences in the ability of A1AT to inhibit NSPs in the 
presence of elastin. Figures 5.2 and 5.4 demonstrate that when proteinases were introduced 
to a mixture of both elastin and serum (containing the inhibitors A1AT and A2M), NE in 
particular was inhibited much less effectively in the presence of elastin. These findings are 
consistent with elastin-bound NE being poorly inhibited by A1AT compared to free 
enzyme. This concept has been explored in animal studies [272, 273] that demonstrated 
that in order to protect the lungs from proteolytic damage, synthetic elastase inhibitors 
needed to be administered prior to the release of elastase. If inhibitors were administered 
following an elastase challenge, little or no protection was achieved, most probably 
because the inhibitors failed to inactivate elastin-bound NE. The ineffective inhibition of 
elastin-bound NE has biological relevance to the pathogenesis of emphysema, and possibly 
to other disease processes. Thus, further studies investigating the mechanisms of inhibiting 
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the activity of NE bound to elastin are warranted. However, the results presented here 
suggest that PR3 may be inhibited by A1AT more effectively than NE in the presence of 
elastin. An in vitro study [123] has reported that the elastolytic rate of PR3 is one eighth 
that of NE using bovine neck ligament elastin, and that ongoing elastolysis by PR3 can be 
almost completely inhibited by A1AT, although these findings remain to be verified in 
vivo. These results could potentially be explained by PR3 having fewer binding sites on 
elastin compared to NE, and PR3 may be able to dissociate more readily from elastin 
compared to NE [123] and therefore be more susceptible to inhibition by the surrounding 
A1AT. 
 
The NE inhibition assays using PiMM, PiZZ, PiFZ and PiSZ sera (Figures 5.1A, 5.3A, 5.5 
and 5.6) were similar to each other, suggesting that the A1AT in these samples inhibited 
NE activity towards elastin in a similar manner in molar terms (and likewise for PR3 with 
PiMM and PiZZ sera). However, since the graphs show molar ratios of A1AT to 
proteinases and not total concentrations of A1AT, they do not fully reflect the environment 
in the lungs where lower concentrations of A1AT with an increased susceptibility to 
polymerisation (and possibly reduced function) would be present in A1ATD subjects. 
 
When comparing the results presented here (using elastin as the substrate) with the results 
presented in Chapter 3 (using small peptide substrates), it appears that A2M:NE complexes 
may be less active towards elastin than against low molecular weight peptide substrates. 
The residual activities of NE (which represent the activities of A2M:NE complexes since 
the A1AT was in a molar excess) were greater when peptide substrates were used 
compared to elastin. These findings are consistent with those reported elsewhere [254] and 
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could possibly be due to a proportion of the complexes containing two molecules of NE, 
which would not allow simultaneous activity of these two NE molecules towards a 
macromolecular substrate such as elastin. 
 
The in vitro experiments described in this Chapter have some limitations when considering 
events taking place in vivo. Firstly, the elastin used in these experiments was derived from 
bovine neck ligament which was readily available, although it differs structurally from that 
found in human lung elastic fibres. Secondly, the experiments were performed using a 
single buffer at a pH of 8.8 to optimise enzyme activity, which may not represent the 
inflammatory environment of the lungs. Thirdly, other inhibitors such as SLPI were not 
present in these experiments, which although not relevant to the PR3 experiments, should 
be considered in the NE experiments since SLPI can inhibit NE bound to elastin [185] 
although its inhibitory activity is less than with free NE [266]. Finally, these in vitro 
experiments have considered individual proteinases and their interactions with inhibitors 
and substrates. In the local environment of the inflamed lung, several proteinases are likely 
to be present which can interact with each other and with their inhibitors as shown in 
Figure 1.7. However, despite these limitations, no studies to date have examined the ability 
of PR3 complexes with A2M to degrade elastin, or the ability of serum from A1ATD 
subjects to inhibit PR3 activity towards elastin. 
 
Further studies will be necessary to determine whether A2M:NE complexes are important 
in diseases where excessive activities of NSPs have been implicated. These initial studies 
could involve the instillation of human A2M:NE complexes into animal lungs to determine 
whether emphysema-like lesions develop. Although, in view of the tight epithelial 
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junctions it is probable that a large molecule like A2M may not gain access to the 
interstitium to damage the lung connective tissue. Alternatively, studies of human samples 
could involve the measurement of A2M:NE complexes in lung secretions (sputum or 
BAL) to determine their presence and concentration, and hence destructive potential. 
However, proteinases trapped by A2M may not readily bind to their specific antibodies 
[274] due to the inaccessibility of their epitopes which are trapped within the large A2M 
molecule. Hence, the development of ELISA techniques for the measurement of A2M:NE 
complexes has proven difficult. Adeyemi et al [275] described a technique which 
necessitated the addition of phenylmethylsulphonyl fluoride (PMSF) to plasma and serum 
samples in order to measure A2M:NE complexes. However, PMSF is toxic and requires 
stringent safety precautions in the laboratory. The same research group [276] subsequently 
reported that pre-incubation of the A2M:NE complex with an anti-human A2M antibody 
was necessary in order for the complexed NE to bind to its specific antibody. To date, 
there have been no published methods for measuring A2M:PR3 complexes in biological 
fluids. 
 
In summary, this Chapter has demonstrated that NE activity towards elastin is not fully 
inhibited by normal (PiMM), A1ATD (PiZZ) or other A1AT variant (PiFZ, PiSZ) sera, 
which may be due to elastolytic activity of A2M:NE complexes, or (less likely) to 
dissociation of A1AT:NE complexes and subsequent poor inhibition of elastin-bound NE. 
In contrast, PR3 activity towards elastin is fully inhibited by PiMM or PiZZ sera. Overall, 
the results suggest that PR3 complexes with A2M are unlikely to play a significant role in 
degradation of mature elastin, and that the inhibitory activity of A1AT towards PR3 is (at 
least partly) preserved in the presence of elastin.  
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6 Association rate constants for A1AT variants and 
proteinases  
6.1 Introduction 
Previous studies into the association rate constants (Kass) of A1AT have shown that Z 
variant A1AT is a less competent inhibitor of NE than M variant A1AT [154]. Thus, 
individuals with the PiZZ genotype not only have lower concentrations of A1AT, but it is 
also less functional as an inhibitor of NE [155] and, in addition, has an increased tendency 
to form polymers which are not functional as inhibitors [173]. The S variant of A1AT is 
reported as having a similar inhibitory activity towards NE compared to the normal M 
variant [277, 278]. The F and I variants have been less well studied but have been reported 
to have a reduced ability to inhibit NE, much like that of the Z variant [169, 279].  
 
There have however been few studies of association rate constants for PR3 with A1AT. 
The M variant of A1AT is a less competent inhibitor of PR3, with Kass values being 
reported as ten-fold lower than those with NE [117, 280]. To date, no studies into the 
association rate constants of other A1AT variants with PR3 have been reported. 
 
The work in this Chapter aims to provide new information on the second order association 
rate constants for A1AT variants and NE or PR3 which are currently not well described. 
These data will increase our understanding of how these proteinases partition to inhibitors 
in the presence of neutrophilic inflammation. To study the clinical significance of co-
inheritance of a dysfunctional A1AT variant with a deficiency variant, the clinical 
characteristics of subjects with the PiFZ phenotype have been studied in further detail. 
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6.2 Methods 
6.2.1 Treatment of serum with methylamine to inactivate A2M 
In order to measure Kass for A1AT in serum with NE or PR3, it was first necessary to 
inactivate A2M. This was achieved by treating the serum samples (PiMM, PiZZ, PiSS, 
PiFZ, PiIZ) with 0.1M methylamine (Fisher Scientific, UK) for 10 minutes at 37°C [281]. 
Inactivation of A2M by methylamine is a sequential two-step process where thiol ester 
cleavage is followed by a conformational change in the protein which results in the loss of 
proteinase binding capacity [282]. The inactivation of A2M was confirmed indirectly by 
measuring NE and PR3 inhibition by serum samples with and without treatment with 
methylamine. The substrate used for these experiments was MSaapvN at 0.6mg/ml in 
0.1M Hepes, pH 7.5, 9.5% dimethyl sulfoxide (DMSO). 
 
6.2.2 Measurement of Kass for A1AT variants and NE 
Pure NE of known activity was diluted to an active concentration of 100nM with NSP 
assay buffer. Pure A1AT (M or Z variant) or methylamine-treated serum samples (PiMM, 
PiZZ, PiSS, PiFZ, PiIZ) were also diluted to an A1AT concentration of 100nM and these 
samples were titrated against NE to determine the percentage of active A1AT. For these 
experiments, variable amounts of sample containing A1AT were added to 10µL of 100nM 
NE in a 96-well plate (Costar, USA). The wells were made up to 110µL with buffer and 
the plates incubated for 30 minutes at room temperature to allow complex formation. The 
residual NE activity was determined by adding 150µL of MSaapvN at 0.6mg/ml in 0.1M 
Hepes, pH 7.5, 9.5% DMSO. The OD at 410nm was then read at 5 minute intervals up to 
60 minutes using a Biotek Synergy HT plate reader. The activity of A1AT in the sample 
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was determined by plotting the percentage of remaining NE activity against the A1AT 
concentration. The linear portion of the slope was extrapolated to the x-axis, and the molar 
amount of A1AT required to inhibit each mole of NE was calculated. From this 
calculation, the percentage of A1AT activity was obtained. Each assay was performed in 
triplicate and the average result was used for all subsequent studies. 
 
Following this initial step, the time-dependent measurements were performed by 
incubating equimolar amounts of NE and active A1AT (1nM each) in a 1ml polystyrene 
cuvette with a 1cm pathlength at 23°C. The buffer used for these experiments was NSP 
assay buffer and the detergent was present in the buffer to minimise the adhesion of free 
proteinases to plastic and glass surfaces when in dilute solution [240]. Residual NE 
activity at 1-5 minutes was measured by the addition of 200µL of MSaapvN and 
measurement of the change in wavelength over 10 minutes using a spectrophotometer 
(Jasco V550). At each time point, the percentage of NE inhibition was determined. The 
Kass was calculated by plotting the inverse of NE activity at each time point versus time. 
From the linear portion of the slope, the half time (t½) of the reaction was calculated using 
the formula; 
t½ = y intercept/slope 
 
Kass was calculated using the equation [154]; 
Kass = (Concentration of NE x t½)
-1 
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6.2.3 Measurement of Kass for A1AT variants and PR3 
Pure PR3 of known activity was diluted to an active concentration of 400nM using NSP 
assay buffer. Pure A1AT (M or Z variant) or methylamine-treated serum samples were 
also diluted to an A1AT concentration of 400nM and these samples were titrated against 
PR3 to determine the percentage of active A1AT. For these experiments, variable volumes 
of sample containing A1AT were added to 10µL of 400nM PR3 in a 96-well plate. The 
wells were made up to 120µL with buffer and the plate was incubated for 30 minutes at 
room temperature to allow complex formation. The residual PR3 activity was determined 
by adding 3µL of Boc-ala-ONp (Sigma, UK) at a concentration of 20mM in methanol. The 
OD at 347.5nm was then read at 5 minute intervals up to 30 minutes using a Biotek 
Synergy HT plate reader. The activity of A1AT in the sample was determined by plotting 
the percentage of remaining PR3 activity against the A1AT concentration. The linear 
portion of the slope was extrapolated to the x-axis, and the number of moles of A1AT 
required to inhibit each mole of PR3 was calculated. From this calculation, the percentage 
of A1AT activity was obtained. Each assay was performed in triplicate and the average 
result was used for all subsequent studies. 
 
The time-dependent measurements were then performed by incubating equimolar amounts 
of PR3 and active A1AT (1nM each) in a black opaque polypropylene low binding plate 
(Sigma, UK) at 23°C with a well volume of 150µL. Residual PR3 activity at 1-5 minutes 
was measured by stopping the reaction with 3μL of the PR3 specific Förster resonance 
energy transfer (FRET) substrate Abz-VAD-norV-ADRQ-EDDnp (Alta Biosciences, UK) 
at a concentration of 1mM [283]. The change in fluorescence (excitation 320nm, emission 
420nm) was measured every 2 minutes for 20 minutes using a Biotek Synergy 2 Multi-
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Mode Microplate Reader. At each time point, the percentage of PR3 inhibition was 
determined. The Kass was calculated using the same method as that used for NE. 
 
6.2.4 Determining the clinical significance of the PiFZ phenotype 
The clinical characteristics of PiMZ and PiSZ heterozygotes have been studied previously 
[284, 285]. However, the PiFZ phenotype has been less well studied. In order to increase 
understanding of its clinical significance, the U.K. A1ATD national registry was searched 
and six subjects with the PiFZ phenotype were identified. Data was collected from these 
subjects including; demographic data, A1AT concentration, smoking history, body mass 
index (BMI), PFTs, frequency of exacerbations, quality of life scores as measured by the 
St George’s Respiratory Questionnaire (SGRQ) and CT scan appearance. 
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6.3 Results 
6.3.1 Treatment of serum with methylamine 
In order to measure Kass for A1AT in serum with NE or PR3, it was first necessary to 
inactivate A2M. The inactivation of A2M by methylamine was confirmed indirectly by 
performing NE and PR3 inhibition assays with serum samples with and without treatment 
with methylamine. The results for PiMM (Graphs A and C) and PiZZ sera (Graphs B and 
D) are shown in Figure 6.1 (data for other sera not shown). The results show that treatment 
of serum samples with methylamine prior to performing the assay inactivated the A2M, 
and the inhibition was thus due to A1AT alone. In the graphs where untreated PiZZ serum 
was used, some enhancement of proteinase activity was seen as the concentration of A2M 
increased which has been described previously [255] and discussed in Chapter 4. 
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Figure 6.1 (A-D)- Inhibition of NE and PR3 activity by serum samples with and without 
treatment with methylamine 
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Figure 6.1 (A-D): Inhibition of proteinases using PiMM and PiZZ serum samples 
with or without treatment with methylamine. Each graph shows the results from 
single experiments. 
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6.3.2 Calculation of Kass 
After incubating equimolar amounts of proteinase and A1AT for various time points, the 
residual proteinase activity was measured for each time point, and the percentage of 
proteinase inhibition was calculated using the formula [154]; 
 
% Inhibitory activity of A1AT = (Proteinase activity without A1AT - Proteinase activity with A1AT) x 100 
      Proteinase activity without A1AT 
 
The Kass was calculated by plotting the inverse of the proteinase activity at each time 
point versus time. An example of the data obtained is shown in Figure 6.2. From the linear 
portion of the slope, the half time (t½) of the reaction was calculated using the formula; 
 
t½ = y intercept/slope 
 
Kass was calculated using the formula; 
 
Kass = (Concentration of proteinase x t½)
-1 
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Figure 6.2- Calculation of Kass for PR3 and Z A1AT 
 
 
Figure 6.2: The time-dependent inhibition of PR3 with Z A1AT. 1nM each of active 
PR3 and Z A1AT were incubated at 23ºC for various time points as shown. The 
reaction was stopped and the residual PR3 activity was measured by the addition of a 
PR3 specific substrate. Data from a single experiment are shown.  
0
5
10
15
20
25
30
35
40
45
0 100 200 300 400
%
 In
h
ib
it
io
n
 o
f 
P
R
3
 
Time (s) 
Time-dependent inhibition of PR3 by Z A1AT 
PR3 Inhibition
y = 0.0017x + 1.1447 
R² = 0.9854 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 100 200 300 400
1
/P
R
3
 A
ct
iv
it
y 
(n
M
) 
Time (s) 
Series1
Linear (Series1)
  
 
 152 
 
Using the data from Figure 6.2, the t½ = 1.1447/0.0017 = 673 seconds. Therefore Kass = 
(1nM x 673s)
-1
 = 0.001485nM
-1
s
-1
 or 1.49 x 10
6
 M
-1
s
-1
 from this experiment. 
 
6.3.3 Kass for A1AT variants and NE or PR3 
The Kass values for different variants of A1AT with NE or PR3 using this methodology 
are shown in Table 6.1 and are shown graphically in Figure 6.3. The values show the mean 
of three experiments and the SEM. Values for NE were greater than PR3 for all A1AT 
variants studied. 
 
Table 6.1-Kass for A1AT variants and NE or PR3 
A1AT variant Enzyme Association rate constant  
(Mean ± SEM) at 23°C (M
-1
 s
-1
) 
M NE 1.45 (0.02) x 10
7 
S NE 1.14 (0.36) x 10
7 
Z NE 7.34 (0.03) x 10
6 
FZ NE 5.75 (1.43) x 10
6 
IZ NE 8.64 (1.22) x 10
6 
M PR3 9.24 (0.48) x 10
5 
S PR3 9.51 (3.00) x 10
5 
Z PR3 1.10 (0.21) x 10
6 
FZ PR3 1.43 (0.29) x 10
6 
IZ PR3 1.00 (0.12) x 10
6 
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Figure 6.3-Kass for A1AT variants and NE or PR3 
 
Figure 6.3: Second order association rate constants (Kass) for A1AT variants and NE 
or PR3. Bars show the mean±SEM. Values for NE were greater than PR3 for all 
A1AT variants. 
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6.3.4 Clinical characteristics of subjects with the PiFZ phenotype 
The F variant of A1AT is usually associated with a normal serum concentration of A1AT, 
although the results presented here suggest that it is dysfunctional in its ability to inhibit 
NE activity. The potential significance of co-inheriting this dysfunctional variant with the 
main deficiency variant (Z) has been studied briefly here.  
 
The clinical characteristics of the six subjects identified from the U.K. A1ATD national 
registry with the PiFZ phenotype are shown in Table 6.2. All subjects had A1AT 
concentrations above the generally accepted protective threshold of 11µM. However, five 
had evidence of emphysema on their CT scan, which was panacinar emphysema with a 
lower zone predominance (usually associated with the PiZZ phenotype) in two. 
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Table 6.2- Clinical characteristics of subjects with the PiFZ phenotype 
Clinical 
Parameter 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Age 
(years) 
59 47 70 74 76 53 
Sex M M F M M M 
A1AT level 
(µM) 
18.7 21.6 24.0 11.8 18.3 19.7 
Smoking 
history 
(pack years) 
24 24 23 19 8 40 
BMI 
(kg/m
2
) 
23 33 19 29 29 20 
FEV1 
(% predicted) 
29 110 33 99 32 38 
FEV1/FVC 
ratio 
0.22 0.77 0.32 0.55 0.31 0.21 
KCO 
(% predicted) 
26 100 57 63 87 40 
PO2 on air 
(KPa, 
capillary 
blood gas) 
7.3 8.8 7.8 9.3 7.8 8.8 
Average 
number of 
exacerbations 
per year 
2 0 2 2 4 1 
SGRQ 
(total score) 
63 20 75 42 68 26 
CT scan 
appearance 
Upper zone 
emphysema 
Normal Diffuse 
emphysema 
in all zones 
Basal 
emphysema 
Basal 
emphysema & 
bronchiectasis 
Diffuse 
emphysema 
in all zones 
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6.4 Discussion  
The measurement of second order association rate constants in this Chapter (Table 6.1) has 
demonstrated that the Z variant of A1AT has an association rate constant which is half that 
of M variant A1AT for NE, consistent with other published results [154, 155]. In addition, 
the S variant of A1AT has a similar Kass with NE compared to the M variant, consistent 
with results published elsewhere [277]. For the current experiments, it was not possible to 
use serum from F or I homozygotes since no patients have been identified in the U.K. For 
these reasons, PiFZ or PiIZ heterozygotes were selected since Z A1AT made a relatively 
small contribution to the overall concentration of A1AT and studies have shown that 
A1AT from PiMZ heterozygotes has a similar Kass with NE to M A1AT alone [279]. The 
results presented in this Chapter demonstrate that IZ A1AT had a reduced Kass with NE 
compared to M A1AT. Mahadeva et al [169] previously showed that purified I A1AT had 
a Kass value with NE comparable to that obtained with Z A1AT, consistent with the 
findings of the current study. Similarly, the results presented here show that FZ A1AT has 
a Kass value with NE comparable to that obtained with the Z variant, and are consistent 
with results published by Cook et al [279], who used partially purified F A1AT. These 
observations support the validity of serum results from PiFZ and PiIZ heterozygotes in the 
current experiments. 
 
Some variations in published Kass values can be found in the literature [147, 286, 287], 
which may relate to changes in experimental conditions. Both temperature [279] and pH 
[288] can affect measured Kass values. For these reasons, the experiments in this Chapter 
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were performed at a constant pH of 7.4 and temperature of 23°C to allow comparisons to 
be made between A1AT variants and between enzymes. 
 
Serum contains A2M in addition to A1AT (which could interfere with the assays 
described) and therefore methylamine was added to inactivate A2M (Figure 6.1). The Kass 
values for M and Z variants of A1AT with NE and PR3 in these studies were similar when 
using pure A1AT or methylamine-treated serum, supporting the use of methylamine-
treated serum for experiments involving S, F and I variants of A1AT where purified A1AT 
was not available. 
 
Association rate constants for PR3 and A1AT variants (other than the M variant [117, 
280]) have not been published previously. The results presented here show that normal M 
A1AT has a Kass value for PR3 which is ten times lower than that for NE. Therefore, in 
the inflammatory environment in lungs where several proteinases may be present, A1AT 
will preferentially inhibit NE compared to PR3, and active PR3 has the potential to drive 
the pathophysiological processes that influence COPD and its progression. The data 
presented here show that other variants of A1AT (Z, S, FZ, IZ) have similar Kass values 
for PR3 to that of the normal M variant, suggesting a less significant effect of mutations in 
A1AT on its ability to inhibit PR3. Therefore, mole for mole, these variants are equally 
capable of forming an enzyme-inhibitor complex with PR3 as the normal M variant, 
although the lower concentration of A1AT will also influence its ability as an inhibitor. 
For all A1AT variants studied here, the Kass with NE was greater than that with PR3 
(Figure 6.3). For this reason, in addition to the greater amounts of PR3 contained within 
the neutrophil azurophilic granules, and the fact that PR3 is not inhibited by SLPI, it is 
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likely that PR3 is more important in the pathophysiology of COPD than has previously 
been thought, especially in subjects with A1ATD as its activity is likely to persist longer in 
the neutrophilic environment than NE (especially in the lung). 
 
The association rate constants at 23ºC for both NE and PR3 with A2M have been 
measured previously (NE 4.1 x 10
7
 M
-1
s
-1
, PR3 1.1 x 10
7
 M
-1
s
-1
) [117, 190]. As discussed 
in Chapters 3 and 4, proteinases partition between their inhibitors depending on their local 
concentrations and their association rate constants. When comparing the in vitro 
association rate constants for A1AT and A2M with NE, it would appear that the rates at 
which M A1AT and A2M associate with NE are similar. However, the in vivo significance 
of these values must also consider that in subjects with the PiMM phenotype, the molar 
concentration of A1AT is approximately 10 times greater than that of A2M and therefore 
A1AT is the predominant inhibitor of NE especially in serum. However, PiZZ 
homozygotes (and PiFZ or PiIZ heterozygotes) have a lower concentration of A1AT with a 
lower Kass relative to A2M, which alters the partitioning of NE more towards A2M and 
supports the results presented in Chapter 3. PR3 on the other hand has a greater Kass with 
A2M compared to all A1AT variants studied here, and therefore if the concentrations of 
A1AT and A2M were similar (such as in PiZZ subjects), PR3 would preferentially bind to 
A2M. PR3 complexes with A2M can retain their proteolytic potential towards low 
molecular weight substrates (Chapter 4) although probably not towards high molecular 
weight substrates such as elastin (Chapter 5). Nevertheless, the amount of PR3 released 
from neutrophils is also greater and at present the physiological significance of partitioning 
remains uncertain. 
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This Chapter has not considered the contribution of SLPI to the inhibitory capacity of NE 
in the airways. SLPI is a reversible inhibitor of NE with a Kass of 6.4 x 10
6
 M
-1
s
-1
 and a 
dissociation rate constant of 2.3 x 10
-3
 s
-1
 at 37ºC [289]. Elafin is also present in the lungs 
and is a reversible inhibitor of NE and PR3. The association and dissociation rate constants 
at 25ºC for elafin are 3.6 x 10
6
 M
-1
s
-1
 and 6.0 x 10
-4
 s
-1
 respectively for NE [290] (although 
greater Kass values have been reported when using different buffers [291]), and 4.0 x 10
6
 
M
-1
s
-1
 and 1.7 x 10
-3
 s
-1
 respectively for PR3 [291], which again adds complexities to the 
local dynamics. The contribution of these inhibitors in the upper airways is considered 
further in Chapter 9. 
 
The F variant of A1AT has not been studied in detail previously and has been classified as 
a normal variant since it is present in near normal A1AT concentrations in the circulation. 
However, co-inheritance of the F allele with a deficiency allele has been described and is 
associated with an increased susceptibility to emphysema and liver disease [165]. To date, 
no PiFF homozygotes have been reported in the literature, although there has been one 
case report of an individual with COPD and the PiFnull phenotype [166]. The U.K. 
A1ATD national registry contains six PiFZ heterozygotes (Table 6.2). All six subjects had 
A1AT concentrations above the generally accepted protective threshold of 11µM, 
comparable with concentrations found in PiMZ heterozygotes who are not believed to be 
at particular risk of emphysema. Five of the PiFZ subjects had evidence of emphysema on 
their CT scan which was panacinar emphysema with a lower zone predominance (usually 
associated with PiZZ homozygotes) in two. These findings could have clinical 
consequences because measurement of A1AT concentration alone would not identify 
carriers of the F allele, and PiFZ heterozygotes possibly have an increased risk of 
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developing emphysema by a concentration-independent mechanism, although referral bias 
could have influenced these findings. 
 
Many of the mutations of A1AT that have been implicated in the deficiency phenotypes 
are associated with reduced serum concentrations of A1AT. In many cases, this is the 
result of the mutation perturbing the structure of the serpin leading to polymerisation 
[173]. The F mutation does not appear to produce a deficiency phenotype and its 
susceptibility to polymerisation has not been reported in the literature to date, but instead 
results in a reduction in Kass which in turn may predispose to disease. This suggests that 
the position of the mutation (arginine replaced by cysteine at position 223) specifically 
disrupts the inhibitory mechanism of A1AT. Examination of the structure of A1AT shows 
that the mutation is in the C-sheet underlying the RCL. With the normal M variant, an 
arginine at position 223 forms an electrostatic interaction with the side chain of glutamate 
354 in the RCL [292]. However, with the F variant, the cysteine at position 223 cannot 
make this electrostatic interaction and the consequence is likely to be a disruption of the 
RCL architecture which alters the conformation of the P1-P1’ region and may explain the 
reduced Kass observed here. 
 
In conclusion, this Chapter has demonstrated that A1AT (M, Z, S, F and I variants) has a 
lower association rate constant for PR3 than NE, and therefore in situations where the 
concentration of A1AT is insufficient to inhibit both proteinases, NE would be 
preferentially inhibited. Uninhibited PR3 can replicate the pathological features of COPD 
associated classically with NE. This Chapter has also highlighted the importance of 
considering not only the concentration of inhibitors present, but also their function. Some 
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clinicians may exclude a diagnosis of A1ATD based on a normal A1AT concentration. 
However, the F variant in particular is associated with normal serum levels of A1AT but is 
dysfunctional in its ability to inhibit NE activity. Therefore if A1ATD is suspected 
clinically, phenotyping and genotyping should be requested. 
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7 In vitro effects of A1AT augmentation therapy  
7.1 Introduction 
Intravenous augmentation therapy by the infusion of pooled human A1AT is currently the 
most direct and efficient means of elevating A1AT levels in the plasma and in the lung 
interstitium [293, 294]. Population and in vitro studies suggest a minimum plasma 
threshold A1AT level of 11µM, below which there is insufficient A1AT to protect the lung 
effectively, leading to an increased risk of developing emphysema [157, 159]. 
 
An early study looking at clinical efficacy of augmentation therapy was conducted by 
Seersholm et al [295]. They compared the rate of FEV1 decline amongst 97 former 
smokers from Denmark with severe A1AT deficiency (PiZZ or Znull) who did not receive 
augmentation therapy with the rate of decline in 198 severely deficient (PiZZ) German 
former smokers who received weekly infusions over a mean of 3.2 years. Overall, the rate 
of decline of FEV1 was lower amongst the treated German patients than amongst the 
untreated Danish patients (-53 mL per year versus -75 mL per year, p=0.02), with subset 
analysis showing that the overall difference was mainly due to an effect of augmentation 
therapy in subjects with an FEV1 between 31 and 65 percent predicted. 
 
The U.S. National Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin 
conducted a multi-centre, prospective cohort study sponsored by the National Heart, Lung, 
and Blood Institute of the National Institutes of Health (NHLBI) [296].  Published data 
from the Registry showed that survival was enhanced in recipients of augmentation 
therapy compared with non-recipients [296]. In the subset of patients with FEV1 35 to 49 
 163 
 
percent predicted, the rate of FEV1 decline was also slowed in recipients of augmentation 
therapy. Subsequently, a meta-analysis [297] demonstrated that the protective effect of 
augmentation therapy (as determined by FEV1 decline) reflected predominantly the results 
from a subset of patients with FEV1 30 to 65 percent predicted. 
 
Other observational studies indicative of the efficacy of augmentation therapy include 
those by Lieberman [298]  and Stockley et al [299]. Lieberman retrospectively determined 
that the use of augmentation therapy reduced the frequency of lung infections as reported 
by the patients. Stockley et al found that augmentation therapy led to a rise in sputum 
A1AT concentrations and a fall in sputum leukotriene B4 suggesting an anti-inflammatory 
effect that may be a surrogate for efficacy. 
 
Interpretation of these data remains complex. Effects on the decline in FEV1 would only 
be detectable when it is declining fastest. Furthermore, patients receiving regular infusions 
also get weekly exposure to health care professionals, which could influence exacerbation 
rate and mortality. These issues clearly affect the robust nature of any conclusions from 
such observational studies. In addition, the reduction in inflammation alone does not 
necessarily predict clinical outcome. Therefore, the importance of conducting randomised 
controlled studies was highlighted. 
 
A randomised controlled trial was first performed by Dirksen et al [300], who allocated 28 
PiZZ subjects to receive intravenous A1AT infusions for at least 3 years and a further 28 
PiZZ subjects to receive placebo infusions. No differences were observed in the rate of 
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decline in FEV1 between the two groups. However, when analysing the results of CT 
densitometry, a trend was noted towards a slower annual rate of loss of lung density in 
those receiving augmentation therapy. This difference did not however achieve the pre-
determined level of statistical significance (p=0.07). 
 
The EXAcerbations and Computed Tomography scan as Lung End-points (EXACTLE) 
study [301] explored the use of CT densitometry and exacerbations for the assessment of 
the therapeutic effect of augmentation therapy in subjects with A1ATD. This was a 
randomised, double-blind, placebo-controlled, parallel-group study conducted at three 
European centres. Seventy seven patients (PiZZ) were randomised to weekly infusions of 
pooled human A1AT or placebo for 2-2.5 years. CT densitometry demonstrated a 
significant decline in both groups over the course of the study (p<0.001 for both groups), 
consistent with emphysema progression. There was once again a trend towards benefit in 
the treated group although this did not reach statistical significance using the primary 
analysis methodology (p=0.07). No significant differences were found in FEV1 or gas 
transfer decline between the two groups. Exacerbation frequency was unaltered by 
treatment, but a reduction in exacerbation severity was observed in the treatment group. A 
subsequent analysis of this data by Parr et al [302] showed that a beneficial effect was 
present if analysis was confined to the basal region where the emphysema predominates. 
 
The overall results of a combined analysis of these 2 randomised controlled trials (thereby 
increasing the numbers) concluded that intravenous augmentation therapy reduces the 
decline in lung density as measured by CT scanning [303]. 
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A1AT replacement therapy delivered by inhalation may be an alternative therapeutic 
option. In animal studies, inhaled A1AT provides protection against the development of 
cigarette smoke-induced emphysema [304]. Human phase 2-3 studies of inhaled A1AT in 
A1ATD subjects with emphysema are currently underway [305], although the primary 
outcome is exacerbation frequency and severity. 
 
This Chapter aims to study the in vitro effects of A1AT augmentation of serum samples 
from subjects with varying A1AT genotypes (PiSZ, PiFZ, PiZZ) and its effect on 
partitioning of NE or PR3 between the serum inhibitors A1AT and A2M. These 
experiments were designed to test the hypothesis that serum from A1ATD individuals 
augmented with M variant A1AT would give in vitro results for inhibiting NSP activities 
similar to those seen with normal (PiMM) serum. The amount of M A1AT used was 
initially chosen to mimic the nadir values seen in PiZZ subjects receiving weekly 
augmentation therapy, although the effect of augmenting to greater thresholds was also 
explored. PiSZ and PiFZ sera were augmented up to A1AT concentrations found in PiMM 
homozygotes. 
 
7.2 Methods 
7.2.1 Inhibition of NE by serum samples augmented in vitro with M A1AT 
(SlaaapN) 
Serum samples were obtained from subjects with PiSZ, PiFZ and PiZZ genotypes and 
A1AT concentration was determined by ELISA as shown in Table 3.1. Pure M A1AT of 
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pre-determined activity was added to the serum samples in order to augment the A1AT 
concentration into a pre-determined range. The PiSZ and PiFZ sera were augmented to 
A1AT concentrations equivalent to those of PiMM homozygotes (>25µM for the purposes 
of these experiments). The PiZZ serum was augmented to various A1AT concentrations; 
11µM which was taken as the nadir value in subjects receiving weekly augmentation 
therapy and has been recognised as the “protective threshold,” 20µM which is equivalent 
to the average concentration found in PiMZ heterozygotes, and 30µM which is similar to 
the average concentration found in PiMM homozygotes. The augmented serum samples 
were then diluted in NE assay buffer to an A1AT concentration of 1.5µM. Pure NE of pre-
determined activity was also diluted to 1.5µM in NE assay buffer and the NE inhibition 
assays were performed using the methods described in section 3.2.1.1 with SlaaapN 
(1mg/ml in NE assay buffer) as the substrate. Serum samples with or without added A1AT 
were assayed on the same plate to allow comparison of the results. 
 
7.2.2 Inhibition of NE by serum samples augmented in vitro with M A1AT 
(elastin-fluorescein) 
The same serum samples were used as those in section 7.2.1, except the PiZZ serum was 
augmented only to 11µM. The samples were then diluted in elastin buffer to an A1AT 
concentration of 1.5µM. Pure NE of pre-determined activity was diluted to 1.5µM in 
elastin buffer and the NE inhibition assays were performed using the methods described in 
section 5.2.2 with elastin-fluorescein as the substrate. Again, serum samples with or 
without added A1AT were assayed together to allow comparison of the results. Due to 
limitations on time and resources, these experiments were not performed with PR3. 
 
 167 
 
7.2.3 Inhibition of PR3 by serum samples augmented in vitro with M A1AT 
(MSaapvN) 
The same serum samples were used as those in section 7.2.2 but with the PiZZ serum 
being augmented to 30µM. The samples were then diluted in NSP assay buffer to an 
A1AT concentration of 1.5µM. Pure PR3 of pre-determined activity was diluted to 1.5µM 
in NSP assay buffer and the PR3 inhibition assays were performed using the methods 
described in section 3.2.2.2 with MSaapvN (0.2mg/ml in NSP assay buffer) as the 
substrate. Again, serum samples with or without added A1AT were assayed together to 
allow comparison of the results. 
 
7.3 Results 
7.3.1 Inhibition of NE by serum samples augmented in vitro with M A1AT 
(SlaaapN) 
The results of the NE inhibition assays using PiSZ, PiFZ and PiZZ sera with and without 
augmentation with M variant A1AT are shown in Figures 7.1, 7.2 and 7.3 respectively, 
using SlaaapN as the substrate. These results demonstrate that the addition of M A1AT to 
serum from A1ATD subjects (PiSZ, PiFZ and PiZZ genotypes) changed the pattern of the 
NE inhibition slopes by reducing the residual NE activity (when the A1AT was in a molar 
excess). Furthermore, augmentation of PiZZ serum to 20µM led to a greater reduction in 
the residual NE activity than augmentation to 11µM. No enhancement of NE activity 
above that of free enzyme was observed in the augmented PiZZ samples studied here. 
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Figure 7.1- Inhibition of NE with PiSZ serum ± augmentation with M A1AT (SlaaapN) 
 
Figure 7.1: Inhibition of NE activity using PiSZ serum with or without augmentation 
with M A1AT to an A1AT concentration equivalent to that found in a PiMM 
homozygote. SlaaapN was used as the substrate. Points show the mean of triplicate 
results from a single plate. 
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Figure 7.2- Inhibition of NE with PiFZ serum ± augmentation with M A1AT (SlaaapN) 
 
Figure 7.2: Inhibition of NE activity using PiFZ serum with or without augmentation 
with M A1AT to an A1AT concentration equivalent to that found in a PiMM 
homozygote. SlaaapN was used as the substrate. Points show the mean of triplicate 
results from a single plate. 
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Figure 7.3- Inhibition of NE with PiZZ serum ± augmentation with M A1AT (SlaaapN) 
 
Figure 7.3: Inhibition of NE activity using PiZZ serum with or without augmentation 
with M A1AT. Augmentation to greater A1AT concentrations reduced the residual 
activity of NE (when A1AT was in a molar excess). The rationale for the A1AT 
concentrations used is given in the text. SlaaapN was used as the substrate and the 
enhanced NE activity observed when PiZZ serum was used alone has been noted 
previously (Chapters 3 and 4). Points show the mean of triplicate results from a 
single plate. 
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7.3.2 Inhibition of NE by serum samples augmented in vitro with M A1AT 
(elastin-fluorescein) 
The results of the NE inhibition assays using PiSZ, PiFZ and PiZZ sera with and without 
augmentation with M variant A1AT and using elastin-fluorescein as the substrate are 
shown in Figures 7.4, 7.5 and 7.6 respectively. The NE inhibition slopes were similar for 
PiSZ, PiFZ and PiZZ sera with or without the addition of M A1AT. However, the results 
show the molar ratios of A1AT to NE, and do not take into account the greater A1AT 
concentrations in augmented sera compared to non-augmented sera. 
 
Figure 7.4- Inhibition of NE with PiSZ serum ± augmentation with M A1AT (elastin-
fluorescein) 
 
Figure 7.4: Inhibition of NE activity using PiSZ serum with or without augmentation 
with M A1AT to an A1AT concentration equivalent to that found in a PiMM 
homozygote. Elastin-fluorescein was used as the substrate. Results from single 
experiments are shown.  
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Figure 7.5- Inhibition of NE with PiFZ serum ± augmentation with M A1AT (elastin-
fluorescein) 
 
Figure 7.5: Inhibition of NE activity using PiFZ serum with or without augmentation 
with M A1AT to an A1AT concentration equivalent to that found in a PiMM 
homozygote. Elastin-fluorescein was used as the substrate. Results from single 
experiments are shown. 
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Figure 7.6- Inhibition of NE with PiZZ serum ± augmentation with M A1AT (elastin-
fluorescein) 
 
Figure 7.6: Inhibition of NE activity using PiZZ serum with or without augmentation 
with M A1AT to an A1AT concentration of 11µM. Elastin-fluorescein was used as the 
substrate and results from single experiments are shown. 
 
7.3.3 Inhibition of PR3 by serum samples augmented in vitro with M A1AT 
(MSaapvN) 
The results of the PR3 inhibition assays using PiSZ, PiFZ and PiZZ sera with and without 
augmentation with M A1AT and using MSaapvN as the substrate are shown in Figures 
7.7, 7.8 and 7.9 respectively. The results demonstrate that the addition of M A1AT to 
serum from A1ATD subjects (PiSZ, PiFZ and PiZZ genotypes) changed the pattern of the 
PR3 inhibition slopes by reducing the residual PR3 activity (when A1AT was in a molar 
excess).  
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Figure 7.7- Inhibition of PR3 with PiSZ serum ± augmentation with M A1AT (MSaapvN) 
 
Figure 7.7: Inhibition of PR3 activity using PiSZ serum with or without 
augmentation with M A1AT to an A1AT concentration equivalent to that found in a 
PiMM homozygote. MSaapvN was used as the substrate. Points show the mean of 
triplicate results from a single plate. 
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Figure 7.8- Inhibition of PR3 with PiFZ serum ± augmentation with M A1AT (MSaapvN) 
 
Figure 7.8: Inhibition of PR3 activity using PiFZ serum with or without 
augmentation with M A1AT to an A1AT concentration equivalent to that found in a 
PiMM homozygote. MSaapvN was used as the substrate. Points show the mean of 
triplicate results from a single plate. 
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Figure 7.9- Inhibition of PR3 with PiZZ serum ± augmentation with M A1AT (MSaapvN) 
 
Figure 7.9: Inhibition of PR3 activity using PiZZ serum with or without 
augmentation with M A1AT to an A1AT concentration equivalent to that found in a 
PiMM homozygote. MSaapvN was used as the substrate. Points show the mean of 
triplicate results from a single plate. 
 
7.4 Discussion  
The NE inhibition assays using SlaaapN as the substrate (Figures 7.1, 7.2 and 7.3) 
demonstrate that the addition of M A1AT to serum from A1ATD subjects (PiSZ, PiFZ and 
PiZZ genotypes) changes the pattern of the NE inhibition slopes. Since the graphs show 
the molar ratios of A1AT to NE on the x-axis, these changes are not related to 
concentration of A1AT alone but likely reflect a change in the partitioning between the 
two proteinase inhibitors A1AT and A2M as described in Chapters 3 and 4. When M 
A1AT was added to PiSZ and PiFZ sera, there was a reduction in the residual baseline 
activity of NE (when A1AT was in a molar excess) from around 60% to 30%, approaching 
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that seen with PiMM serum (Figure 3.1). This change in the partitioning between the 
inhibitors results in less NE being bound to A2M in the augmented samples (where it 
shows enhanced activity towards SlaaapN), and a greater proportion being bound to A1AT 
where it is inactivated. Similarly, when M A1AT was added to PiZZ serum (Figure 7.3), 
there was a reduction in the residual baseline activity of NE which was greater when the 
PiZZ serum was augmented to 20µM than to 11µM. Furthermore, following the addition 
of M A1AT there was no longer any enhancement of NE activity above that of free NE. 
Again, this is likely to be due to a shift in the partitioning of NE towards binding to A1AT 
where it is inactivated and therefore less binding to A2M where it shows enhanced activity 
towards this substrate. In PiZZ homozygotes, not only is the concentration of A1AT 
reduced in serum (and hence the ratio of A2M:A1AT is increased), the Kass for NE and Z 
A1AT is lower than the Kass for NE and A2M (Chapter 6) which favours binding of 
released NE to A2M. Augmentation with M A1AT (which has a similar Kass with NE to 
that of A2M) therefore shifts the partitioning of released NE towards being inactivated by 
A1AT. Thus the amount of NE that complexes with A2M would be dramatically reduced 
which may reduce the clinical consequences. 
 
The NE inhibition assays using elastin-fluorescein as the substrate (Figures 7.4, 7.5 and 
7.6) showed that the NE inhibition slopes were similar for PiSZ, PiFZ and PiZZ sera with 
and without the addition of M A1AT. However, the results show the inhibitory potential of 
the samples (as shown by molar ratio of A1AT to NE) and not the capacity, since 
augmented serum has a greater A1AT concentration than non-augmented serum. The 
results presented in this Chapter are consistent with those presented in Chapter 5, which 
demonstrated that the pattern of NE inhibition was similar for PiZZ and PiMM sera, and 
that A1AT was less functional as an inhibitor of NE when elastin-fluorescein was used as 
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the substrate (extrapolation of the slopes in Figures 7.4, 7.5 and 7.6 to the x-axis suggests 
that NE is inhibited when the molar ratio of A1AT:NE is 1.2-1.4:1). The lack of difference 
observed here in the residual baseline activities of NE (when the A1AT was in a molar 
excess) between augmented and non-augmented samples may potentially be because 
A2M:NE complexes are less active towards elastin than against low molecular weight 
peptide substrates. Potentially, a proportion of these complexes may contain two molecules 
of NE which would not be simultaneously active towards a macromolecular substrate such 
as elastin, leading to a saturation effect. Although PR3 inhibition assays were not 
performed using augmented serum with elastin-fluorescein as the substrate, earlier results 
(Chapter 5) suggested that PiZZ serum could completely inhibit PR3 activity towards 
elastin with a molar ratio for A1AT:PR3 of 1:1, similar to results found with PiMM serum. 
 
The PR3 inhibition assays using MSaapvN as the substrate (Figures 7.7, 7.8 and 7.9) 
demonstrate that the augmentation of PiSZ, PiFZ or PiZZ sera alters the pattern of the 
inhibition slopes in a similar manner to that observed with NE when using a low molecular 
weight peptide substrate. The baseline activities of PR3 in the augmented serum samples 
were reduced compared to the non-augmented samples, which again likely represents a 
change in the partitioning of PR3 between its serum inhibitors, with a greater proportion of 
PR3 being inactivated by A1AT in the augmented samples. Any physiological significance 
of active PR3 complexes with A2M remains uncertain at present. 
 
Future studies could explore the inhibitory capacity of serum from A1ATD patients before 
and after receiving intravenous augmentation therapy to gain a closer insight into the 
effects of augmentation therapy in vivo. Earlier experiments (Chapters 3 and 4) have 
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suggested that A1AT does not inhibit NE or PR3 bound to A2M, and poorly inhibits NE 
bound to elastin and therefore augmentation therapy would be less efficacious where 
enzyme is released in high concentrations and close to connective tissue. However, weekly 
intravenous augmentation therapy does result in serum A1AT levels that exceed the 
protective threshold over the full dosing interval and the A1AT maintains its functional 
activity [286]. The effects of local A1AT concentration on neutrophil cell surface 
expression of NE and PR3 are explored further in Chapter 8. 
 
In summary, this Chapter has demonstrated that augmentation of A1ATD serum in vitro 
changes the pattern of the NE and PR3 inhibition slopes towards that found with PiMM 
serum when peptide substrates were used. Greater concentrations of M A1AT were 
associated with a greater reduction of the residual baseline activities of NE and PR3 and 
hence a reduction in the proportion of these NSPs bound to A2M (where they retain 
proteolytic activity). Furthermore, in PiZZ serum, augmentation to an A1AT concentration 
of 20µM had a greater impact on these characteristics than augmentation to the accepted 
protective threshold of 11µM. 
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8 Neutrophil cell surface expression of proteinases  
8.1 Introduction 
Earlier Chapters have studied the ability of normal (PiMM) and A1ATD (PiZZ) sera to 
inhibit activity of NSPs and the in vitro effects of altering the A1AT concentration by 
augmentation therapy. In this Chapter, the neutrophil cell surface expression of NE and 
PR3 has been studied in subjects with A1ATD (PiZZ), usual COPD (PiMM) and healthy 
controls (PiMM), as well as the local effects of A1AT concentration on neutrophil 
expression of these NSPs. NSPs bound to the cell membrane of stimulated neutrophils 
remain catalytically active towards both synthetic peptide and high molecular weight 
biological substrates such as fibronectin [54, 108, 240, 306]. This activity of membrane-
bound NSPs could facilitate penetration through tissue barriers and enable local 
degradation of extracellular matrix proteins without significant injury to surrounding 
tissues. However, excessive cell surface NSP activity may also play a role in the 
pathogenesis of disease. 
 
NE and CG are minimally expressed on quiescent neutrophils [54] whereas PR3 is 
constitutively expressed on the surface of quiescent neutrophils from healthy controls 
[108] but may not be active on these cells [307]. This constitutively expressed PR3 is 
unlikely to originate from the azurophilic granules since other markers of granule 
exocytosis are not present [308]. The proportion of cells constitutively expressing PR3 on 
their surfaces has been reported to vary amongst individuals but remains stable in each 
individual over time, suggesting a genetic background to this feature [308]. This 
hypothesis has been supported by both family and twin studies [309, 310]. 
 181 
 
 
Stimulation of neutrophils by chemoattractants or cytokines results in the mobilisation of 
the azurophilic granules to the cell surface and increased membrane expression of PR3, 
NE and CG [51]. Exposure of neutrophils to exogenous NSPs also results in greater 
membrane expression of NSPs, suggesting that proteinases can spontaneously bind to sites 
on the neutrophil cell membrane [54]. The mechanism of binding of NE and CG to the 
neutrophil cell membrane is by a charge-dependent mechanism. These cationic 
proteineases bind to the negatively charged sulphate groups of heparan sulphate and 
chondroitin sulphate containing proteoglycans [306]. However, PR3 binding to the cell 
membrane does not occur in a charge-dependent manner [102]. David et al [311] 
suggested that membrane-bound PR3 co-localises with the adhesion molecule beta-2 
integrin (CD11b/CD18). Subsequent experiments have suggested that PR3 binding to the 
cell membrane is likely to occur via the glycosylphosphatidylinositol (GPI)-anchored 
neutrophil receptors FcγRIIIb (CD16b) [312] and/or the NB1 (CD177) receptor [313], 
although the exact mechanism has not been fully elucidated and requires further 
investigation [314]. A physiological role for membrane-bound PR3 has been suggested by 
Kim et al [315] in mediating phagocytosis of non-opsonized bacteria. In addition, PR3 is 
expressed on the cell membrane at an early stage of apoptosis, in the absence of 
degranulation [316]. This PR3 expression decreases macrophage phagocytosis, delaying 
neutrophil clearance [317] and potentially amplifies inflammatory processes and 
autoimmunity. 
 
PR3 is a major antigenic target of ANCAs in Wegener’s granulomatosis (WG) [115]. 
ANCAs can bind to PR3 expressed on neutrophil cell membranes and amplify cell 
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activation. Neutrophil activation occurs when ANCAs cross-link PR3 with FcγRIIa 
(CD32) inducing the oxidative burst [314, 318, 319]. Witko-Sarsat et al reported that 
individuals with WG had a greater proportion of neutrophils expressing PR3 on their cell 
membrane compared to healthy controls [310] but did not find any relationship with 
disease activity or treatment. In contrast, others have reported that neutrophil PR3 
expression is greater with acute vasculitis and lower during remission of disease [320, 
321]. Overall, cell membrane expression of PR3 seems to be related to WG but the 
mechanisms of this association remain uncertain. In addition, a deficiency of A1AT (the 
major circulating inhibitor of PR3) is a risk factor for WG [228]. Campbell et al [108] 
demonstrated that exogenous PR3 could bind to the neutrophil cell membrane in a dose-
dependent manner. Therefore, it could be hypothesized that in subjects with a deficiency of 
A1AT, the concentration of free PR3 in the vicinity of activated neutrophils (following 
degranulation) would be greater than in subjects with normal concentrations of A1AT (due 
to local A1AT binding to PR3), and thus PR3 binding to the neutrophil cell membranes 
may also be greater with A1ATD. 
 
These concepts are explored further in this Chapter by measuring NE and PR3 expression 
on the cell surface of neutrophils from A1ATD subjects, non-deficient COPD subjects and 
healthy controls. Experiments have also been performed to study the local effects of A1AT 
concentration on neutrophil surface expression of NE and PR3. As described above, NSPs 
on the neutrophil cell membrane may play a role in disease due to their persistent activity. 
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8.2 Methods 
8.2.1 Subject selection 
For the experiments where neutrophil cell surface expression of NE and PR3 were 
measured, nine clinically stable subjects with A1ATD (PiZZ or PiZnull phenotypes) who 
met the diagnostic criteria for COPD were identified from the UK national registry for 
A1ATD, and were recruited during outpatient appointments. Nine healthy controls who 
were partners of patients with A1ATD (and therefore age-matched) were also recruited. 
The healthy controls had a normal PiMM A1AT genotype, no significant medical history, 
normal spirometry, were on no regular medication and were non- or ex-smokers. In 
addition, six clinically stable subjects with usual COPD (PiMM A1AT phenotype) were 
recruited from outpatient clinics. All subjects had basic demographic data collected, 
venous blood was collected and neutrophils were extracted (as described in section 2.2.2) 
and prepared for flow cytometry as described below. 
 
For the experiments studying the local effects of A1AT concentration on neutrophil cell 
surface expression of NE and PR3, six subjects with A1ATD (PiZZ phenotype) and six 
healthy controls were recruited. Venous blood was collected both for neutrophil extraction 
and for plasma.  
 
8.2.2 Preparation of neutrophils for flow cytometry 
Neutrophils were used either unstimulated or stimulated with 100nM N-formyl-
methionine-leucine-phenylalanine (fMLP; Sigma, UK). The freshly extracted neutrophils 
were suspended in RPMI 1640 medium (Sigma, UK) in two aliquots; one had fMLP added 
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for comparison with unstimulated cells. The neutrophil solutions were incubated at room 
temperature for 30 minutes. Following incubation, the tubes were centrifuged at 460 x g 
for 10 minutes at room temperature and the supernatants (containing the stimulant in one 
of the tubes) were removed. The neutrophils were then re-suspended in RPMI 1640 
medium without stimulant. 
 
The cells were prepared for flow cytometry in a flexible u-bottomed 96-well plate (Fisher, 
UK). The wells were labelled and coated with 2% BSA (Sigma, UK) in PBS to minimise 
cell adhesion to the plate. The neutrophil solutions (200µL) were added to the labelled 
wells, and the plate was centrifuged at 300 x g for 4 minutes at 4ºC. The supernatants were 
removed and 50µL of labelled antibodies were added per well. The antibodies used were 
mouse monoclonal PR3 labelled with fluorescein isothiocyanate (FITC) (abcam, UK) and 
mouse monoclonal NE antibody (AbD Serotec, UK) labelled with Alexa Fluor 647 using a 
monoclonal antibody labelling kit (Invitrogen, UK). The antibodies were diluted in 2% 
BSA in PBS and the optimal dilution of the antibody was determined by performing 
titration experiments with a range of antibody concentrations. Wells for isotype controls 
and cells only were included, the latter had only 2% BSA added. The plate was incubated 
on ice and protected from light for 20 minutes. Following this time period, the cells were 
washed by adding 2% BSA to all of the wells and spinning the plate in the centrifuge as 
before. This step was repeated to ensure that any free antibody was removed. The cells 
were then re-suspended in 2% BSA and added to round bottom tubes suitable for flow 
cytometry.  
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Analysis was performed using an Accuri® C6 flow cytometer. Neutrophils were gated 
based on their forward scatter (FS) and side scatter (SS), and a second gate based on cell 
width was used to ensure that single cells only were counted. Ten thousand events were 
recorded for each measurement. The mean fluorescence intensities (MFI) were recorded 
for cells labelled with PR3 and NE antibodies (following subtraction of the control MFI), 
and the percentage of cells expressing each proteinase was also measured. 
 
Results presented in this Chapter for PR3 and NE expression on the neutrophil cell 
membrane are primarily presented in the arbitrary units of MFI (following subtraction of 
the control MFI). However, the results showing the percentage of cells expressing each 
proteinase are also discussed for completeness, but not presented graphically. 
 
8.2.3 Determining the effect of A1AT on PR3 and NE expression on the 
neutrophil cell membrane 
Neutrophils were extracted as described in section 2.2.2 and diluted to a concentration of 2 
million cells per ml in RPMI 1640 medium. Six 1ml aliquots of the neutrophil solution 
were measured into 15ml Falcon tubes, which had been coated with 2% BSA to minimise 
cell adhesion. The tubes were centrifuged at 460 x g for 10 minutes at room temperature 
and the supernatants were removed to leave a pellet of cells. The cells were then re-
suspended in either RPMI 1640 medium (2 tubes), PiZZ plasma (2 tubes) or PiMM plasma 
(2 tubes). For each pair of tubes, neutrophils were either unstimulated in one tube or 
stimulated with 100nM fMLP in the second tube. The solutions were incubated at room 
temperature for 30 minutes and subsequently the tubes were centrifuged at 460 x g for 10 
minutes and the supernatants removed. The neutrophils were then re-suspended in RPMI 
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1640 medium without stimulant and prepared for flow cytometry as described above. 
Analysis was performed using an Accuri® C6 flow cytometer as described above. 
 
8.2.4 Statistical analysis 
Statistical analyses were performed using PASW statistics 18 for Windows. Normality was 
tested using the Kolmogorov-Smirnov test. For non-parametric data, Mann-Whitney U 
tests or Wilcoxon signed rank tests were used for comparisons of independent or paired 
samples respectively. For normally distributed data, independent or paired T-tests were 
used for comparisons of independent or related samples respectively. When comparing 
neutrophil cell surface expression of NE and PR3 in the three subject groups, two tailed p-
values were used.  To test the hypothesis that NE and PR3 expression on the neutrophil 
cell surface is greater when the surrounding A1AT concentration is reduced, one tailed p-
values were used. Results were deemed statistically significant if p≤0.05. 
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8.3 Results 
8.3.1 Subject demographics 
For the experiments where neutrophil cell surface expression of NE and PR3 was 
measured, there was no difference in sex between the three subject groups (A1ATD, 
healthy controls and usual COPD). The mean ages of the groups (±SEM) were 60.8±3.2 
years for A1ATD subjects, 59.2±4.0 years for healthy controls and 74.2±3.7 years for 
usual COPD patients. The COPD patients were significantly older than the A1ATD 
subjects (p=0.018) and the healthy controls (p=0.022). However, importantly, baseline cell 
membrane expression of PR3 is not thought to be related to age [310]. 
 
For the experiments studying the local effects of A1AT concentration on neutrophil cell 
surface expression of NE and PR3, there was no significant difference in age between the 
A1ATD subjects and the healthy controls (54.3±3.2 years vs 45.5±3.1 years; p=0.064). 
However, the A1ATD subjects were predominantly male (83%) and the healthy controls 
were predominantly female (83%). Nevertheless, these experiments were designed to 
compare NE and PR3 neutrophil cell surface expression in the presence of either normal 
(PiMM plasma) or reduced (PiZZ plasma) A1AT concentrations in the same individual, 
and no direct comparisons were made between the two subject groups. 
 
8.3.2 NE and PR3 expression on the neutrophil cell membrane 
8.3.2.1 NE and PR3 expression on unstimulated neutrophils 
PR3 expression on the cell surface of unstimulated neutrophils as measured by the MFI 
was significantly greater in A1ATD subjects (median 2449 MFI, IQR 1503-2593 MFI) 
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than healthy controls (median 1506 MFI, IQR 879-1884 MFI; 2-tailed p=0.048) and 
subjects with usual COPD (median 1249 MFI, IQR 749-1840 MFI; 2-tailed p=0.046). 
However, NE expression was not significantly different between the 3 subject groups 
(A1ATD 1421 MFI, IQR 1121-3128 MFI; healthy 874 MFI, IQR 416-2140 MFI; COPD 
883 MFI, IQR 522-2087 MFI; 2-tailed p>0.05 in all cases). These data are summarised in 
Figure 8.1. 
 
The percentage of these unstimulated neutrophils expressing PR3 was greater in A1ATD 
subjects compared to controls (50.0±7.3% vs 27.5±6.3%; 2-tailed p=0.033) but was not 
significantly different compared to subjects with usual COPD (50.0±7.3% vs 30.1±9.4%; 
2-tailed p=0.116). The percentage of unstimulated neutrophils expressing NE was greater 
in A1ATD subjects compared to those with usual COPD (53.8±10.1% vs 21.5±8.3%; 2-
tailed p=0.036) but was not significantly different when compared to healthy controls 
(53.8±10.1% vs 31.1±10.1%; 2-tailed p=0.161). 
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Figure 8.1- Cell surface expression of PR3 and NE on unstimulated neutrophils from 
A1AT deficient subjects, healthy controls and subjects with usual COPD 
 
 
Figure 8.1: Expression of proteinases on the cell surface of unstimulated neutrophils. 
The y-axis shows the MFI measured by flow cytometry. Each point represents data 
from a single patient in each of the 3 subject groups. The bars show the median and 
IQR. Statistically significant differences are highlighted using 2-tailed p-values. 
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8.3.2.2 NE and PR3 expression on neutrophils following stimulation with fMLP 
Following stimulation with 100nM fMLP for 30 minutes, expression of PR3 and NE on 
the cell membrane as measured by MFI was increased in all subject groups, with the 
exception of neutrophils from A1ATD subjects where there was no significant increase in 
NE expression after stimulation. Cell surface expression of PR3 increased proportionally 
in A1ATD subjects and healthy controls, but showed a greater proportional increase in 
subjects with COPD. These results are summarised in Figure 8.2 (NS = not significant). 
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Figure 8.2- Cell surface expression of PR3 and NE before and after stimulation with fMLP 
 
 
 
Figure 8.2: PR3 & NE expression on the neutrophil cell surface pre/post stimulation 
(median and IQR). Different scales are used on the y-axis for each subject group. 
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PR3 expression on the cell surface of stimulated neutrophils as measured by the MFI was 
significantly greater in A1ATD subjects (median 4681 MFI, IQR 4205-6149 MFI) 
compared to healthy controls (median 3856 MFI, IQR 1856-4439 MFI; 2-tailed p=0.042), 
but was not significantly different when compared to subjects with usual COPD (median 
3572 MFI, IQR 1945-7559 MFI; 2-tailed p=0.78). NE expression was not significantly 
different between the three subject groups (A1ATD 2220 MFI, IQR 1085-4975 MFI; 
healthy 1431 MFI, IQR 758-2920 MFI; COPD 1938 MFI, IQR 1538-8653 MFI; 2-tailed 
p>0.05 in all cases). These data are summarised in Figure 8.3. 
 
The percentage of stimulated neutrophils expressing PR3 on their cell surface was not 
significantly different between the three subject groups (A1ATD 68.2±7.2%, healthy 
56.9±7.1%, COPD 67.6±8.5%; 2-tailed p>0.05 in all cases) and the same was true for NE 
expression (A1ATD 57.0±9.3%, healthy 46.0±9.5%, COPD 59.7±11.7%; 2-tailed p>0.05 
in all cases) indicating that the changes were due to increased expression on cells and not 
solely due to recruitment of more positive cells. 
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Figure 8.3- Cell surface expression of PR3 and NE on stimulated neutrophils from A1AT 
deficient subjects, healthy controls and subjects with usual COPD 
 
 
Figure 8.3: Expression of proteinases on the cell surface of neutrophils stimulated 
with 100nM fMLP. The y-axis shows the MFI measured by flow cytometry. Each 
point represents data from a single patient in each of the 3 subject groups. The bars 
show the median and IQR. Statistically significant differences are highlighted using 
2-tailed p-values.  
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8.3.3 The effect of local A1AT concentration on PR3 and NE expression on 
neutrophil cell membranes 
8.3.3.1 NE and PR3 expression on neutrophils from A1ATD subjects following 
incubation in PiMM or PiZZ plasma 
When neutrophils were isolated from A1ATD subjects and incubated in their own plasma, 
PR3 expression as measured by MFI was significantly greater (median 795 MFI, IQR 614-
1106 MFI) than when they were incubated in PiMM plasma containing normal A1AT 
levels (median 584 MFI, IQR 384-965 MFI; p=0.031). Furthermore, cell surface PR3 
expression was greater when neutrophils were incubated in RPMI 1640 medium (in the 
absence of plasma) compared to both PiZZ and PiMM plasma (median 2469 MFI, IQR 
1410-2569; p=0.016 for PiZZ and PiMM plasma). There was no difference in NE 
expression between the neutrophils incubated in PiZZ or PiMM plasma (PiZZ median 558 
MFI, IQR 384-1626 MFI; PiMM median 880 MFI, IQR 288-1486 MFI; p=0.422) or 
neutrophils incubated in RPMI 1640 medium (median 583 MFI, IQR 230-1170; p=0.219 
compared to PiMM plasma, p=0.156 compared to PiZZ plasma). These data are 
summarised in Figure 8.4.  
 
The percentage of cells expressing PR3 on their cell surface was greater in the presence of 
PiZZ plasma compared to PiMM plasma (mean 14.3±4.4% vs 7.6±1.9%; p=0.031). 
Furthermore, the percentage of cells expressing PR3 was greater when the cells were 
incubated in RPMI 1640 medium than PiZZ and PiMM plasma (mean 41.1±10.1%; 
p=0.031 for PiZZ plasma and p=0.016 for PiMM plasma). There was no difference in the 
percentage of cells expressing NE between those incubated in PiZZ and PiMM plasma 
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(mean 19.6±9.3% vs 27.8±11.8%; p=0.344) or RPMI 1640 medium (15.1±8.3%; p=0.219 
compared to PiMM plasma, p=0.156 compared to PiZZ plasma).  
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Figure 8.4- Cell surface expression of PR3 and NE on neutrophils isolated from A1AT 
deficient subjects and incubated in PiZZ or PiMM plasma 
 
 
Figure 8.4: Baseline expression (MFI) of proteinases on the cell surface of neutrophils 
extracted from six A1ATD subjects and incubated in either PiM or PiZ plasma or 
RPMI 1640 medium prior to labelling with antibodies for flow cytometry. Horizontal 
lines represent the medians and IQR. Significant differences are labelled. 
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8.3.3.2 NE and PR3 expression on neutrophils from A1ATD subjects following 
stimulation with fMLP in the presence of PiMM or PiZZ plasma 
When neutrophils from A1ATD subjects were stimulated with fMLP in the presence of 
either PiZZ or PiMM plasma or RPMI 1640 medium, the PR3 expression was significantly 
greater compared to unstimulated cells in both PiZZ (p=0.028) and PiMM plasma 
(p=0.028), and RPMI 1640 medium (p=0.031). However, the increase in PR3 cell surface 
expression was similar in all groups, being approximately two-fold. Consequently, the cell 
surface expression of PR3 was significantly greater on the cells stimulated in the presence 
of PiZZ plasma (median 1390 MFI, IQR 1030-2046 MFI) compared to those stimulated in 
PiMM plasma (median 986 MFI, IQR 855-1640 MFI; p=0.016). Furthermore, cell surface 
PR3 expression was greater on neutrophils stimulated in the presence of RPMI 1640 
medium (in the absence of plasma) compared to both PiZZ and PiMM plasma (median 
3484 MFI, IQR 2856-4444 MFI; p=0.016 for PiZZ and PiMM plasma). 
 
Neutrophil cell surface expression of NE increased significantly following stimulation 
with fMLP in the presence of RPMI 1640 medium (p=0.016) and PiZZ plasma (p=0.028), 
but not in the presence of PiMM plasma (p=0.116). There was still however no significant 
difference in NE expression between the neutrophils activated in the presence of PiZZ or 
PiMM plasma (PiZZ median 1407 MFI, IQR 602-2766 MFI; PiMM median 1630 MFI, 
IQR 792-2428 MFI; p=0.5) or RPMI 1640 medium (median 1803 MFI, IQR 853-3323 
MFI; p=0.078 compared to PiMM plasma, p=0.344 compared to PiZZ plasma). These data 
are summarised in Figure 8.5. 
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The percentage of cells expressing PR3 or NE on their cell surface was not significantly 
different between cells activated in the presence of PiZZ or PiMM plasma (mean PR3 
expression 30.3±6.1% in PiZZ plasma vs 22.6±5.6% in PiMM plasma; p=0.078, and mean 
NE expression 21.6±6.9% in PiZZ plasma vs 28.6±9.9% in PiMM plasma; p=0.281). 
However, the percentage of cells expressing PR3 was greater when cells were activated in 
RPMI 1640 medium than when they were activated in PiZZ or PiMM plasma (59.4±7.4%, 
p=0.016 for PiZZ and PiMM plasma). In addition, when cells were activated in RPMI 
1640 medium, the percentage of cells expressing NE on their surface was greater than 
when they were activated in PiZZ plasma (41.4±7.4%; p=0.016), but was not different to 
cells activated in PiMM plasma (p=0.078). 
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Figure 8.5- Cell surface expression of PR3 and NE on neutrophils isolated from A1AT 
deficient subjects and activated with fMLP in the presence of PiZZ or PiMM plasma 
 
 
Figure 8.5: Expression of proteinases (MFI) on the cell surface of neutrophils 
extracted from six A1ATD subjects and activated with fMLP in either PiM or PiZ 
plasma or RPMI 1640 medium prior to labelling with antibodies for flow cytometry. 
Horizontal lines represent medians and IQR. Significant differences are labelled.  
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8.3.3.3 NE and PR3 expression on neutrophils from healthy controls following 
incubation in PiMM or PiZZ plasma 
When neutrophils were isolated from healthy subjects and incubated in either their own or 
PiZZ plasma (from an A1ATD subject), the PR3 expression was significantly higher on 
the neutrophils that were incubated in PiZZ plasma (median 924 MFI, IQR 452-1316 MFI) 
compared to those incubated in PiMM plasma (median 621 MFI, IQR 341-997 MFI; 
p=0.047). Cell surface PR3 expression was greater when neutrophils were incubated in 
RPMI 1640 medium (median 897 MFI, IQR 530-1465 MFI) than PiMM plasma 
(p=0.016), but not PiZZ plasma (p=0.219). There was no difference in NE expression 
between the neutrophils incubated in PiZZ or PiMM plasma (PiZZ median 1657 MFI, IQR 
319-2395 MFI; PiMM median 1199 MFI, IQR 615-1988 MFI; p=0.109) or RPMI 1640 
medium (median 627 MFI, IQR 363-2314 MFI; p=0.219 compared to both PiMM and 
PiZZ plasma). These data are summarised in Figure 8.6.  
 
The percentage of cells expressing PR3 or NE on their cell surface was not significantly 
different between cells incubated in PiZZ or PiMM plasma (mean PR3 expression 
13.0±4.0% in PiZZ plasma vs 9.1±3.4% in PiMM plasma; p=0.281, mean NE expression 
42.9±13.9% in PiZZ plasma vs 27.8±12.3% in PiMM plasma; p=0.156). When cells were 
incubated in RPMI 1640 medium, the percentage of cells expressing PR3 on their surface 
was greater than when they were incubated in PiMM plasma (17.3±5.9%; p=0.0156), but 
not different to when they were incubated in PiZZ plasma (p=0.109). The percentage of 
cells expressing NE on their surface was not significantly different when incubated in 
RPMI 1640 medium compared to PiZZ or PiMM plasma (30.1±14.3%; p=0.5 for PiZZ and 
PiMM plasma).  
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Figure 8.6- Cell surface expression of PR3 and NE on neutrophils isolated from healthy 
subjects and incubated in PiZZ or PiMM plasma 
 
 
Figure 8.6: Baseline expression (MFI) of proteinases on the cell surface of neutrophils 
extracted from six healthy subjects and incubated in either PiM or PiZ plasma or 
RPMI 1640 medium prior to labelling with antibodies for flow cytometry. Horizontal 
lines represent medians and IQR. Significant differences are labelled.  
 202 
 
8.3.3.4 NE and PR3 expression on neutrophils from healthy controls following 
stimulation with fMLP in the presence of PiMM or PiZZ plasma 
When neutrophils from healthy subjects were stimulated with fMLP in the presence of 
either PiZZ or PiMM plasma or RPMI 1640 medium, the PR3 expression was significantly 
greater compared to unstimulated cells in both PiZZ (p=0.028) and PiMM plasma 
(p=0.028), and RPMI 1640 medium (p=0.016). The increase in PR3 cell surface 
expression was approximately two-fold in the presence of either PiZZ or PiMM plasma, 
and approximately three-fold in the presence of RPMI 1640 medium. Consequently, the 
PR3 expression was significantly greater on the cells stimulated in the presence of PiZZ 
plasma (median 1921 MFI, IQR 866-2525 MFI) compared to PiMM plasma (median 1352 
MFI, IQR 695-1529 MFI; p=0.031). Cell surface PR3 expression was greater on 
neutrophils stimulated in the presence of RPMI 1640 medium (median 2415 MFI, IQR 
1505-6018 MFI) than those stimulated in the presence of PiMM plasma (p=0.016), but not 
PiZZ plasma (p=0.109). 
 
Neutrophil cell surface expression of NE increased significantly following stimulation 
with fMLP in the presence of PiZZ plasma (p=0.028), PiMM plasma (p=0.046) or RPMI 
1640 medium (p=0.016). There was no significant difference in NE expression between 
the neutrophils activated in the presence of PiZZ or PiMM plasma (PiZZ median 3014 
MFI, IQR 580-4553 MFI; PiMM median 2876 MFI, IQR 524-3384 MFI; p=0.156), but 
neutrophils activated in RPMI 1640 medium (median 3683 MFI, IQR 2329-4474 MFI) 
had greater NE expression than cells activated in PiMM plasma (p=0.016). These data are 
summarised in Figure 8.7. 
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The percentage of cells expressing PR3 on their cell surface was also greater when the 
cells were activated in the presence of PiZZ plasma compared to PiMM plasma (mean 
33.5±8.8% vs 24.5±6.3%, p=0.031). Furthermore, the percentage of cells expressing PR3 
was greater when cells were activated in RPMI 1640 medium than when they were 
activated in PiZZ or PiMM plasma (54.1±10.4%; p=0.031 for PiZZ plasma, p=0.016 for 
PiMM plasma). There was no difference in the percentage of cells expressing NE between 
cells activated in the presence of PiZZ plasma or PiMM plasma (mean 46.1±13.3% vs 
36.6±14.3%, p=0.281). When cells were activated in RPMI 1640 medium, the percentage 
of cells expressing NE on their surface was greater than when they were activated in 
PiMM plasma (56.0±12.2%; p=0.016), but was not different to cells activated in PiZZ 
plasma (p=0.281). 
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Figure 8.7- Cell surface expression of PR3 and NE on neutrophils isolated from healthy 
subjects and activated with fMLP in the presence of PiZZ or PiMM plasma 
 
 
Figure 8.7: Expression of proteinases (MFI) on the cell surface of neutrophils 
extracted from six healthy subjects and activated with fMLP in either PiM or PiZ 
plasma or RPMI 1640 medium prior to labelling with antibodies for flow cytometry. 
Horizontal lines represent medians and IQR. Significant differences are labelled. 
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8.4 Discussion  
This work has confirmed that PR3 is present on the cell membrane of unstimulated 
neutrophils as previously reported [108]. Neutrophil expression of PR3 (as measured by 
MFI) was greater in subjects with A1ATD compared to both healthy controls and subjects 
with usual COPD (Figure 8.1), suggesting that this finding was not solely related to the 
underlying pulmonary inflammation but was influenced by deficiency of A1AT.  This 
work also found that NE was present on the cell membrane of unstimulated cells in 
contrast to previously published work [54], although NE expression (as measured by MFI) 
was not significantly different between the 3 subject groups.  
 
Neutrophil isolation procedures may result in partial cell activation which could modify 
the expression of NSPs on the cell membranes [322]. The degree of cell activation could 
depend on the source of the blood and whether it contains primed neutrophils, which are 
more susceptible to activation than quiescent neutrophils. However, it is unlikely that 
isolation procedures or the source of the sample would account for the observed 
differences in PR3 expression between the subject groups for two reasons; firstly, 
stimulation of the cells with fMLP led to a significant increase in PR3 expression in all 
subject groups compared to baseline, and secondly, PR3 expression increased 
proportionally in A1ATD subjects and healthy controls following stimulation with fMLP. 
However, it could be hypothesized that isolation procedures or the presence of primed 
neutrophils may have a greater influence on NE expression on the cell membrane, which is 
not believed to be constitutively expressed [54], and could potentially explain why NE was 
detected on unstimulated cells and why NE expression on neutrophils from A1ATD 
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subjects was not significantly different before and after stimulation with fMLP. Indeed, 
differences between PR3 and NE and their interactions with the cell membrane have been 
described previously [51]. 
 
Following stimulation with fMLP, cell surface expression of PR3 increased proportionally 
in A1ATD subjects and healthy controls (approximately two-fold) and therefore, PR3 
expression (as measured by MFI) remained greater on stimulated neutrophils from A1ATD 
subjects compared to healthy controls (Figure 8.3), as found with unstimulated cells. 
However, cell surface expression of PR3 showed a greater proportional increase in 
subjects with COPD following stimulation with fMLP (3-4 fold, shown in Figure 8.2). 
Altered neutrophil function in COPD subjects has been reported previously including; 
increased spontaneous adherence to endothelium under flow conditions [47], enhanced 
chemotaxis, increased spontaneous extracellular proteolysis [48], and greater production of 
reactive oxygen species [323], which may be consistent with the enhanced response in 
PR3 expression seen here. 
 
NE expression increased 2-3 fold on neutrophils from both healthy controls and subjects 
with usual COPD following stimulation, and these findings are consistent with those of 
Owen et al [54], who reported a 2-3 fold increase in the cell surface expression of NE and 
CG following stimulation with fMLP with a similar concentration and time course. 
However, as previously discussed, no significant increase was observed on neutrophils 
from subjects with A1ATD. Figure 8.3 shows that following stimulation with fMLP, no 
differences were found in neutrophil expression of NE between subjects with A1ATD, 
usual COPD and healthy controls, as observed with unstimulated cells. 
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The current studies have demonstrated that PR3 expression on the neutrophil cell surface 
was greater when the surrounding concentration of A1AT was lower. Neutrophils 
extracted and incubated in PiZZ plasma (with a low A1AT concentration) had greater PR3 
expression than cells incubated in PiMM plasma (with a normal A1AT concentration), as 
shown in Figures 8.4 and 8.6. This was true for neutrophils from both subjects with 
A1ATD and healthy controls, so was independent of the source of the neutrophils. 
Following stimulation of neutrophils with fMLP in the presence of plasma, PR3 
expression was significantly greater than on unstimulated cells in both PiZZ and PiMM 
plasma, and the proportional increases were similar in both PiZZ and PiMM plasma. 
Therefore, as found with unstimulated cells, neutrophils stimulated in the presence of PiZZ 
plasma showed greater PR3 expression than cells stimulated in the presence of PiMM 
plasma (Figures 8.5 and 8.7). However, neutrophil cell surface expression of NE did not 
appear to be influenced by the local concentration of A1AT in these studies (as discussed 
further below), and was not significantly different on cells incubated in either PiZZ or 
PiMM plasma, or on cells stimulated in the presence of PiZZ or PiMM plasma.  
 
Previous studies have reported conflicting information about the ability of proteinase 
inhibitors (such as A1AT) to inactivate NSPs on the neutrophil cell membrane. Owen et al 
[54] reported that cell surface-bound NE on fixed cells was resistant to inhibition by 
naturally occurring proteinase inhibitors such as A1AT and, to a lesser extent, SLPI. 
Campbell et al [108] later reported that membrane-bound PR3 was resistant to inhibition 
by A1AT and elafin. However, they used unstimulated fixed cells with exogenous PR3 
bound to the cell membrane due to the lack of availability of a PR3 specific substrate at the 
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time of publication. Subsequently, Korkmaz et al [324] compared fixed and unfixed 
neutrophils and showed that NE bound to the cell surface of unfixed activated neutrophils 
could be fully inhibited by stoichiometric amounts of A1AT, whereas this was not the case 
when using fixed neutrophils (where the accessibility of epitopes was found to be altered 
by fixation). They concluded that membrane-bound NE could be removed from the 
neutrophil membrane following complex formation with A1AT. The same group [307] 
later studied membrane-bound PR3 and suggested that constitutively expressed PR3 on 
quiescent neutrophils did not interact with A1AT, whereas PR3 on the surface of 
stimulated cells could be inhibited by A1AT and cleared from the cell membrane. 
However, unlike NE, PR3 remained bound to the membrane when inhibited by low 
molecular weight inhibitors such as elafin, which may be a reflection of the different 
binding mechanisms of NE and PR3 to the neutrophil cell membrane. The ability of A2M 
to interact with membrane-bound NSPs remains uncertain. 
 
The ability of A1AT to interact with membrane-bound PR3 and subsequent clearance of 
the complex would be consistent with the findings of the current studies where greater 
amounts of A1AT were associated with less neutrophil cell surface expression of PR3. 
Although this trend was also noted with unstimulated cells, the cell purification process 
can result in partial cell activation as discussed earlier, and should be considered when 
interpreting in vitro neutrophil studies. This hypothesis is further supported by comparing 
the MFI values for PR3 expression between the cells incubated in RPMI 1640 medium 
with those from cells incubated in plasma. The data presented in this Chapter show that 
MFI values for PR3 expression are greater for cells incubated or stimulated in RPMI 1640 
medium compared to cells incubated or stimulated in plasma. 
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In the studies presented here, there was a similar proportional increase in surface PR3 
expression on the neutrophil following stimulation in the presence of different 
concentrations of A1AT. However, a small study by Matsumoto et al [325] showed that 
neutrophils from 3 healthy controls showed a suppressed increase in membrane PR3 
expression when stimulated in the presence of A1AT or healthy plasma. In that study, 
neutrophils were stimulated with both TNFα and a greater concentration of fMLP (1µM) 
which could explain the discrepancy with the current results. Previous studies have shown 
that different stimulants at different concentrations produced variable increases in 
membrane NSP expression, with increases of up to 30 fold when PMA was used [54] 
(although this is unlikely to be physiological). The lack of a consistent association between 
cell surface NE expression and local A1AT concentration in the current studies could 
therefore potentially be related either to the modest increases of surface NE expression 
observed when using fMLP 100nM as the stimulant or to the sample sizes studied. 
However, a genuine lack of association may exist, and paradoxically Owen et al [54] 
found that neutrophils activated [using bacterial lipopolysaccharide (LPS) and fMLP] in 
the presence of 20% serum expressed greater quantities of cell surface NE compared to 
cells activated in buffer alone, and the authors suggested that this may be related to the 
presence of LPS-binding protein in the serum which augments the biological activities of 
LPS. Therefore, further studies are necessary to establish any relationship between 
neutrophil surface NE expression and local A1AT concentration. 
 
The association between A1ATD and WG suggests that the proteinase/anti-proteinase 
imbalance may play a role in the pathogenesis of this disease. Previous studies have shown 
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that subjects with WG with the PiZZ genotype have more aggressive disease than subjects 
with the PiMZ or PiMM genotypes [326]. Rooney et al [327] studied the local effects of 
A1AT on anti-PR3 antibody-induced activation of neutrophils. The authors reported that 
A1AT could inhibit binding of anti-PR3 antibodies and hence reduce activation of 
neutrophils from subjects with active WG. These observations, in addition to the findings 
of the current study, may suggest a potential therapeutic role for A1AT augmentation 
therapy particularly in the sub-group of A1ATD patients with acute episodes of vasculitis 
due to WG. 
 
In this Chapter, neutrophil cell membrane expression of PR3 and NE has been measured 
by flow cytometry using both MFI and percentage of positive cells. Unstimulated 
neutrophils from A1ATD subjects showed greater PR3 expression as measured by both 
MFI and as a percentage of positive cells compared to healthy controls. However, results 
from the experiments studying the local effects of A1AT on neutrophil cell surface 
expression of NE and PR3 showed significant effects detected by MFI but not on the 
percentage of positive cells. This discrepancy is possibly related to the small sample sizes 
used, since combining the data from the 2 subject groups (and therefore increasing the 
numbers) confirmed that the percentage of PR3 positive cells was significantly greater 
when cells were incubated or stimulated in PiZZ plasma compared to PiMM plasma. 
However, the differences in percentage of positive cells are not always consistent with the 
overall differences in MFI suggesting that increased expression may not solely be due to 
greater numbers of positive cells. In the literature, there is no standard method for 
presenting data obtained by flow cytometry, as some authors use MFI [49] and others use 
percentage of positive cells [310]. The data presented here suggest that both parameters are 
required to understand changes. 
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The Accuri® C6 flow cytometer used for these studies gives different MFI values to other 
available cytometers (unpublished personal observations) and therefore comparisons 
cannot be made between instruments. For these reasons, all of the studies reported here 
were performed on the same cytometer. The use of the Accuri® C6 flow cytometer has 
previously been validated in the literature [328, 329] providing confidence of the 
differences observed between groups reported here. 
 
In summary, this Chapter has demonstrated that PR3 expression on neutrophil cell 
membranes is greater in subjects with A1ATD compared to healthy controls, and that 
membrane PR3 expression is greater when the surrounding concentration of A1AT is 
lower. This could be of clinical importance especially since membrane bound NSPs retain 
their activity and hence tissue damaging potential. The increased membrane PR3 
expression could also potentially play a role in autoimmunity since PR3-ANCA positive 
vasculitis (Wegener’s granulomatosis) is associated with A1ATD where more PR3 surface 
expression occurs. In the future, a better understanding of the mechanism of PR3 binding 
to the neutrophil cell membrane may facilitate therapeutic approaches to modulate 
membrane expression of PR3. These therapeutic approaches may prove valuable both in 
PR3-ANCA positive vasculitis and other inflammatory diseases (such as COPD with and 
without A1ATD). 
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9 The activities of serine proteinases in airway secretions 
from subjects with A1AT deficiency or usual COPD 
9.1 Introduction 
An imbalance between the activities of NSPs and their inhibitors (the anti-proteinases) is 
widely believed to play a role in the pathophysiology of COPD, and this imbalance is even 
greater in subjects with A1ATD. Previous studies have considered the contribution of NE 
to the proteinase/anti-proteinase imbalance [330], but to date there has been little direct 
evidence of the role of PR3, and until recently, research has been hindered by poor 
availability of specific PR3 substrates and inhibitors. 
 
The studies described in this Chapter were designed to investigate the presence and 
activity of PR3 compared to NE in sol-phase sputum from subjects with A1ATD or usual 
COPD, together with the concentrations of their airway inhibitors. Previous Chapters have 
considered the partitioning of these NSPs between their circulating inhibitors A1AT and 
A2M. However, this Chapter also considers the contribution of the locally produced 
airway inhibitors SLPI and elafin, as well as relationships between NSP activities and 
clinical parameters. 
 
The aim of this Chapter is to provide insight into the contribution of PR3 to the proteolytic 
activity in the lungs, and hence its potential role and implications as a therapeutic target. 
The work presented in this Chapter has been published in a peer-reviewed journal [331]. 
 
 213 
 
9.2 Methods 
9.2.1 Subject selection 
Twenty eight clinically stable subjects (at least 8 weeks after any acute infection) with 
A1ATD (PiZZ phenotype) and a history of chronic bronchitis were identified from the UK 
national registry for A1ATD, and spontaneously produced sputum was collected as 
described previously [332]. None of these patients were receiving A1AT augmentation 
therapy. 
 
Twenty two patients with usual COPD (PiMM phenotype) were recruited from primary 
care with a clinical diagnosis of COPD, confirmed by spirometry and/or radiological 
findings to meet the diagnostic criteria [333]. Sputum was collected at the start of an acute 
exacerbation (day 1) and then after resolution of the episode during convalescence (day 
56). In total, 12 day 1 samples and 22 day 56 samples of sufficient volume were available 
for this study. 
 
All subjects had full demographic data collected including smoking history, full PFTs and 
HRCT scans performed in the stable clinical state. The A1ATD subjects had their health 
status assessed using the SGRQ. 
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9.2.2 Measurement of PR3 and NE activities in sol-phase sputum 
Sputum samples were processed as described in section 2.2.3. The enzymatic activities of 
PR3 and NE in the sol-phase of sputum were evaluated by measuring the hydrolysis of 
specific substrates using pure proteinases (active site titrated) as standards. 
 
The PR3 activity assays were performed using the FRET substrate Abz-VAD-norV-
ADRQ-EDDnp (Alta Biosciences, UK) which was prepared as described previously [283]. 
This substrate has a catalytic constant Kcat/Km of 3400mM
-1
s
-1
 and shows no significant 
hydrolysis by NE [334] or CG (Prof. T Moreau, Rheims, France; personal 
communication). This was confirmed by adding 3µL of 1mM FRET substrate to 150µL of 
10nM solutions of PR3, NE, CG (Sigma, UK) compared to NSP assay buffer as a control. 
The fluorescence (excitation 320nm, emission 420nm) was read at 5 minute intervals for 
as long as the curve was linear using a Biotek Synergy 2 Multi-Mode Microplate Reader, 
and unlike PR3, no change in fluorescence was observed when using pure NE, CG or 
buffer alone (data not shown). The activity of the CG was confirmed in a separate 
experiment by using a CG substrate, suc-val-pro-phe-pNa (Bachem, Switzerland). 
 
To measure PR3 activities in sol-phase sputum, standards were prepared by diluting pure 
PR3 in NSP assay buffer to an active concentration of 10nM and serially diluting the PR3 
in the same buffer to 0.63nM, with buffer alone as a blank for the assay. Sol-phase sputum 
samples were diluted 1 in 60 and the standards and samples (150µL) were added to a black 
opaque polypropylene low binding plate (Sigma, UK) in duplicate. Subsequently, 3µL of 
1mM FRET substrate was added to each well and the fluorescence was measured 
(excitation 320nm, emission 420nm) at regular intervals for as long as the curve was linear 
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using a Biotek Synergy 2 Multi-Mode Microplate Reader at 37°C. The activities of PR3 in 
the samples were obtained by interpolation from the standard curve. Any sample with a 
value above or below that of the standard curve was repeated at a suitable dilution. Using 
this FRET substrate, reliable measurements were obtained for PR3 in the range of 0.1-
10nM [283]. The intra-assay CV was 3.98% and the inter-assay CV was 13.35%. All 
results were corrected for the initial sample dilution. 
 
The NE activity assays were performed using SlaaapN as the substrate which has a 
catalytic constant Kcat/Km of 465M
-1
s
-1
 and shows no significant hydrolysis with PR3 
[119]. Pure NE was diluted in NSP assay buffer to 1µM and then serially diluted to 
15.6nM, and buffer alone was used as a blank for the assay. Sol-phase sputum samples 
were studied undiluted with appropriate controls to minimise the effect of the inherent 
colour of the samples on the OD measurement. The standards, samples and control 
samples (30µL) were added to a 96 well plate in duplicate and the substrate SlaaapN 
(150µL of 1mg/ml) was added, except for the control wells where buffer was added 
instead of substrate. The OD at 410nm was read at regular intervals up to 60 minutes using 
a Biotek Synergy HT plate reader at 37°C. The activities of NE in the samples were 
obtained by interpolation from the standard curve after subtraction of control values. The 
lower limit of detection for this substrate was 15nM and the intra- and inter-assay CVs 
were 3.48% and 4.76% respectively. Any samples with values below this level were re-
assayed using the NE specific FRET substrate Abz-APEEIMRRQ-EDDnp (Alta 
Biosciences, UK) providing reliable measurements for NE in the range of 0.1-10nM [283]. 
The intra-assay CV was 3.42% and the inter-assay CV was 4.76%. 
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9.2.2.1 Determining any effect of Pseudomonas aeruginosa proteinases 
The enzymatic activities of both Pseudomonas aeruginosa culture supernatants and pure 
Pseudomonas elastase (Merck, UK) were assessed using the above substrates to confirm 
no cross-reactivity with the assays for human proteinases. 
 
Pseudomonas aeruginosa was grown on chocolate agar plates (Oxoid, UK) from a sputum 
sample. Colonies were picked off the plate and added to 5ml of LB medium (made using 
10g tryptone, 5g yeast and 10g NaCl made up to 1 litre with deionised water and 
autoclaved to sterilise) and incubated overnight at 37ºC. Following incubation, 1ml of the 
cloudy medium was measured into a 1.5ml eppendorf tube and centrifuged in a MSE 
micro centaur centrifuge at 13,000 RPM for 5 minutes. Following centrifugation, a visible 
pellet had formed and 100µL of supernatant was added per well to a 96-well plate. The 
substrates used in the above experiments were added to the culture supernatant and any 
change in fluorescence (for the FRET substrates) or absorbance (for SlaaapN) was 
measured. 
 
In addition, pure Pseudomonas elastase was made at 100µg/ml (3µM) in PPE buffer. The 
substrates used in the above experiments were added to the pure Pseudomonas elastase and 
any change in fluorescence (for the FRET substrates) or absorbance (for SlaaapN) was 
measured. NE or PR3 were used as positive controls, and buffer alone was used as a 
negative control. 
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9.2.3 Measurement of PR3 and NE concentrations in sol-phase sputum 
The concentrations of PR3 and NE in the samples were measured by ELISA using 
commercially available kits according to the manufacturer’s instructions. The PR3 ELISA 
(Biorbyt, UK) only detects unbound PR3 (information from manufacturer), whereas the 
NE ELISA (Cambridge Bioscience, UK) detects both free and inhibitor-bound NE 
(information from manufacturer). The lower limits of detection were 5pM for the PR3 
ELISA and 14pM for the NE ELISA. The intra- and inter-assay CVs for these ELISAs 
were 3.59% and 9.19% respectively for the PR3 ELISA and 5.07% and 13.76% 
respectively for the NE ELISA. 
 
9.2.4 Measurement of inhibitors in sol-phase sputum 
The concentration of A1AT was measured by ELISA as described in section 2.6.1.2. The 
concentrations of SLPI and elafin were measured using commercially available ELISA kits 
(R&D systems, UK) according to the manufacturer’s instructions. The intra- and inter-
assay CVs were 6.37% and 10.76% respectively for the SLPI ELISA and 7.67% and 
4.46% respectively for the elafin ELISA. The concentration of A2M was also measured by 
ELISA using a commercially available kit (Universal Biologicals Cambridge, UK) which 
was capable of detecting lower concentrations of A2M than the method described in 
Section 4.2.2 (standards ranged from 0.002-0.5µg/ml; 2.8-690pM). The minimum 
detectable level of A2M using this ELISA kit was 2ng/ml (2.8pM) and the intra- and inter- 
assay CVs were 5.10% and 7.01% respectively. 
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9.2.5 Other measurements in sol-phase sputum 
Markers of neutrophilic inflammation were measured when sufficient sample remained, 
including interleukin (IL)-8, leukotriene (LT)-B4 and myeloperoxidase (MPO). IL-8 and 
LTB4 were measured using commercially available ELISA kits (R&D systems, UK). The 
intra- and inter-assay CVs were 5.97% and 7.22% respectively for the IL-8 ELISA and 
6.34% and 11.90% respectively for the LTB4 ELISA. MPO activity was measured as 
described previously [335] by another member of the research group. The intra- and inter- 
assay CVs for the MPO activity assays were 3.85% and 10.07% respectively. 
 
9.2.6 Statistical analysis 
Statistical analyses were performed using PASW statistics 18 for Windows. Normality was 
tested using the Kolmogorov-Smirnov test. PR3 activity, PR3 concentration, NE activity, 
NE concentration, IL-8, LTB4, MPO, A1AT, SLPI, FEV1 and SGRQ total score were not 
normally distributed therefore non-parametric tests were used and data are presented as 
medians and IQR. Mann-Whitney U tests or Wilcoxon signed rank tests were used for 
comparisons of independent or related data respectively. Correlations were assessed using 
Spearman’s rank correlation coefficient. Normally distributed data are presented as mean 
±SEM and independent or paired T-tests were used for comparisons of data for 
independent or related measures respectively. To compare variables between A1ATD and 
COPD subjects after adjusting for baseline differences, the data were log transformed and 
linear regression was used with group as one of the independent factors. The 
unstandardized residuals were tested for normality. For statistical purposes, enzyme 
activity below the lower limit of detection was taken as 0.1nM. Results were deemed 
statistically significant if p≤0.05. 
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9.3 Results 
9.3.1 Baseline characteristics 
Baseline characteristics of the two subject groups are shown in Table 9.1. The A1ATD 
subjects were younger, had a lower pack year smoking history, FEV1 (% predicted), 
FEV1/FVC ratio and KCO (% predicted) compared to the subjects with usual COPD. 
There were no significant differences in sex distribution or radiological evidence of 
emphysema between the two groups. 
 
Table 9.1-Baseline characteristics of the subject groups 
 A1ATD COPD p-value 
Age 
Mean (SEM) 
55 (1.9) 65 (1.9) 0.002 
Number of males (%) 
 
22 (79%) 19 (86%) NS 
Smoking history (pack years) 
Mean (SEM) 
21 (3.9) 54 (10.0) 0.004 
FEV1 (% predicted) 
Mean (SEM) 
49 (5.9) 72 (5.8) 0.004 
FEV1/FVC ratio 
Mean (SEM) 
0.41 (0.04) 0.49 (0.04) 0.031 
KCO (% predicted) 
Mean (SEM) 
69 (5.2) 101 (6.1) 0.001 
Number with radiological evidence of 
emphysema on HRCT (%) 
22 (79%) 14 (64%) NS 
NS= not significant 
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9.3.2 PR3 and NE activities in sputum from clinically stable subjects 
Detectable PR3 activity was found in all sputum samples from the A1ATD subjects 
(median 128nM, IQR 33-558nM) and in 64% of samples from subjects with usual COPD 
(median 22nM, IQR 0-103nM). PR3 activity was greater in A1ATD subjects compared to 
those with usual COPD (p=0.004) after adjusting for baseline differences in age, pack year 
smoking history, FEV1 (% predicted) and KCO (% predicted). These results are shown in 
Figure 9.1. Unbound PR3 concentration measured by ELISA confirmed these differences 
and values correlated strongly with PR3 activity (Spearman’s rho 0.879, p<0.001) 
indicating that most of the unbound PR3 was enzymatically active, as shown in Figure 9.2. 
 
Detectable NE activity was found in 21% of A1ATD sputum samples (median 0nM, IQR 
0-0nM) and 5% of usual COPD samples (median 0nM, IQR 0-0nM). The concentration of 
NE measured by ELISA (free and bound) was not significantly different (p=0.296) 
between subjects with A1ATD (median 330nM, IQR 140-813nM) and usual COPD 
(median 214nM, IQR 84-564nM). 
 
PR3 activity was greater than NE activity in subjects with A1ATD (p=0.004) and those 
with usual COPD (p=0.015). However, in the A1ATD group, 3 subjects had higher NE 
activity than PR3 activity. These 3 subjects were colonised with Pseudomonas aeruginosa 
whilst none of the subjects with usual COPD were. The greater PR3 activity in sputum 
from A1ATD subjects compared to COPD subjects remained even when subjects 
colonised with P. aeruginosa were excluded (p=0.006). Neither Pseudomonas aeruginosa 
culture supernatants nor purified Pseudomonas elastase were able to hydrolyse the 
 221 
 
substrates used for the NE or PR3 assays, suggesting that the NE and PR3 activities were 
specific. These results are shown in Figure 9.3 (data for PR3 substrate not shown). 
 
Figure 9.1- PR3 and NE activities in sol-phase sputum 
 
Figure 9.1: PR3 and NE activities in sol-phase sputum spontaneously produced by 
clinically stable subjects with A1ATD (n=28) and usual COPD (n=22). Each point 
represents data from an individual subject. Horizontal lines represent the median 
and IQR. The y-axis shows proteinase activity on a logarithmic scale. Samples with 
undetectable proteinase activity are indicated at a value of 0.1nM which is the lower 
limit of detection of the substrates used. 
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Figure 9.2-Correlation between PR3 activity and PR3 concentration 
 
 
Figure 9.2: Correlation between PR3 activity measured using the specific FRET 
substrate and unbound PR3 concentration measured by ELISA. 
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Figure 9.3- The effect of Pseudomonas elastase on the substrates used for NE assays 
 
 
Figure 9.3: Graphs A and B show that pure Pseudomonas elastase (PSE) was not able 
to hydrolyse the NE substrates SlaaapN and the NE specific FRET substrate. Similar 
results were found using Pseudomonas aeruginosa culture supernatants (data not 
shown). 
 
0
0.5
1
1.5
2
2.5
3
0 5 10 15 20 25 30 35
A
b
so
rb
an
ce
 (
4
1
0
n
m
) 
Time (mins) 
A) NE and Pseudomonas elastase (PSE) 
activity with SlaaapN 
NE
PSE
0
200
400
600
800
1000
1200
1400
1600
1800
0 2 4 6 8 10 12 14
Fl
u
o
re
sc
e
n
ce
 u
n
it
s 
Time (mins) 
B) NE and Pseudomonas Elastase Activity 
with NE specific FRET substrate 
NE
PSE
Control
 224 
 
9.3.3 NSP inhibitory proteins in sputum 
As expected, the concentration of A1AT was higher in sputum from subjects with usual 
COPD compared to those with A1ATD (COPD median 405nM IQR 234-744nM, A1ATD 
median 51nM IQR 19-83nM: p<0.001). In addition, usual COPD subjects also had higher 
concentrations of SLPI (COPD median 2.8µM IQR 1.7-4.4µM, A1ATD median 1.3µM 
IQR 0.8-2.7µM: p=0.002) and elafin (mean 316±37pM vs 200±39pM: p=0.039). However, 
A2M concentrations were greater in subjects with A1ATD (COPD median 1.2nM IQR 
0.4-4.7nM, A1ATD median 3.2nM IQR 0.4-4.7nM: p=0.046). The ratio of A1AT/A2M 
was greater in sputum than in serum in both subject groups, suggesting that diffusion of 
A2M into the lungs was somewhat limited by its large molecular size. SLPI was 
quantitatively the predominant NSP inhibitor in sputum from both subject groups. The 
contribution to the total airway inhibitory capacity of elafin was negligible, being found in 
sub-nanomolar concentrations in all samples. As shown in Figure 9.4, airway inhibitors of 
PR3 were quantitatively less than those of NE. 
 
The median concentration of NE measured by ELISA (free and inhibitor-bound) was less 
than the median total concentration of its cognate inhibitors both in subjects with A1ATD 
and usual COPD, as shown in Figure 9.5 and would explain why the majority of sputum 
samples from both subject groups showed no detectable NE activity. It was not possible to 
measure the total PR3 concentrations since the ELISA available was only able to detect 
unbound PR3. Nevertheless, the presence of PR3 activity in the sputum samples indicated 
that the amount of PR3 exceeded the functional concentration of its inhibitors. 
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Figure 9.4- NSP inhibitory capacity in sputum from stable subjects with A1ATD & COPD 
 
 
Figure 9.4: Mean concentrations (nM) of airway inhibitors in sol-phase sputum from 
subjects with A1ATD and usual COPD. The predominant inhibitor of NE in both 
subject groups was SLPI. The contributions of elafin and A2M in the upper airways 
were relatively small and are therefore not demonstrable on these graphs. PR3 thus 
has fewer and significantly reduced quantities of its airway inhibitors than NE. 
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Figure 9.5- Concentration of NE and its inhibitors in sol-phase sputum 
 
Figure 9.5: Median concentrations (nM) of NE (free and bound to inhibitors) and the 
median sum of its inhibitors A1AT, SLPI, A2M and elafin in sol-phase sputum from 
stable subjects with A1ATD and COPD are shown. In both subject groups, the total 
concentration of NE was well below that of its inhibitors, particularly in subjects with 
usual COPD. The lack of NE activity in the majority of sputum samples was 
therefore due to the dominance of its inhibitors. 
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(p=0.037). These data are shown in Figure 9.6. In this sub-group of patients, no significant 
difference was found in NE activity between exacerbation and stable clinical state (data 
not shown). 
 
Markers of neutrophilic inflammation were measured in the majority (n=21) of usual 
COPD samples and in a subset of A1ATD samples (n=11) where sufficient sample 
remained. The demographics of the COPD subjects where the measurements could be 
made were not significantly different to those where it could not. The A1ATD subjects 
who did not have the measurements available were older (59 years vs 50 years: p=0.026) 
and had a lower KCO (59% predicted vs 82% predicted: p=0.031) than those where 
measurements were available. However, there were no significant differences in sex, pack 
year smoking history, smoking status, FEV1 % predicted, FEV1/FVC ratio, residual lung 
volumes or SGRQ total score between subjects with or without the measurements. 
 
The concentrations of IL-8 (A1ATD median 6.86nM IQR 2.02-12.39nM, COPD median 
2.77nM, IQR 1.13-8.24nM: p=0.312), LTB4 (A1ATD median 6.52nM IQR 4.15-
20.02nM, COPD median 4.72nM IQR 2.77-17.50nM: p=0.463) and the MPO activities 
(A1ATD median 0.40 units/ml IQR 0.19-0.57 units/ml, COPD median 0.58 units/ml IQR 
0.28-1.65 units/ml: p=0.293) were not significantly different between patient groups. 
 
The correlations between PR3 activity and other parameters are summarised in Table 9.2. 
PR3 activity correlated positively with NE activity in the A1ATD subjects (Spearman’s 
rho=0.586, p=0.001) even though NE activity was detectable only in 6 subjects. PR3 
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activity correlated positively with IL-8 quantity in both patient groups (A1ATD 
Spearman’s rho=0.791 p=0.004, COPD Spearman’s rho=0.650 p=0.001) and MPO activity 
(A1ATD Spearman’s rho=0.612 p<0.001, COPD Spearman’s rho=0.799 p<0.001). In the 
usual COPD group, PR3 activity also correlated positively with LTB4 (Spearman’s 
rho=0.434, p=0.049). 
 
PR3 activity was found to correlate with the total pathogenic bacterial load in the A1ATD 
group (Spearman’s rho=0.578, p=0.001). Subjects with Pseudomonas aeruginosa on 
quantitative microbiological culture had significantly higher NE activity (p<0.001) and 
PR3 activity (p=0.025) in their sputum compared to subjects who did not. Higher PR3 
activity was also found in samples that grew Haemophilus influenzae compared to those 
that did not (p=0.003) but NE activity was not different. 
 
A significant correlation was also found between PR3 activity and SGRQ total score in the 
A1ATD subjects (Spearman’s rho=0.621, p=0.001). The SGRQ scores were not available 
for the subjects with usual COPD. No correlations were found between PR3 activity and 
FEV1 (% predicted) or KCO (% predicted) in either subject group. 
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Figure 9.6- PR3 activity in COPD patients during an exacerbation and at 8 weeks 
following the exacerbation when clinically stable 
 
Figure 9.6: PR3 activity in sol-phase sputum from 12 subjects with COPD taken on 
day 1 of an exacerbation and day 56 when clinically stable. Horizontal lines represent 
the median and IQR. The y-axis shows PR3 activity on a logarithmic scale. 
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Table 9.2- Correlations of PR3 activity in sol-phase sputum 
Diagnosis Measurement Number of Samples 
with Measurement 
Spearman’s 
rho 
p-value 
A1ATD 
 
MPO 
 
11 0.612 <0.001 
IL-8 
 
11 0.791 0.004 
LTB4 
 
11 0.291 NS 
SGRQ total 
 
25 0.621 0.001 
Total 
pathogenic 
bacterial load 
28 (18 positive) 0.578 0.001 
COPD MPO 
 
20 0.799 <0.001 
IL-8 
 
21 0.650 0.001 
LTB4 
 
21 0.434 0.049 
Total 
pathogenic 
bacterial load 
22 (8 positive) 0.291 NS 
NS= not significant 
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9.4 Discussion  
The work presented in this Chapter has provided direct evidence that active PR3 is present 
in sol-phase sputum from clinically stable subjects with chronic bronchitis associated with 
A1ATD as well as usual COPD. PR3 activity was greater than NE activity in these 
subjects (Figure 9.1), which likely reflects both the lower airway inhibitory capacity for 
PR3 (Figure 9.4) and the greater amount of PR3 contained within the azurophilic granules 
of the neutrophil compared to NE [108]. In addition, the association rate constants of 
A1AT and elafin for PR3 are orders of magnitude lower than for NE [123] and therefore 
NE is likely to be preferentially inhibited compared to PR3 in the inflammatory 
environment. Indeed, NE activity was largely undetectable in the samples studied, which is 
likely to be due to a dominance of its inhibitors (Figure 9.5). Furthermore, PR3 is not 
inhibited by SLPI which is present in large amounts in respiratory epithelial lining fluid 
and is the predominant inhibitor of NE in the upper airways (Figure 9.4). In addition, PR3 
is capable of degrading SLPI [127], thus potentially enhancing the biological activities of 
other NSPs that are usually inhibited by SLPI. 
 
PR3 activity was greater in subjects with A1ATD than in subjects with non-deficient 
COPD, which highlights the greater proteinase/anti-proteinase imbalance in A1ATD 
subjects. Figure 9.4 shows that the A1ATD subjects had little anti-proteinase protection 
against PR3 and would explain why active PR3 was detectable in all sputum samples from 
this subject group. 
 
PR3 activity was found to be greater during exacerbations than during periods of clinical 
stability (Figure 9.6). Exacerbations are often associated with an increased neutrophilic 
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inflammation [44], and would account for the correlations of PR3 activity with other 
neutrophilic markers (Table 9.2). Of interest, PR3 activity showed a positive correlation 
with worsening health status as measured by the SGRQ. PR3 activity is thus a marker of 
increased airway inflammation and exacerbations, which are both associated with impaired 
health status in subjects with chronic respiratory disease [336, 337] suggesting it is an 
association rather than cause and effect.  
 
These results do not however demonstrate any relationship between PR3 activity and lung 
function parameters. In a previous study where PR3 concentration was measured in 
sputum from 49 subjects with cystic fibrosis (CF), a negative correlation was observed 
between PR3 concentration and FEV1 (% predicted) [75]. It is possible therefore that the 
work presented here did not involve sufficient numbers to detect such a relationship 
between FEV1 and PR3 activity, although other features such as variable bacterial 
colonisation (see below) will also complicate this potential relationship. The current study 
also did not find a significant difference in markers of neutrophilic inflammation (IL-8, 
LTB4 and MPO) between subjects with A1ATD and those with non-deficient COPD. 
Again, this could be related to the size of the subject groups studied since previous work 
by Hill et al [338]  reported that subjects with A1ATD (n=42) had greater inflammation in 
the upper airways with increased LTB4 and MPO compared to subjects with non-deficient 
chronic bronchitis (n=39). 
 
The studies presented in this Chapter have directly measured both PR3 and NE activities in 
biological samples using highly sensitive and specific substrates. Some previously 
published studies of NSP activities in airway secretions have used non-specific “elastase” 
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substrates (such as MSaapvN) and potentially measured the combined activities of PR3 
and NE [19, 339, 340]. Other studies have indirectly measured PR3 activity by measuring 
the combined activities of PR3 and NE with and without an NE inhibitor [75]. The direct 
measurement of individual NSP activities in lung secretions using highly sensitive and 
specific substrates (as described here) allows the contribution of each NSP to the total 
proteinase burden to be determined specifically. Although NSPs are released from 
neutrophils simultaneously upon activation and degranulation, their concentrations can 
differ due to local factors such as binding to the cell membrane [108], their affinities to 
endogenous inhibitors at the inflammatory site and their specificities toward peptide or 
protein substrates [123]. Biological consequences are only likely to occur in the presence 
(especially persistent presence and quantity) of active enzyme. 
 
The results described in this Chapter are derived from subjects with A1ATD and usual 
COPD with a chronic bronchitis phenotype. Subjects with chronic bronchitis show a 
higher airway inflammatory burden compared to subjects who do not expectorate, which is 
not related to smoking status [19]. Sputum production may also be associated with an 
accelerated decline in FEV1 in COPD [20]. Therefore, although it is important to 
understand the role of NSPs in this subgroup of patients, the results presented here may not 
be generalizable to subjects who are not spontaneous sputum producers. However, 
spontaneous sputum collection is non-invasive and minimises dilutional errors found with 
other techniques such as broncho-alveolar lavage [341] and induced sputum collection and 
may thus provide critical data especially in this important phenotype. 
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Three of the subjects with A1ATD were colonised with Pseudomonas aeruginosa and had 
significantly higher NE and PR3 activities in their sputum compared to subjects who were 
not. The presence of Pseudomonas proteinases in these sputum samples could not have 
accounted for these elevated NSP activities (Figure 9.3). However, Pseudomonas elastase 
is able to cleave SlaaapN between the first and second alanine residues, rendering the 
cleaved substrate ineffective and potentially under-estimating NE activity in the presence 
of Pseudomonas proteinases [342]. However, the NE specific FRET substrate gave results 
consistent with those using SlaaapN, providing confidence in the activity values reported 
here. 
 
In addition to the elevated NSP activities in samples that grew Pseudomonas aeruginosa, 
greater PR3 activity was also found in samples that grew Haemophilus influenzae 
compared to those that did not. Hill et al [343] have previously shown that in patients with 
bronchiectasis, Pseudomonas aeruginosa provokes a more intense inflammatory response 
(with elevated NE and MPO activities) compared to Haemophilus influenzae, which in 
turn is greater than that with Moraxella catarrhalis. Correlations of PR3 activity with 
airway bacterial load and airway inflammation (NE and MPO activities) support the role of 
colonisation in airway neutrophilic inflammation (as indicated previously [343, 344]), but 
highlights the association with PR3 activity, which has the potential to drive the 
pathophysiological processes that influence COPD and its progression. This enzyme may 
therefore be more important in COPD than has previously been thought.  
 
In conclusion, the results presented in this Chapter suggest that PR3 activity should be 
determined when evaluating the proteinase/anti-proteinase imbalance in the airways. 
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Whether or not it is central to the pathological process remains to be determined as it 
remains possible that several proteinases may play a role in the pathogenesis of COPD, 
either individually, additively or synergistically. In addition to NSPs, both MMPs [345] 
and cysteine proteinases [212, 214] have been associated with tissue destruction in 
emphysema both directly and indirectly via their interactions with NSPs and their 
inhibitors (as shown in Figure 1.7). Strategies to reduce the burden of proteinases in the 
lungs could potentially offer novel therapies for COPD. Even abrogation of one enzyme 
may positively abrogate a proteinase cascade involving others. Recently, Jegot et al [346] 
have developed specific PR3 inhibitors. Selective inhibitors of PR3 may thus provide 
further insight into its role in disease and the inflammatory cascade. Such approaches 
(based on the studies presented here) could therefore potentially be of therapeutic value in 
a variety of inflammatory lung diseases, but specifically COPD. 
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10 Overall discussion and future work 
COPD remains a significant medical condition characterised by pulmonary inflammation 
in response to inhaled substances. At present, the pharmacological therapies available for 
COPD do not convincingly alter disease progression or mortality, and therefore there is an 
urgent need for novel therapies. To date, there has been a substantial body of evidence 
implicating proteinases in the pathophysiology of COPD [100], and notably NE has been a 
strong focus. However, limited short-term studies of selective NE inhibitors have not been 
fully effective in controlling neutrophil-mediated damage in the airways [98] and have not 
demonstrated clinical benefits [99]. Furthermore, other serine proteinases as well as MMPs 
and cysteine proteinases have been both directly and indirectly implicated in COPD [212, 
214, 345], and may play a synergistic or even more central role in tissue destruction than 
has previously been recognised. In addition, interactions exist between different classes of 
proteinases, their substrates, their inhibitors and other inflammatory mediators. Thus, the 
pathophysiology of COPD is complex and uncertainty has led to a reluctance to develop 
and trial specific anti-proteinase agents. 
 
The results presented in this thesis provide novel data on the biological interactions of 
NSPs with their inhibitors and substrates, and on the potential importance of PR3 in 
inflammatory lung disease. These findings along with potential future studies are discussed 
in further detail below. 
 
 237 
 
10.1 Interactions between NSPs and their inhibitors and substrates 
10.1.1 The potential role of proteinase complexes with A2M 
The major circulating inhibitors of NE and PR3 are A1AT and A2M which differ in their 
mechanism of inhibition. Complex formation between A1AT and NSPs results in the 
enzyme being inactivated. However, “inhibition” of proteinases by A2M does not block 
the active site of the enzyme and it retains proteolytic activity, at least towards low 
molecular weight substrates [196]. The results presented in Chapters 3 and 4 demonstrate 
that NE bound to A2M remains active towards low molecular weight nitroanilide 
substrates, and shows enhanced activity towards certain substrates, consistent with 
previous findings [255]. In addition, these results have demonstrated that PR3 bound to 
A2M also remains proteolytically active towards the small peptide substrate MSaapvN. 
When these NSPs are introduced to serum, they partition between their major inhibitors 
depending on both the local concentrations of inhibitors and their association rate 
constants (as shown in Figure 4.1). Therefore, in situations where A1AT is deficient or 
dysfunctional, a greater proportion of released NSPs would partition towards A2M and 
likely remain active in vivo. 
 
The potential biological significance of A2M complexes with NSPs was explored in 
Chapter 5 where elastin was used as a more physiological substrate. The results suggest 
that A2M:NE complexes are capable of elastin degradation in vitro. Firstly, when NE was 
pre-incubated with PiMM serum (containing a molar excess of A1AT) and elastin was 
subsequently introduced, some elastin degradation was still observed (Figure 5.1A), which 
did not occur when pure A1AT was used (Figure 5.7), indicating that the elastin 
degradation was due to NE bound to A2M. Secondly, when NE was pre-incubated with a 
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three-fold molar excess of A2M and elastin was subsequently introduced, elastin 
degradation was again observed (Figure 5.8). The three-fold molar excess of A2M used in 
these experiments should have theoretically been sufficient to bind all of the free NE, as 
Moore et al [254] found that a 1.5 molar excess of A2M was sufficient to bind all free NE 
under similar experimental conditions. It does however remain possible that some of the 
trapped NE could have dissociated from A2M. Although this is unlikely, the absence of 
free NE could be confirmed in future studies by size exclusion chromatography. 
 
The role of A2M:NE complexes in disease has yet to be fully elucidated, but active 
A2M:NE complexes have been implicated in the pathogenesis of emphysema in animal 
models [201], and other studies have shown that A2M:NE complexes may play a role in 
the adult respiratory distress syndrome in humans [253] and the degradation of cartilage 
matrix in rheumatoid arthritis [254]. However, other studies have suggested that A2M:NE 
complexes are unable to degrade macromolecular substrates (such as mature elastin) [267]. 
Therefore, further studies are necessary to determine whether A2M:NE complexes are 
important in diseases where excessive activities of NSPs have been implicated. These 
initial studies could involve the instillation of human A2M:NE complexes into animal 
lungs to determine whether emphysema-like lesions develop. Additional studies of human 
samples could involve the measurement of A2M:NE complexes in lung secretions (sputum 
or BAL), and their relation to clinical outcomes such as PFTs or emphysema severity 
determined by CT densitometry. 
 
The significance of A2M:PR3 complexes has not been explored previously. Although PR3 
bound to A2M remains proteolytically active towards low molecular weight peptide 
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substrates (Chapters 3 and 4), A2M:PR3 complexes appear to be less likely than A2M:NE 
complexes to play an important role in elastin degradation. The results presented in 
Chapter 5 show that both PiMM (Figure 5.1B) and PiZZ (Figure 5.3B) sera were able to 
completely inhibit PR3 activity towards elastin when the A1AT was in a molar excess, and 
PR3 activity towards elastin was at least partly inhibited following pre-incubation with 
A2M (Figure 5.8). Despite these findings, PR3 may still play an important role in the 
tissue damage associated with emphysema because it is more abundant than NE and has 
fewer airway inhibitors (Chapter 9). 
 
10.1.2 The effect of elastin on NSP inhibition 
The studies in Chapter 5 highlighted differences in how NSPs interact with their inhibitors 
in the presence of elastin. When NE was pre-incubated with pure A1AT (Figure 5.7), 
inhibition of NE activity towards elastin occurred when the molar ratio of A1AT:NE was 
1.2:1. The studies using serum samples to inhibit NE activity also demonstrated that serum 
A1AT inhibited NE activity towards elastin when the molar ratio of A1AT:NE was 1.2-
1.4:1 following extrapolation of the slope to the x-axis, suggesting that A1AT was less 
functional as an inhibitor when elastin-fluorescein was used as the substrate. Indeed, 
previous work by Kramps et al [271] reported that A1AT had a specific inhibitory activity 
of 40-85% of that observed with synthetic nitroanilide substrates when elastin-fluorescein 
was used, possibly due to a degree of dissociation of the A1AT:NE complex with 
subsequent poor inhibition of elastin-bound NE. The same was not true of PR3, which was 
fully inhibited with 1:1 stoichiometry by A1AT in both PiMM and PiZZ sera when elastin-
fluorescein was used as the substrate. 
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Morrison et al [266] reported that airway inhibitors such as A1AT and SLPI were less 
effective against NE bound to elastin compared to free NE. The studies presented in 
Chapter 5 were consistent with these findings, since NE added to a mixture of both elastin-
fluorescein and serum was poorly inhibited even when the concentration of inhibitors was 
in a molar excess (Figures 5.2 and 5.4), which reflects differential partitioning to the 
elastin substrate in competition with the inhibitors. This “ineffective” inhibition of NE in 
the presence of elastin may have biological relevance to the pathogenesis of emphysema 
which results from damage to elastin in the lung parenchyma. Therefore, further studies 
will be necessary to investigate this more complex system. However, the studies presented 
in Chapter 5 suggested that PR3 added to a mixture of both elastin-fluorescein and serum 
could be inhibited, although less effectively in the presence of elastin (Figures 5.2 and 
5.4). A previous in vitro study by Ying and Simon [123] reported that the elastolytic rate 
of PR3 was one eighth that of NE using bovine neck ligament elastin (as was used in the 
studies presented in this thesis), and that ongoing elastolysis by PR3 was almost 
completely inhibited by M variant A1AT, although these findings remain to be verified in 
vivo or in situations where the A1AT concentration is low or the protein is dysfunctional 
(such as in PiZZ homozygotes). 
 
10.1.3 Differences between NE and PR3 and their association rate constants 
with inhibitors 
The M variant of A1AT has been reported to be a less competent inhibitor of PR3 
compared to NE, with its Kass with PR3 being ten-fold lower than that with NE [117, 
280]. However, the second order association rate constants for other A1AT variants and 
PR3 had not been described previously. The results presented in Chapter 6 showed that the 
second order association rate constants for all A1AT variants studied (M, Z, S, FZ, IZ) 
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were greater for NE than PR3 (Figure 6.3). Therefore, if the concentration of A1AT were 
to be insufficient to inhibit both proteinases during neutrophilic inflammation, NE would 
be preferentially inhibited. For this reason, in addition to the greater amounts of PR3 
contained within the neutrophil azurophilic granules [108], and the fact that PR3 is not 
inhibited by the local lung inhibitor SLPI [109], it is likely that PR3 is more important in 
the pathophysiology of COPD than has previously been thought (especially in subjects 
with A1ATD) since its activity is likely to persist longer in the neutrophilic environment 
than NE. 
 
The association rate constants for both NE and PR3 with A2M have been measured 
elsewhere [117, 190]. The in vitro association rate constants for A1AT and A2M with NE 
are similar. Nevertheless, in subjects with the PiMM phenotype, the molar concentration of 
A1AT is approximately 10 times greater than that of A2M and therefore released NE is 
likely to partition predominantly to A1AT in serum. However, PiZZ homozygotes (and 
PiFZ or PiIZ heterozygotes) have lower concentrations of A1AT with lower association 
rate constants relative to A2M, which would alter the partitioning of NE more towards 
A2M where it retains proteolytic activity as discussed earlier. PR3 on the other hand has a 
greater Kass with A2M compared to all A1AT variants studied here, and therefore if the 
concentrations of A1AT and A2M were similar (such as in PiZZ subjects), PR3 would 
preferentially bind to A2M where it will remain active, at least towards low molecular 
weight substrates. At present, the physiological significance of A2M:PR3 complexes 
remains uncertain, and further studies will be necessary to determine whether these 
complexes are able to degrade the elastin precursor tropoelastin, and hence affect the 
repair process. 
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In the airways, the chelonianin inhibitors SLPI and elafin are present in addition to A1AT 
and A2M. SLPI is a reversible inhibitor of NE but does not inhibit PR3 [109]. 
Furthermore, PR3 can inactivate SLPI [127] thus potentiating the activities of other 
proteinases usually inhibited by SLPI. Overall, the anti-proteinase protection in the 
airways against PR3 activity appears to be relatively weak since PR3 has quantitatively 
fewer airway inhibitors than NE (Figure 9.4). In addition, the association rate constants for 
A1AT and elafin are lower for PR3 than NE, and therefore these inhibitors would also 
preferentially associate with NE in the context of neutrophilic inflammation. The potential 
in vivo significance of these observations is discussed in further detail below. 
 
Knowledge of the association rate constants for enzyme-inhibitor interactions and the local 
concentrations of airway inhibitors could potentially allow a mathematical model to be 
constructed in order to determine the partitioning of released NSPs between their 
inhibitors, and the effects of different A1AT variants on this partitioning. For example, 
Rao et al [117] predicted that if both NE and PR3 were released at similar concentrations 
in the lower respiratory tract, M variant A1AT would distribute between the two NSPs 
such that 89% of it would be bound to NE and 11% of it would be bound to PR3. A more 
complex mathematical model could potentially consider the presence of additional 
inhibitors such as A2M and SLPI, and provide theoretical support to the differences in 
partitioning of enzymes between their inhibitors observed in Chapter 3. 
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10.1.4 The in vitro effects of augmentation therapy on NSP activities and 
partitioning between inhibitors 
Increasing the A1AT level in deficient subjects increases the total inhibitory capacity. 
However, the studies described in Chapter 7 demonstrated that the addition of M variant 
A1AT to serum from subjects with A1ATD (PiSZ, PiFZ or PiZZ genotypes) also alters the 
partitioning of NSPs between their serum inhibitors even at equivalent concentrations of 
A1AT. With the augmented serum samples, greater proportions of NE or PR3 became 
bound to A1AT where they are inactivated, resulting in fewer active complexes between 
NE or PR3 and A2M. In addition to changes in the partitioning of NSPs between A1AT 
and A2M, the inhibitory capacity of augmented serum would be greater due to its higher 
A1AT concentration, the greater Kass of M variant A1AT with NE and a reduced tendency 
to form inactive polymers. However, A1AT augmentation therapy would still not inhibit 
elastin-bound NE as discussed previously, and different mechanisms of inhibiting elastin-
bound NE should be explored. 
 
10.2 The role of PR3 in A1ATD and COPD 
10.2.1 Neutrophil cell surface expression of PR3 and its importance in A1ATD 
Previous work has shown that NSPs bound to the cell membrane of stimulated neutrophils 
remain catalytically active towards both synthetic peptide and high molecular weight 
biological substrates such as fibronectin [54, 108]. In addition, PR3 expressed on the 
neutrophil cell membrane is a major antigenic target for ANCAs in WG, and A1ATD is a 
risk factor for the development of WG [228]. The studies in Chapter 8 showed that PR3 
expression on the surface of both unstimulated and stimulated neutrophils was greater in 
subjects with A1ATD (PiZZ phenotype) compared to healthy controls. In addition, 
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neutrophil cell surface PR3 expression was greater when the local concentration of A1AT 
was reduced. However, neutrophil cell surface expression of NE did not appear to be 
influenced by the local concentration of A1AT in the studies presented here. The greater 
neutrophil expression of PR3 in A1ATD could potentially contribute to the proteinase/anti-
proteinase imbalance observed in this condition, since membrane bound PR3 retains its 
activity and hence its tissue damaging potential. Furthermore, the proteinase/anti-
proteinase imbalance may play a role in the pathogenesis of WG, and previous studies 
have suggested that subjects with WG with the PiZZ genotype have more aggressive 
disease than subjects with the PiMZ or PiMM genotypes [326] which likely reflects the 
amount of neutrophil membrane-bound PR3. In addition, A1AT can inhibit binding of 
anti-PR3 antibodies to membrane PR3 by steric hindrance [327] and hence reduce 
activation of neutrophils by this process in subjects with active WG. Overall, these 
observations may suggest a potential therapeutic role for A1AT augmentation therapy 
particularly in the sub-group of A1ATD patients with acute episodes of vasculitis due to 
WG. Clearly, further clinical studies in this sub-group of patients are warranted to 
determine the efficacy of such an approach. 
 
In the future, a better understanding of the mechanism of PR3 binding to the neutrophil 
cell membrane may facilitate therapeutic approaches to modulate membrane expression of 
PR3, which may be beneficial for WG and other conditions where the proteinase/anti-
proteinase imbalance plays a role (such as COPD). One strategy may involve blocking the 
interaction between PR3 and the NB1 receptor. Choi et al [347] have identified 
compounds which can inhibit binding of exogenous PR3 to human neutrophils and reduce 
TNFα-mediated increases in membrane PR3 on NB1 positive cells. These compounds 
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could potentially provide a potential therapeutic tool to reduce membrane PR3 expression 
by preventing its binding to the NB1 receptor. 
 
10.2.2 PR3 activity in airway secretions from subjects with A1ATD and usual 
COPD 
The studies presented in Chapter 9 showed that active PR3 was present in sol-phase 
sputum from clinically stable subjects with chronic bronchitis associated with A1ATD as 
well as usual COPD, whereas NE activity was undetectable in the majority of these 
samples. Therefore, in both groups of patients, the amount of active PR3 was greater than 
the amount of active NE (Figure 9.1) which most likely reflected the greater anti-
proteinase protection against NE in the upper airways (Figure 9.4). In addition, PR3 
activity was even greater in subjects with A1ATD than non-deficient subjects with COPD, 
consistent with the lower concentrations of A1AT and hence the greater proteinase/anti-
proteinase imbalance in A1ATD. 
 
PR3 activity was also found to be greater during exacerbations than during periods of 
clinical stability in subjects with usual COPD (Figure 9.6). Exacerbations are associated 
with an increased neutrophilic inflammation [44], and these findings are supported by the 
positive correlations observed between PR3 activity and other neutrophilic markers (Table 
9.2). PR3 activity also showed positive correlations with worsening health status and 
pathogenic bacterial load in A1ATD subjects. Thus, PR3 activity is a marker of increased 
airway inflammation and exacerbations, both of which are associated with impaired health 
status in subjects with chronic respiratory disease [336, 337]. The reasons for this 
association are likely to relate to the overall nature of the inflammation and its systemic 
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effects. Other factors such as lung function and bacterial colonisation may have 
independent effects on the perception of health, and more extensive studies with greater 
patient numbers would be required to determine whether this association represents cause 
and effect. 
 
In addition to A1AT and the chelonianin inhibitors SLPI and elafin, A2M was found to be 
present in sol-phase sputum from clinically stable subjects with A1ATD or usual COPD. 
A2M enters the lungs predominantly by diffusion, however the ratios of A1AT/A2M were 
greater in sputum than serum in both subject groups, suggesting that diffusion of A2M into 
the airways was somewhat limited by its large molecular size. The presence of A2M in the 
lung secretions may still be of pathological significance since A2M complexes with NE or 
PR3 remain active as discussed previously. Furthermore, proteinases bound to A2M are 
shielded from other airway inhibitors such as A1AT. Although the studies presented here 
did not detect a difference in A2M concentration between exacerbations and clinical 
stability, larger studies [193] have shown that concentrations of A2M in infected samples 
were greater than in non-infected samples. Therefore, any role of complexes between A2M 
and NSPs in tissue damage is likely to be greater during exacerbations, and thus may 
enhance the damaging potential of NSPs. 
 
The results described in Chapter 9 are from subjects with A1ATD or usual COPD with a 
chronic bronchitis phenotype, and therefore the results may not be generalizable to 
subjects who do not produce spontaneous sputum. Future studies in A1ATD or COPD 
could use induced sputum to determine the proteinase burden in the upper airways, or BAL 
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to sample the distal airways. These studies may provide further insight into the role of PR3 
in stable COPD subjects without chronic bronchitis. 
 
The studies described in Chapter 9 have directly measured both PR3 and NE activities in 
sol-phase sputum using highly sensitive and specific FRET substrates. In the past, the role 
of PR3 has not been studied in detail due to a lack of availability of specific PR3 substrates 
and inhibitors. As a result, some previously published studies of NSP activities in airway 
secretions have used non-specific “elastase” substrates (such as MSaapvN) and potentially 
measured the combined activities of PR3 and NE [19, 339, 340], thus over-estimating the 
contribution of NE. Alternatively, previous studies have indirectly measured PR3 activity 
by measuring the combined activities of PR3 and NE with and without an NE inhibitor 
[75]. The direct measurement of individual proteinases is important in order to determine 
the relative contribution of each proteinase to the overall inflammatory burden. This is 
particularly important in lung secretions from subjects with COPD (and other 
inflammatory lung diseases where proteinases have been implicated) where several human 
proteinases of different classes may be present along with bacterial proteinases. Greater 
knowledge of the roles of each proteinase may identify targets for specific therapeutic 
inhibitors, although this will require the development of specific direct substrates for the 
enzymes likely to be present. 
 
Recently, Wysocka et al [348] have developed new FRET substrates that allow all three 
NSPs (NE, PR3, CG) to be quantified at the same time and in the same reaction mixture. 
These substrates are capable of measuring NSP activities on neutrophil cell membranes 
and in other biological fluids. Such substrates could be used in future studies of NSP 
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activities in airway secretions to reduce both time and the amount of sample required, as 
well as providing information on the relative contributions of the individual NSPs 
including CG. 
 
10.3 Discussion and future directions 
As highlighted above, NSPs are likely to play an important role in the pathophysiology of 
COPD, and NE in particular has received the most attention in the literature. However, 
Korkmaz et al [349] studied the competition between the NSPs (NE, PR3, CG) for binding 
to A1AT, and found that NE was the main target of A1AT when identical molar amounts 
of A1AT and the three NSPs were studied together. Both PR3 and CG were only inhibited 
once NE had been totally inhibited. The authors also studied BAL from subjects with acute 
bacterial pneumonia and/or ARDS and again found that NE was the preferred target for 
inhibitors present in BAL fluid. Interestingly, they found that PR3 (both free and bound to 
the neutrophil cell membrane) was the least well controlled NSP by the inhibitors present 
in BAL fluid, perhaps because CG can also be inhibited by SLPI and α1-antichymotrypsin.  
 
To date, the development of anti-proteinase therapies for A1ATD or COPD has not been 
completely successful. Although A1AT augmentation therapy is used in some countries 
for subjects with A1ATD, randomised controlled studies to date have not convincingly 
demonstrated its efficacy in clinical practice [238], although data on emphysema 
progression using CT densitometry as the outcome have been more suggestive of efficacy 
[301-303]. It remains possible that treatment with A1AT augmentation therapy 
predominantly targets NE activity (due to the lower Kass of A1AT with PR3 or CG) and 
does not control the activities of the other NSPs in the airways whilst NE activity remains, 
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as suggested by Korkmaz et al [349]. In usual COPD, specific inhibitors of NE have failed 
to show any clinical benefit in short term randomised studies [99]. Again, this may be 
because NE is the preferred target of endogenous A1AT in these patients, and the 
uncontrolled activities of other proteinases may be of greater importance. 
 
Novel anti-proteinase agents may include specific inhibitors of PR3 (based on the evidence 
presented in this thesis), mechanisms for inhibiting NE bound to A2M or elastin, or 
possibly inhibitors of other classes of proteinases. These areas for future studies are 
discussed in further detail below. 
 
10.3.1 Inhibitors of PR3 
Overall, the results presented both in this thesis and in the literature [75, 349] suggest a 
potential therapeutic role for inhibitors of PR3 activity in inflammatory lung diseases such 
as COPD. Specific PR3 inhibitors have not been reported until recently, and their design 
has been hampered by the fact that all biological inhibitors of PR3 (A1AT, elafin and 
MNEI) preferentially inhibit NE [123, 179]. Recently, Jegot et al [346] were the first to 
develop a specific PR3 inhibitor derived from MNEI. This inhibitor was capable of 
inhibiting both free and neutrophil cell membrane-bound PR3. Subsequently, a reversible 
specific PR3 inhibitor was designed by the same research group based on the sequence of 
one of its specific FRET substrates [350]. This inhibitor is also able to inhibit free and 
neutrophil cell membrane-bound PR3, as well as PR3 in induced sputum and BAL fluid. In 
future studies, specific inhibitors of PR3 will provide further insight into its role in disease 
and the inflammatory cascade. In addition to their anti-proteinase effects, PR3 inhibitors 
could potentially have indirect anti-inflammatory effects since PR3 is able to activate 
 250 
 
TNFα, IL-8, IL-1β, IL-18 and IL-32 [58, 111-113]. These inhibitors could potentially be of 
therapeutic value in a variety of inflammatory lung diseases (including COPD) and could 
be administered either systemically or by inhalation. Therefore, in vivo studies of specific 
PR3 inhibitors will be required to determine their safety and efficacy. 
 
10.3.2 Future directions for NE inhibitors 
Future studies should investigate mechanisms of inactivating elastin-bound NE which is 
poorly inhibited by endogenous inhibitors [266]. Animal studies [272, 273] have shown 
that in order to protect the lungs from proteolytic damage, synthetic elastase inhibitors 
needed to be administered prior to the release of elastase. If inhibitors were administered 
after an elastase challenge, little or no protection was achieved, most probably because the 
inhibitors failed to inactivate elastin-bound NE. This ineffective inhibition of elastin-bound 
NE has biological relevance to the pathogenesis of emphysema, and therefore greater 
knowledge of the mechanisms for inhibiting the activity of elastin-bound NE may lead to 
the development of more effective agents. In addition, any future developments of NE 
inhibitors should consider mechanisms of inactivating NE bound to A2M, which is 
shielded from other biological inhibitors such as A1AT. These complexes may also play a 
significant role in the elastin degradation associated with emphysema, as discussed in 
Chapter 5. 
 
10.3.3 Inhibitors of other proteinases 
It has been recognised that several proteinases may play a role in the pathogenesis of 
COPD, either individually, additively or synergistically. In addition to the NSPs discussed 
in this thesis (NE and PR3), the role of CG in COPD has not been well studied and 
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therefore its relevance remains largely unknown. However, a dual inhibitor of CG and 
chymase has been shown to reduce airway inflammation in animal studies [131]. Recently, 
a fourth NSP has also been identified, NSP4, which shows around 40% sequence 
homology with NE and PR3 [351]. The physiological and pathological roles of this NSP 
remain to be determined. 
 
Although direct experimental and clinical observations have predominantly highlighted the 
importance of NSPs in the pathogenesis of COPD, other classes of proteinases such as 
MMPs and cysteine proteinases have also been implicated in tissue destruction in 
emphysema both directly and indirectly. One study of a broad spectrum MMP inhibitor 
(ilomastat) demonstrated protection against the development of emphysema in cigarette 
smoke-treated mice [352]. A dual inhibitor of MMPs 9 and 12 has also been shown to 
reduce small airways fibrosis in smoke exposed guinea pigs [353]. However, a more recent 
study using MMP-9 knockout mice and human samples suggested that specific inhibition 
of MMP-9 was unlikely to be an effective therapy against cigarette smoke-induced 
emphysema [354]. Two human phase IIa studies of an oral inhibitor of MMPs 9 and 12 
(AZD1236) administered over a six week period to patients with moderate-to-severe 
COPD have demonstrated that the drug was generally well tolerated with an acceptable 
safety profile, but no significant benefits were observed in terms of lung function or other 
clinical parameters [355, 356], although this time frame is far too short for a disease-
modifying study. To date, there have been no human studies of cysteine proteinase 
inhibitors in COPD. 
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10.4 Conclusion 
COPD remains a major cause of morbidity and mortality worldwide. At present, there is an 
urgent need for novel therapies to prevent or reverse progression of the disease, although 
development of such strategies has been limited due to the complex pathophysiology. Our 
overall knowledge of the relationships between proteinases, their inhibitors and other 
inflammatory mediators remains limited, and is further hindered by the lack of suitable 
short-term biomarkers for assessing the potential benefit of therapeutic interventions. The 
studies presented in this thesis have provided novel data on some of the biological 
interactions between NSPs and their inhibitors and substrates, and on the potential 
importance of PR3 in COPD and A1ATD. Selective inhibitors of PR3 are thus required to 
provide further insight into its role in disease and therapeutic potential in COPD and other 
inflammatory lung diseases where a proteinase/anti-proteinase imbalance is thought to be 
central to the pathophysiology. 
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